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Foreword 
Chronic disease of various kinds dominates Australia’s health and healthcare landscapes. 
Growth of chronic disease is driven mainly by population ageing, with the proportion of 
Australians 65 years  and over (now 13%) set to reach 25% by about 2056. Population ageing 
is mostly caused by improving population health, to which ~70% falls in age-standardised 
death rates in Australian men and women from 1909 to 2010 testify. But increasing age 
carries with it an increasing burden of chronic disease. For example, the  
2011–12 Australian National Health Survey found that 4.7% of adult Australians reported a 
doctor or nurse told them they had heart, stroke or vascular disease that was present at the 
time of the survey and had lasted, or was expected to last, 6 months or more. This proportion 
was 27.7% in men and women 75 years of age and over. The increasing burden of chronic 
disease is a major contributor to the ongoing ~4% annual increase in Australian 
hospitalisation rates. 
In consequence, Australia’s health services planners and managers focus more and more on 
the interface between hospitals (chiefly public, acute care hospitals) and out of hospital care, 
especially primary medical care. The logic is simple: the more that general practitioners, and 
nurses and allied health practitioners working in primary care, can contribute to preventing 
chronic disease and caring for chronically ill people in the community, the less the demand 
on hospital services. 
Mechanisms for facilitating effective interaction between acute hospitals and primary 
medical care services were not hardwired into the Australian health system through the 
recent National Health Reform process. There is, however, substantial interaction and 
cooperation developing, at least in New South Wales, between Local Health Districts, the 
unit of regional management of State health (mainly hospital) services, and Medicare Locals, 
regional Commonwealth-funded general practice coordination and planning organisations. 
(Medicare Locals sometimes, but not always, have the same boundaries as Local Health 
Districts.) Increasingly, Local Health Districts and Medicare Locals are represented on each 
other’s boards and are working in other ways to develop shared and interacting services. The 
same is happening in other States and Territories of Australia to a greater or lesser degree. It 
is in circumstances such as these that good information systems are needed to enable 
research into the issues, to provide data for policy, and planning and to evaluate the 
effectiveness and efficiency of new programs.  
There are, at present, no Australian health information systems that can be used to examine 
the interaction between hospitals and primary care in providing patient care and in 
achieving better patient outcomes. BEACH, now releasing General practice activity in Australia 
2012–13 (the 33rd book in the University of Sydney’s General Practice Series) and A decade of 
Australian general practice 2003–04 to 2012–13 (the 34th), provides the nearest to a 
comprehensive account of single, general practice consultations, but does not have the 
capacity to link to other health records, or the capacity to follow patients longitudinally. 
Medicare Australia’s medical and pharmaceutical benefits data collections record outputs 
from general practice consultations and can provide longitudinal data, but generally do not 
collect information on the problem being managed and can only imply outcomes from the 
nature of future medical and pharmaceutical benefits. They are, however, potentially 
linkable to hospital records, which are a rich source of outcome data relevant to services and 
programs at the hospital-general practice interface. 
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Clearly, there is need for a new direction in general practice data collection, which provides 
comprehensive information on patients’ problems and care given, is collected longitudinally 
and is linkable to other health records. BEACH has proposed such a direction—Longitudinal 
BEACH. Building on BEACH experience, LongBEACH would use a modified, computerised 
clinical audit tool to create a longitudinal cohort of general practice patients within existing 
general practice electronic health record systems. This cohort would be linked at least to MBS 
and PBS records, hospital emergency department and separation records, and death records. 
It would provide a rich source of data for investigating general practice and related health 
care activity and measuring health outcomes. 
The investment required to develop such a system might be more readily justifiable if it were 
to be done in close collaboration with teams building links between local health districts and 
Medicare Locals, and gave priority to recruitment of patients who had been recently 
hospitalised. Demonstrating its value as a policy, planning and evaluation tool in this context 
could make support for a wider investment easier to obtain. 
It’s time! 
Bruce Armstrong DPhil, FAFPHM, FAA 
Honorary Professor, Sydney School of Public Health, University of Sydney 
Senior Adviser, Sax Institute, Sydney 
Chair, Bureau of Health Information, Sydney 
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Summary 
This report describes clinical activity at, or associated with, general practitioner (GP) 
encounters, from April 2012 to March 2013, inclusive. It summarises results from the 
15th year of the Bettering the Evaluation and Care of Health (BEACH) program, using a 
nationally representative sample of 97,800 patient encounters with 978 randomly selected 
GPs. After post-stratification weighting, 98,564 encounters were analysed in this report. 
BEACH is a continuous cross-sectional national study that began in April 1998. Every year 
about 1,000 randomly selected GPs, each record details of 100 consecutive encounters on 
structured paper recording forms, and provide information about themselves and their 
practice. BEACH is the only continuous randomised study of general practice activity in the 
world, and the only national program that provides direct linkage of management (such as 
prescriptions, referrals, investigations) to the problem under management.  
The BEACH database now includes information for almost 1.5 million encounters from 
14,793 participants representing 9,630 individual GPs.  
In subsamples of the BEACH encounters, smaller patient-based (rather than encounter-
based) studies are conducted. This publication includes results for patient body mass index, 
smoking status and alcohol consumption, and abstracts (with the research tools) are 
provided for each of the other substudies conducted in 2012–13.  
The companion report highlighting major change over the most recent 10 years of BEACH,  
A decade of Australian general practice activity 2003–04 to 2012–13,1 is available at 
<purl.library.usyd.edu.au/sup/9781743323793>. 
The general practitioners 
Of the 978 participating GPs in 2012–13: 
• 57% were male, 41% were aged 55 years and over, 66% had graduated in Australia 
• spent an average of 37.5 hours per week (median 38 hours) in direct patient care  
• more than 55% were Fellows of the Royal Australian College of General Practitioners 
(RACGP), and 8% were Fellows of the Australian College of Rural and Remote Medicine 
(ACRRM) 
• 53% had provided care in a residential aged care facility in the previous month 
• 69% practised in Major cities (using the Australian Standard Geographical Classification) 
• 51% were in practices of fewer than five full-time equivalent (FTE) GPs (a mean of 4.7 
FTE GPs per practice and a median of 4 FTE GPs) 
• 82% worked in a practice employing practice nursing staff 
• nearly two-thirds (63%) had a co-located pathology laboratory or collection centre in, or 
within, 50 metres of the practice and almost half (49%) had a co-located psychologist  
• 44% worked in a practice that provided their own or cooperative after-hours care 
• 96% of GPs were producing prescriptions electronically, and more than two-thirds (70%) 
reported they used electronic medical records exclusively (that is, were paperless). 
There were no significant differences in the characteristics of the final sample of BEACH 
participants and all GPs in the sample frame in terms of sex, place of graduation, state, or 
practice location by the Australian Standard Geographical Classification. However, in the 
final BEACH GP sample there was a slight under-representation of GPs in the 35–44 year age 
 xiv 
group, and a slight over-representation in the 45–54 year age group, compared with the 
Australian sample frame. 
There was no statistically significant difference in the ‘activity level’ of GP participants 
compared with GPs in the sample frame, based on comparison of the mean number of 
Medicare Benefits Schedule (MBS) claims over the previous year. 
The encounters 
After weighting the data for the minor differences in GP activity and the age–sex distribution 
of the GP participants, the age–sex distribution of patients at BEACH encounters had an 
excellent fit (precision ratios 0.91–1.09), with that of patients at all GP services claimed 
through the MBS.  
• On average, patients gave 155 reasons for encounter (RFEs), and GPs managed about 155 
problems per 100 encounters. 
• Chronic problems accounted for 36%, and new problems for 37% of all problems. 
• Work-related problems were managed at a rate of 2.4 per 100 encounters. 
• At an ‘average’ 100 encounters, problem management involved: 103 medications 
[prescribed, supplied or advised for over-the-counter (OTC) purchase], 47 pathology 
tests/batteries of tests; 37 clinical treatments; 17 procedures; 15 referrals (including 9 to 
medical specialists and 5 to allied health services); and 10 imaging tests. 
• Direct encounters (patient seen) accounted for 98% of encounters at which a payment 
source was recorded. Of these: 97% were claimable either through the MBS or the 
Department of Veterans’ Affairs (DVA); 2% through workers compensation, 1% through 
other sources. 
In a subsample of 34,928 BEACH MBS/DVA-claimable encounters at which start and finish 
times were recorded, mean consultation length was 15.6 minutes, median 14.0 minutes. 
Who were the patients?  
• Females accounted for 57% of encounters, and the greater proportion of encounters in  
all adult age groups. Children (aged < 15 years) accounted for 12% of encounters,  
those aged 15–24 (8%), 25–44 (22%), 45–64 (28%), 65–74 (14%), and 75 and over (16%). 
• The patient was new to the practice at 7% of encounters, held a Commonwealth 
concession card at 46%, and was from a non-English-speaking background at 12%. 
• At 1.5% of encounters the patient identified themselves as an Aboriginal and/or Torres 
Strait Islander person. 
For every 100 encounters, patients gave 155 RFEs: 64 symptom and complaint RFEs, 30 
diagnosis/disease RFEs, and 60 requests for processes of care (e.g. procedures, referrals). 
What problems do GPs manage at patient encounters? 
There were 152,517 problems managed, an average 155 per 100 encounters: one problem was 
managed at 62% of encounters, two or three being managed at 35%, and four at 3%. The 
number managed increased with the age-group of patients. 
Two-thirds (67%) of problems were described as diagnoses or diseases, 19% in terms of 
symptoms or complaints, and 9% as diagnostic or preventive procedures (e.g. check-ups). 
• The most commonly managed were: respiratory problems (20 per 100 encounters), 
problems of a general and unspecified nature (19), musculoskeletal problems (18), skin 
(17), and cardiovascular (17). 
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• Individual problems managed most often were hypertension (8.6 per 100 encounters), 
check-ups (6.4), upper respiratory tract infection (URTI) (5.8), immunisation/vaccination 
(5.0), and diabetes (4.2). 
• At least one chronic problem was managed at 42% of encounters and 56 chronic 
problems were managed per 100 encounters.  
• Over half of all chronic problems managed were accounted for by: non-gestational 
hypertension (15.4% of chronic conditions), non-gestational diabetes (7.6%), depressive 
disorder (7.3%), chronic arthritis (6.8%), lipid disorder (6.0%), oesophageal disease 
(4.7%), and asthma (3.9%). Extrapolation of these results to the 126.8 million Medicare 
GP consultation items claimed in 2012–13 suggests there were 10.9 million encounters 
involving non-gestational hypertension, 5.3 million involving non-gestational diabetes 
and 5.2 million involving depression. 
What management actions were recorded for problems managed? 
For an ‘average’ 100 problems they managed, GPs provided 54 prescriptions and 24 clinical 
treatments, undertook 11 procedures, made 6 referrals to medical specialists and 3 to allied 
health services, and placed 30 pathology test orders and 7 imaging test orders. 
Medications  
There were 101,065 medications, 103 per 100 encounters but only 66 per 100 problems 
managed: 81% were prescribed, 10% supplied by the GP and 9% recommended for OTC 
purchase. Extrapolation of these results suggests that, across Australia in 2012–13, GPs wrote 
about 106 million prescriptions, supplied 12.6 million medications directly to the patient, and 
advised medications for OTC purchase 11.9 million times. 
• At least one medication (most prescribed) was given for 52% of problems managed. 
• No repeats were given for 35% of prescriptions, and five repeats were ordered for 37%. 
The ordering of one repeat was also quite common (16%).  
• Medication types most often prescribed were those acting on: the nervous system  
(23.4% of scripts), particularly opioids (7.2%) and antidepressants (4.8%); and the 
cardiovascular system (19.1%), particularly antihypertensives and lipid lowering agents. 
The most commonly prescribed individual medications were: the antibiotics amoxycillin 
(3.6% of all prescriptions), cephalexin (3.2%) and amoxycillin with potassium clavulanate 
(2.4%); the analgesics paracetamol (3.0%) and paracetamol/codeine (2.1%); the opioid 
oxycodone (2.0%); and the proton pump inhibitor esomeprazole (1.9%). 
• Medications were GP-supplied at a rate of 6 per 100 problems managed and vaccines 
accounted for the vast majority of these. 
• Medications were advised for OTC purchase at a rate of 6 per 100 problems managed. 
Paracetamol accounted for 26% of these and ibuprofen for 6%.  
Other treatments  
At least one other treatment was provided at 41% of encounters and 53,163 other treatments 
were recorded, 68% being clinical treatments (such as advice and counselling).  
Clinical treatments: 36,023 clinical treatments were recorded, 37 per 100 encounters, or 24 
per 100 problems managed. General advice and education (16% of clinical treatments), and 
counselling about the problem being managed (14%) were most common. Preventive 
counselling/advice about nutrition and weight, exercise, smoking, lifestyle, prevention, 
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and/or alcohol, was also frequently provided by GPs (together at a rate of 7.7 per 
100 encounters).  
Of all problems for which clinical treatments were provided, the top 10 accounted for 30%. 
The most common were URTI (6.0% of problems with clinical treatments), depression (5.1%), 
diabetes (3.6%) and hypertension (3.2%).  
Procedural treatments: 17,140 procedural treatments were recorded, 17 per 100 encounters, 
or 11 per 100 problems. The most common were: excision (17% of procedural treatments), 
dressing (14%), local injection (13%) and rehabilitation (8%). 
Practice nurse/Aboriginal health worker activity  
These data are limited to practice nurse (PN) and/or Aboriginal health worker (AHW) work 
associated with recorded GP–patient encounters.  
• PNs/AHWs were involved in 7.4% of encounters and their action(s) recorded at 7.3% of 
encounters for 5% of all problems managed. In this first full BEACH year of data post- 
removal of many PN item numbers from the MBS, a PN/AHW Medicare item number 
was recorded for only 3.9% of those encounters involving a PN/AHW, the most 
common being for care provided to a person with chronic disease (91.8%% of PN/AHW 
item number claims). 
• The majority (86.2%) of their activities were procedural and these procedures 
represented 34.0% of all procedures recorded. Clinical treatments accounted for 13.8% of 
PN/AHW activity, but only 3.1% of all recorded clinical treatments.  
• The most common procedures done by PNs/AHWs were injections (34% of recorded 
procedures), dressings (19%), check-ups (9%) and INR tests (7%).  
Referrals and admissions  
There were a total of 14,561 referrals, 15 per 100 encounters or 10 per 100 problems managed. 
The most frequent were to medical specialists (9 per 100 encounters, 6 per 100 problems 
managed), followed by referrals to allied health services (5 per 100 encounters, 3 per 100 
problems). Very few patients were referred to hospitals or emergency departments (0.6 per 
100 encounters, 0.4 per 100 problems).  
Referrals to specialists were most often to orthopaedic surgeons (9% of specialist referrals), 
surgeons (9%), dermatologists (8%) and ophthalmologists (8%). Malignant skin neoplasms, 
diabetes, osteoarthritis and pregnancy were the problems most often referred to specialists. 
The five problems most frequently referred to each of the ten most common medical 
specialties are described in Section 11.3. They may represent a small or large proportion of all 
problems referred to a particular specialty. For example, the top five problems accounted for 
25.5% of referrals to surgeons (indicative of the broad range of conditions referred to them), 
and for 76.2% of referrals to psychiatrists, suggesting a more defined range of problems 
referred. 
Referrals to allied health services were most often to physiotherapists (28% of allied health 
referrals), psychologists (19%), podiatrists (10%) and dietitians/nutritionists (8%). Problems 
most likely to be referred were depression, diabetes and back complaints.  
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Tests and investigations  
Pathology tests ordered: GPs recorded 46,398 orders for pathology tests/batteries, at a rate 
of 47 per 100 encounters (30 per 100 problems managed). At least one pathology test was 
recorded at 18% of encounters (for 14% of problems managed). 
• Chemistry tests accounted for 59% of pathology test orders, the most common being: 
lipid tests (2.7 per 100 problems managed); electrolytes, urea and creatinine (2.0); multi-
biochemical analysis (1.9); and thyroid function tests (1.8 per 100).  
• Haematology tests accounted for 18% of pathology and included full blood count, the 
most frequently ordered individual test (14% of all pathology), 4.3 being ordered per 100 
problems managed. 
• Microbiology accounted for 13% of pathology orders. Urine microscopy, culture and 
sensitivity was the most frequent test ordered within the group.  
• Almost 40% of all pathology tests were generated by orders for 10 problems, led by 
diabetes, hypertension, general check-ups, and lipid disorders.  
Imaging ordered: There were 10,163 imaging test orders recorded, 10 per 100 encounters and 
7 per 100 problems managed. At least one imaging test was ordered at 9% of encounters (for 
6% of problems managed). Diagnostic radiology accounted for 43%, ultrasound 41%, and 
computerised tomography for 12% of all imaging orders.  
Patient risk factors 
Overweight and obesity in adults (18 years and over): Of 31,452 adults, 61% (69% of males 
and 56% of females) were overweight or obese: 35% being overweight and 27% obese. After 
adjustment for attendance patterns by age–sex, prevalence in adults who attended general 
practice at least once in 2012–13 was estimated as 34% overweight and 26% obese. 
Overweight and obesity in children (2–17 years): Of 3,069 children, 26% were overweight 
(17%) or obese (9%). Prevalence and age pattern did not differ between the sexes. 
Smoking status (adults 18 years and over): Of 32,499 adults, 14% (18% of men and 12% of 
women) were daily smokers and this was most prevalent among 25–44 year olds (21%). 
Adjusted to the attending population, prevalence of daily smoking was 17%. 
Alcohol consumption in adults (18 years and over): Of 31,640 adult patients, 24% (29% of 
men and 21% of women) reported drinking at-risk levels of alcohol. This was most 
prevalence among 18–24 year olds. Adjusted to the attending population, 27% reported at-
risk alcohol consumption. 
Adult risk profile (18 years and over): Of the 30,345 patients for whom all three risk factor 
data were available: 26% had no risk factors, 52% had one, 19% had two, and 3% had three. 
Adjusted to the attending population, one in four patients had at least two risk factors.  
Management of patients with Type 2 diabetes 
Chapter 14 reports changes in policy and practise in the care of patients with Type 2 diabetes 
over the previous decade. It demonstrates the complexity of the care required for these 
patients, 93% of whom have multiple chronic conditions (multimorbidity). It shows that 
these patients attend more often and spend longer with their GP, than other patients. They 
are frequently referred to other medical specialists and allied health professionals, have high 
rates of pathology testing and medication. The implications of these findings are discussed. 
  
1 Introduction 
This publication is the 15th annual report and the 33rd book in the General Practice Series 
from the BEACH (Bettering the Evaluation and Care of Health) program, a continuous 
national study of general practice activity in Australia. It provides the annual results for the 
period April 2012 to March 2013 inclusive, using details of 97,800 encounters between general 
practitioners (GPs) and patients (almost a 0.1% sample of all general practice encounters) from 
a random sample of 978 practising GPs across the country.  
Released in parallel with this report is a summary of results from the most recent 10 years of 
the BEACH program, A decade of Australian general practice activity 2003–04 to 2012–13,1 
available at <purl.library.usyd.edu.au/sup/9781743323793>. The BEACH program began in 
April 1998 and was the culmination of about 20 years research and development work at the 
University of Sydney. BEACH is currently supported financially by government and private 
industry (see Acknowledgments). 
BEACH is the only continuous randomised study of general practice activity in the world, 
and the only national program that provides direct linkage of management actions (such as 
prescriptions, referrals, investigations) to the problem under management. The BEACH 
database now includes information for almost 1.5 million encounters from 14,793 
participants representing 9,630 individual GPs. 
1.1 Background 
In June 2012, the population of Australia was estimated to be 22.7 million people.2 Australia’s 
health expenditure in 2010–11 was $130.3 billion, an average $5,796 per head of population, 
and accounted for 9.3% of GDP. Governments funded 69.9%, with the remainder (30.1%) 
being paid by the non-government sector.3 Government expenditure on general practice 
services (including those of practice nurses) was almost $5.6 billion dollars in the 2011–12 
financial year.4 
GPs are usually the first port of call in the Australian healthcare system. Payment for GP 
visits is largely on a fee-for-service system, there being no compulsory patient lists or 
registration. People are free to see multiple practitioners and visit multiple practices of their 
choice. There is a universal medical insurance scheme (managed by Medicare Australia), 
which covers all or most of an individual’s cost for a GP visit.  
In Australia in 2011, there were 25,056 practising GPs (medical practitioners self-identifying 
as GPs), making up 25,063 full-time equivalents (FTE, based on a 40-hour week), or 109.7 FTE 
GPs per 100,000 people.5  
In the April 2012 to March 2013 year, about 85% of the Australian population claimed at least 
one GP service from Medicare (personal communication, Department of Health and Ageing 
[DoHA], June 2013). In the same period, Medicare paid rebates for about 126.8 million 
claimed general practice service items (excluding practice nurse items),6 at an average of 
about 5.59 GP visits per head of population or 6.57 visits per person who visited at least 
once. This equates to about 2.44 million GP–patient encounters per week.  
While Medicare statistics provide information about frequency and cost of visits claimed 
from Medicare for GP service items, they cannot tell us about the content of these visits. The 
BEACH program fills this gap. 
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1.2 The BEACH program 
In summary, the BEACH program is a continuous national study of general practice activity 
in Australia. Each year an ever changing random sample of about 1,000 practising GPs 
participate, each recording details of 100 patient encounters on structured paper-based 
recording sheets (Appendix 1). This provides details of about 100,000 GP–patient encounters 
per year. They also provide information about themselves and their major practice 
(Appendix 2). The BEACH methods are described in Chapter 2 of this report. 
Aims 
The three main aims of the BEACH program are to: 
• provide a reliable and valid data collection process for general practice that is responsive 
to the ever-changing needs of information users, and provides insight into the evolving 
character of GP–patient encounters in Australia 
• provide an ongoing database of GP–patient encounter information 
• assess patient risk factors and health states, and the relationship these factors have with 
health service activity. 
Current status of BEACH 
BEACH began in April 1998 and is now in its 16th year. The BEACH database now includes 
records for 1,479,300 GP–patient encounters from 14,793 participating GPs. Each year we 
publish an annual report of BEACH results collected in the previous 12 months. This 
publication reports results from April 2012 to March 2013. The companion publication  
A decade of Australian general practice activity 2003–04 to 2012–13,1 provides summaries of 
changes in the most frequent events over the decade.  
The strengths of the BEACH program 
• BEACH is the only national study of general practice activity in the world that is 
continuous, relying on a random ever-changing sample of GPs, and directly linking 
management actions to the morbidity under management.  
• The sheer size of the GP sample (1,000 per year) and the relatively small cluster of 
encounters around each GP provide more reliable estimates than a smaller number of 
GPs with large clusters of patients and/or encounters.7 Our access to a regular random 
sample of recognised GPs in active practice, through DoHA, ensures that the GP sample 
is drawn from a very reliable sample frame of currently active GPs. 
• There are sufficient details about the characteristics of all GPs in the sample frame to test 
the representativeness of the final sample, and to apply post-stratification weighting to 
correct for any under or over-representation in the sample when compared with the 
sample frame. The ever-changing nature of the sample (where each GP can participate 
only once per triennium) ensures reliable representation of what is happening in general 
practice across the country. The sampling methods ensure that new entrants to the 
profession are available for selection because the sample frame is based on the most 
recent Medicare data.  
• Where data collection programs use a fixed set of GPs over a long period, they are 
measuring what that group is doing at any one time, or how that group has changed 
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over time, and there may well be a ‘training effect’ inherent in longer-term participation. 
Such measures cannot be generalised to the whole of general practice. Further, where 
GPs in the group have a particular characteristic in common (for example, all belong to a 
professional organisation to which not all GPs belong; all use a selected software system 
which is not used by all GPs), the group is biased and cannot represent all GPs. 
• Each GP records for a set number of encounters (100), but there is wide variance among 
them in the number of patient consultations they conduct in any one year. DoHA 
therefore provides an individual count of activity level (that is, number of Medicare GP 
service items claimed in the previous period) for all randomly sampled GPs, allowing us 
to give a weighting to each GP’s set of encounters commensurate with his or her 
contribution to total general practice encounters. This ensures that the final encounters 
represent encounters with all GPs. 
• The structured paper encounter form leads the GP through each step in the encounter, 
encouraging entry of data for each element (see Appendix 1), with instructions and an 
example of a completed form. In contrast, systems such as electronic health records rely 
on the GP to complete fields of interest without guidance. 
• BEACH includes all patient encounters and management activities provided at these 
encounters, not just those encounters and activities funded by Medicare.  
• The medication data include all prescriptions, rather than being limited to those 
prescribed medications covered by the Pharmaceutical Benefits Scheme (PBS).  
• BEACH is the only source of information on medications supplied directly to the patient 
by the GP, and about the medications GPs advise for over-the-counter (OTC) purchase, 
the patients to whom they provide such advice and the problems managed in this way.  
• The inclusion of other (non-pharmacological) treatments such as clinical counselling and 
procedural treatments provides a broader view of the interventions used by GPs in the 
care of their patients than other data sources.  
• The link from all management actions (for example, prescribing, ordering tests) to the 
problem under management provides a measure of the ‘quality’ of care rather than just a 
count of the number of times an action has occurred (for example, how often a specific 
drug has been prescribed). 
• The use of an internationally standard well-structured classification system (ICPC-2)8 
designed specifically for general practice, together with the use of an extended 
vocabulary of terms which facilitates reliable classification of the data by trained 
secondary coders, removes the guesswork often applied in word searches of available 
records (in free text format) and in classification of a concept.  
• The use of the World Health Organization’s (WHO) Anatomical Therapeutic Chemical 
(ATC) classification for pharmaceuticals at the generic level ensures reporting of 
medications data is in terms of the international standard. 
• The analytical techniques applied to the BEACH data ensure that the clustering inherent 
in the sampling methods is dealt with. Results are reported with 95% confidence 
intervals. Users are therefore aware of how reliable any estimate might be. 
• Reliability of the methods is demonstrated by the consistency of results over time where 
change is not expected, and by the measurement of change when it might be expected.  
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1.3 Using BEACH data with other national data 
Users of the BEACH data might wish to integrate information from multiple national data 
sources, to gain a more comprehensive picture of the health and health care of the Australian 
community. It is therefore important that readers are aware of how the BEACH data differ 
from those drawn from others. This section summarises differences between BEACH and 
other national sources of data about general practice in Australia. 
The Pharmaceutical Benefits Scheme  
Prescribed medications paid under the PBS are recorded by Medicare Australia. The PBS 
data: 
• count the prescription each time it crosses the pharmacist’s counter (so that one 
prescription written by the GP with five repeats in BEACH would be counted by the 
PBS six times if the patient filled all repeats) 
• count only those prescribed medications subsidised by the PBS and costing more than 
the minimum subsidy (and therefore covered by the PBS for all patients), or medications 
prescribed for those holding a Commonwealth concession card or for those who have 
reached the safety net threshold  
• will change with each change in the PBS co-payment level for non-Commonwealth 
concession cardholders – when the co-payment level increases, those medications  
that then fall under the new level will no longer be counted in the PBS for  
non-Commonwealth concession cardholders9 
• hold no record of the problem being managed (with the exception of authority 
prescriptions, which require an indication and account for a small proportion of PBS 
data). Morbidity cannot be reliably assumed on the basis of medication prescribed.10-12 
In BEACH: 
• total medications include those prescribed (whether covered by the PBS or not), those 
supplied to the patient directly by the GP, and those advised for OTC purchase 
• each prescription recorded, reflects the GP’s intent that the patient receives the 
prescribed medication, and the specified number of repeats; the prescription, irrespective 
of the number of repeats ordered, is counted only once  
• the medication is directly linked to the problem being managed by the GP 
• there is no information on the number of patients who do not present their prescription 
to be filled (this also applies to the PBS). 
These differences have a major impact on the numbers of prescriptions counted and also 
affect their distribution. For example, the majority of broad spectrum antibiotics such as 
amoxycillin fall under the PBS minimum subsidy level and would not be counted in the 
PBS data, except where patients received the medication under the PBS because they are 
Commonwealth concession cardholders or had reached the annual safety net threshold.9 
Medicare Benefits Schedule 
Consultations with GPs that are paid for in-part, or in-full, through the Medicare Benefits 
Schedule (MBS) are recorded by Medicare Australia. 
• Publicly available MBS claims data do not include data about patients and encounters 
funded through the Department of Veterans’ Affairs (DVA).  
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• The MBS data include GP services that have been billed to Medicare. BEACH includes 
all consultations, irrespective of whether a charge is made or who pays for it.  
• The MBS data reflect the item number charged to Medicare for a service and some 
patient demographics, but hold no information about the content of the consultation. 
• BEACH participants were limited to recording three Medicare item numbers for each 
encounter. In contrast, MBS data include all Medicare item numbers claimed. In the 
BEACH data set this may result in a lower number of ‘other’ Medicare items than would 
be counted in the Medicare data.  
• In activities of relatively low frequency with a skewed distribution across individual 
GPs, the relative frequency of the event in the BEACH data may not reflect that reported 
in the MBS data. For example, a 2002 study of early uptake of some enhanced primary 
care items by GPs demonstrated that almost half the enhanced primary care items 
claimed came from about 6% of active GPs.13 Where activity is so skewed across the 
practising population, a national random sample will provide an underestimate of 
activity because the sample reflects the population rather than the minority. 
• One of the advantages of BEACH over the MBS is also the relative consistency over time 
of the data collection form. BEACH is relatively resilient to changes in MBS payment 
policies, such as the inclusion or removal of items from the MBS.  
Pathology data from the MBS 
Pathology tests undertaken by pathologists that are charged to Medicare are recorded by 
Medicare Australia. However, these Medicare data are not comparable with BEACH data. 
• MBS pathology data reflect pathology orders made by GPs and other medical specialists. 
About 70% of the volume of MBS pathology data are generated by GP orders.14 
• Each pathology company can respond differently to a specific test order label recorded 
by the GP. For example, the tests completed by a pathologist in response to a GP order 
for a multi-biochemical analysis may differ between companies. 
• The pathology companies can charge through the MBS only for the three most expensive 
items undertaken, even when more were actually done. This is called ‘coning’ and is part 
of the DoHA pathology payment system. This means that the tests recorded in the MBS 
include only those charged for, not all those that were done. Coning applies only to GP 
pathology orders, not to those generated by medical specialists. 
• This means that the MBS pathology data reflect those tests billed to the MBS after 
interpretation of the order by the pathologist, and after selection of the three most 
expensive items.  
• Pathology MBS items contain pathology tests that have been grouped on the basis of cost 
(for example, ‘any two of the following … tests’). Therefore an MBS item often does not 
give a clear picture of the precise tests performed. 
In BEACH, the pathology data: 
• include details of pathology tests ordered by the participating GPs; however, the GP is 
limited to the recording of five tests or battery of tests at each encounter, and as the 
number of tests/batteries ordered on any single occasion is increasing,15 an increasing 
number of additional tests ordered will be lost 
• reflect the terms used by GPs in their orders to pathologists, and for reporting purposes 
these have been grouped by the MBS pathology groups for comparability.  
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The distributions of the two data sets will therefore differ, reflecting on the one hand the GP 
order and on the other the MBS-billed services from the pathologist. 
Pathology ordering by GPs is described in Chapter 12 of this report. Those interested in 
pathology test ordering by GPs should also view the following publications: 
• Are rates of pathology test ordering higher in general practices co-located with pathology 
collection centres?16 This publication investigated the independent effect of general 
practice co-location with pathology collection centres on GP pathology test ordering in 
Sydney and Melbourne metropolitan areas.  
• Evidence-practice gap in GP pathology test ordering: a comparison of BEACH pathology data and 
recommended testing.17 
• Changes in pathology ordering by general practitioners in Australia 1998–2001.18  
Imaging data from the MBS 
Some of the issues discussed regarding pathology data also apply to imaging data. Although 
coning is not an issue for imaging, radiologists can decide whether the test ordered by the 
GP is the most suitable and whether to undertake other tests of their choosing. The MBS data 
therefore reflect the tests that are actually undertaken by the radiologist, whereas the 
BEACH data reflect those ordered by the GP.  
The Australian Health Survey 
The 2011–13 Australian Health Survey, conducted by the Australian Bureau of Statistics 
(ABS), includes the National Health Survey, the National Nutrition and Physical Activity 
Survey and the National Health Measures Survey. The National Health Survey provides 
estimates of population prevalence of some diseases, and a measure of the problems taken to 
the GP by people in the two weeks before the survey. The National Health Measures Survey 
includes biomedical measures related to chronic disease and nutritional biomarkers.19 
• Prevalence estimates from the National Health Survey are based on self-reported 
morbidity from a representative sample of the Australian population, using a structured 
interview to elicit health-related information from participants. Prevalence estimates 
from the National Health Measures Survey are based on biomedical measures of 
diagnosed and undiagnosed disease.19  
• Community surveys such as the National Health Survey have the advantage of accessing 
people who do not go to a GP as well as those who do. They can therefore provide an 
estimate of population prevalence of disease and a point estimate of incidence of disease. 
Prevalence estimates based on biomedical measures have the advantage of measuring 
diagnosed and undiagnosed disease. 
• Self-report has been demonstrated to be susceptible to misclassification because of a lack 
of clinical corroboration of diagnoses.20 
Management rates of health problems in general practice represent GP workload for a health 
problem. BEACH can be used to estimate the period incidence of diagnosed disease 
presenting in general practice through the number of new cases of that disease. The 
management rates of individual health problems and management actions can be 
extrapolated to national management rates.  
The general practice patient population sits between the more clinical hospital-based 
population and the general population,21,22 with about 85% of Australians visiting a GP at 
least once in 2012–13 (personal communication, DoHA, June 2013). Disease management 
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rates are a product of both the prevalence of the disease/health problem in the population, 
and the frequency with which a patient visits a GP for the treatment of that problem. Those 
who are older and/or have more chronic disease, are therefore likely to visit more often, and 
have a greater chance of being sampled in the encounter data.  
Prevalence of selected diseases among patients seen in general practice can be investigated 
using the Supplementary Analysis of Nominated Data method (see Section 2.6). Those 
interested in disease prevalence should refer to the following papers: Estimating prevalence of 
common chronic morbidities in Australia,23 Prevalence and patterns of multimorbidity in Australia,24 
and Prevalence of chronic conditions in Australia.25 
1.4 Access to BEACH data 
Different bundles of BEACH data are available to the general public, to 
BEACH-participating organisations, and to other organisations and researchers. 
Public domain 
This annual publication provides a comprehensive view of general practice activity in 
Australia. The BEACH program has generated many papers on a wide variety of topics in 
journals and professional magazines. All published material from BEACH is available at 
<sydney.edu.au/medicine/fmrc/publications>. 
Since April 1998, a section at the bottom of each encounter form has been used to investigate 
aspects of patient health or healthcare delivery not covered by general practice 
consultation-based information. These additional substudies are referred to as SAND 
(Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. Abstracts of results and the research tools used in all SAND substudies from 
April 1998 to March 2013 have been published. Those from: 
• April 1998 to March 1999 were published in Measures of health and health care delivery in 
general practice in Australia26 
• April 1999 to July 2006 were published in Patient-based substudies from BEACH: abstracts 
and research tools 1999–200627 
• August 2006 to March 2012 were published in each of the BEACH annual reports28-33 
• April 2012 to March 2013 are included in Chapter 15 of this report. 
Abstracts of results for all SAND substudies are also available on the Family Medicine 
Research Centre’s (FMRC) website <sydney.edu.au/medicine/fmrc/publications/sand-
abstracts> where you can search by topic. 
Participating organisations 
Organisations providing funding for the BEACH program receive summary reports of the 
encounter data quarterly, and standard reports or specifically designed analyses about their 
subjects of interest. Participating organisations also have direct access to straightforward 
analyses on any selected problem, medication, pathology or imaging test through an 
interactive web server. All data made available to participating organisations have been 
further ‘de-identified’. Patients’ are not identifiable even from the original encounter data 
forms, but are further stripped of date of birth (replaced with age in years and months) and 
postcode of residence (replaced with state and area type). GP characteristics data are 
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provided only in the form of grouped output (for example, GPs aged less than 35 years) to 
any organisation. 
External purchasers of reports 
Non-contributing organisations may purchase standard reports or other ad hoc analyses. 
Charges are outlined at <sydney.edu.au/medicine/fmrc/beach/data-reports/for-
purchase>. The FMRC should be contacted for specific quotations. Contact details are 
provided at the front of this publication. 
Analysis of the BEACH data is a complex task. The FMRC has designed standard reports 
that cover most aspects of a subject under investigation. Examples of a problem-based 
standard report (subject: ischaemic heart disease in patients aged 45 years and over), a group 
report (subject: female patients aged 15–24 years) and a pharmacological-based standard 
report (subject: allopurinol) for a single year’s data are available at 
<sydney.edu.au/medicine/fmrc/beach/data-reports/for-purchase>. 
Customised data analyses can be done where the specific research question is not adequately 
answered through standard reports.  
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2 Methods  
In summary: 
• each year, BEACH involves a new random sample of about 1,000 GPs 
• each GP records details about 100 doctor–patient encounters of all types  
• the GP sample is a rolling (ever-changing) sample, with about 20 GPs participating in 
any one week, 50 weeks a year (with 2 weeks break over Christmas) 
• each GP can be selected only once per Quality Improvement & Continuing Professional 
Development (QI & CPD) Program triennium (that is, once in each three-year period) 
• the encounter information is recorded by the GPs on structured paper encounter forms 
(Appendix 1) 
• GP participants also complete a questionnaire about themselves and their practice 
(Appendix 2). 
2.1 Sampling methods 
The source population includes all vocationally registered GPs and all general practice 
registrars who claimed a minimum of 375 Medicare general practice items of service in the 
most recently available three-month Medicare data period (which equates to 1,500 such 
claims in a year). This ensures inclusion of the majority of part-time GPs, while excluding 
those who are not in private practice but claim for a few consultations a year. 
The Medicare statistics section of the DoHA updates the sample frame from the Medicare 
records quarterly, using the Medicare claims data, then removes from the sample frame any 
GPs already randomly sampled in the current triennium, and draws a new sample from 
those remaining in the sample frame. This ensures the timely addition of new entries to the 
profession, and timely exclusion of those GPs who have stopped practising, or have already 
participated or been approached in the current triennium. 
2.2 Recruitment methods 
The randomly selected GPs are approached by letter, posted to the address provided by 
DoHA. 
• Over the following 10 days, the telephone numbers generated from the Medicare data 
are checked using the electronic white and yellow pages. This is necessary because many 
of the telephone numbers provided from the Medicare data are incorrect. 
• The GPs are then telephoned in the order they were approached and, referring to the 
approach letter, asked whether they will participate. 
• This initial telephone contact with the practice often indicates that the selected GP has 
moved elsewhere, but is still in practice. Where new address and/or telephone number 
can be obtained, these GPs are followed up at their new address. 
• GPs who agree to participate are set an agreed recording date several weeks ahead. 
• A research pack is sent to each participant before the planned start date. 
• Each GP receives a telephone reminder early in the agreed recording period – this also 
provides the GP with an opportunity to ask questions about the recording process. 
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• GPs can use a ‘freecall’ (1800) number to ring the research team with any questions 
during their recording period. 
• Non-returns are followed up by regular telephone calls for 3 months. 
• Participating GPs earn clinical audit points towards their QI & CPD requirements 
through the Royal Australian College of General Practitioners (RACGP) and/or the 
Australian College of Rural and Remote Medicine (ACRRM). As part of this QI process, 
each receives an analysis of his or her results compared with those of nine other de-
identified GPs who recorded at about the same time. Comparisons with the national 
average and with targets relating to the National Health Priority Areas are also 
provided. In addition, GPs receive some educational material related to the identification 
and management of patients who smoke or consume alcohol at hazardous levels. 
Additional points can be earned if the participant chooses to do a follow-up audit of 
smoking and alcohol consumption among a sample of patients about 6 months later. 
2.3 Ethics approval and informed patient consent 
Ethics approval for this study in 2012–13 was obtained from the Human Ethics Committee of 
the University of Sydney.  
Although the data collected by the GPs is not sufficient to identify an individual patient, 
informed consent for GP recording of the encounter details is required from each patient. 
GPs are instructed to ensure that all patients presenting during their recording period are 
provided with a Patient Information Card (Appendix 3), and they ask the patient if they are 
happy for their data to be included in the study. If the patient refuses, details of the 
encounter are not recorded. This is in accordance with the Ethics requirements for the 
BEACH program. 
2.4 Data elements 
BEACH includes three interrelated data collections: GP characteristics, encounter data and 
patient health status. An example of the form used to collect the encounter data and the data 
on patient health status is included in Appendix 1. The GP characteristics questionnaire is 
provided in Appendix 2. The GP characteristics and encounter data collected are 
summarised below. Patient health status data are described in Section 2.6. 
GP profile form (Appendix 2) 
• GP characteristics: age and sex, years in general practice, number of direct patient care 
hours worked per week, intended changes in hours of direct patient care in 5 years, 
country of graduation, general practice registrar status, Fellow of the RACGP status, 
Fellow of the ACRRM status, use of computers at work, work undertaken in other 
clinical settings, number of practice locations worked in a regular week. 
• Practice characteristics: postcode of major practice; number of individual, and number 
of full-time equivalent GPs working in the practice; number of individual and number of 
full-time equivalent practice nurses working in the practice; usual after-hours care 
arrangements, other health services located at the major practice. 
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Encounter recording form (Appendix 1) 
• Encounter data: date of consultation, type of consultation (direct/indirect) (tick box 
options), up to three MBS/DVA item numbers (where applicable), and other payment 
source (where applicable) (tick boxes). 
• Patient data: date of birth, sex and postcode of residence. Tick boxes (yes/no options) 
are provided for Commonwealth concession cardholder, holder of a Repatriation Health 
Card (from DVA), non-English-speaking background (patient self-report – a language 
other than English is the primary language at home), Aboriginal person (self-
identification), and Torres Strait Islander person (self-identification). Space is provided 
for up to three patient reasons for encounter (RFEs) (see ‘Glossary’). 
• The problems managed at encounter (at least one and up to four). Tick boxes are 
provided to denote the status of each problem as new or continuing for the patient and 
whether the problem is considered by the GP to be work-related. 
• Management of each problem, including: 
– medications prescribed, supplied by the GP and advised for over-the-counter 
purchase including brand name, form (where required), strength, regimen, status 
(new or continuing medication for this problem), number of repeats 
– other treatments provided for each problem, including counselling, advice and 
education, and procedures undertaken, and whether the recorded other treatment 
was provided by practice nurse (tick box) 
– new referrals to medical specialists, allied health services, emergency departments, 
and hospital admissions 
– investigations, including pathology tests, imaging and other investigations ordered.  
2.5 The BEACH relational database 
The BEACH relational database is described diagrammatically in Figure 2.1. Note that:  
• all variables can be directly related to the encounter, the GP and the patient 
characteristics 
• all types of management are directly related to the problem being managed  
• RFEs have only an indirect relationship with problems managed, as a patient may 
describe one RFE (such as ‘repeat prescriptions’) that is related to multiple problems 
managed, or several RFEs (such as ‘runny nose’ and ‘cough’) that relate to a single 
problem (such as upper respiratory tract infection) managed (see Section 6.3). 
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The encounter 
• date 
• direct (face to face) 
— Medicare/DVA item 
number(s) claimable 
— workers compensation 
— other paid 
— no charge 
• indirect (e.g. telephone) 
Patient substudies (SAND) 
• risk factors 
— body mass 
— smoking status 
— alcohol consumption  
• other topics 
Management of each problem 
Medications (up to four per problem) 
• prescribed 
• over-the-counter advised 
• provided by GP 
— drug class 
— drug group 
— generic 
— brand name 
— strength 
— regimen 
— number of repeats  
— drug status (new/continued) 
 
Other treatments (up to two per 
problem) 
• procedural treatments 
• clinical treatments (e.g. advice, 
counselling) 
• practice nurse involvement 
 
Other management 
• referrals (up to two) 
— to specialists 
— to allied health professionals 
— to emergency departments 
— hospital admissions 
• pathology tests ordered (up to five) 
• imaging ordered (up to three) 
GP characteristics 
• age and sex 
• years in general practice 
• country of graduation 
• direct patient care hours/week 
• FRACGP status (yes/no) 
• FACRRM status (yes/no) 
• currently a registrar (yes/no) 
• clinical use of computers  
 
Practice characteristics 
• practice size (no. & FTE GPs) 
• practice nurse(s) (no. & FTE) 
• after-hours arrangements 
• postcode  
• presence of other health services 
Problems managed 
• diagnosis/problem label 
• problem status (new/old) 
• work-related problem status 
The patient 
• age and sex 
• practice status (new/old) 
• Commonwealth concession 
card status 
• Repatriation Health Card status 
• postcode of residence 
• NESB/Indigenous status 
• reasons for encounter 
Note: FRACGP – Fellow of the Royal Australian College of General 
Practitioners; FACRRM – Fellow of the Australian College of Rural 
and Remote Medicine; FTE – full-time equivalent; DVA – Department 
of Veterans’ Affairs; NESB – non-English-speaking background;  
SAND – Supplementary Analysis of Nominated Data. 
Figure 2.1: The BEACH relational database 
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2.6 Supplementary Analysis of Nominated Data  
A section at the bottom of each recording form investigates aspects of patient health or 
health care delivery in general practice not covered by the consultation-based data. These 
additional substudies are referred to as SAND, Supplementary Analysis of Nominated Data. 
• Each year the 12-month data period is divided into ten blocks, each of 5 weeks, with 
three substudies per block. The research team aims to include data from about 100 GPs 
in each block.  
• Each GP’s pack of 100 forms is made up of 40 forms that ask for the start and finish times 
of the encounter, and include questions about patient risk factors: patient height and 
weight (used to calculate body mass index, BMI), alcohol intake and smoking status 
(patient self-report). The methods and results of topics in the SAND substudies for 
alcohol consumption, smoking status and BMI are reported in Chapter 13. The start and 
finish times collected on these encounters are used to calculate the length of consultation. 
The length of consultation for Medicare-claimable encounters is reported in Section 5.3. 
• The remaining 60 forms in each pack are divided into two blocks of 30, so each SAND 
block includes about 3,000 records. Some topics are repeated to increase sample size. 
Different questions are asked of the patient in each block and these vary throughout 
the year. 
• The order of SAND sections is rotated in the GP recording pack, so that 40 patient risk 
factor forms may appear first, second or third in the pad. Rotation of ordering ensures 
there was no order effect on the quality of the information collected. 
Abstracts of results and the research tools used in all SAND substudies from April 1998 to 
March 2012 have been published. Those: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–200627 
• conducted between August 2006 and March 2012 have been published in each of the 
general practice activity annual reports28-33 
• conducted in the 2012–13 BEACH year are provided in Chapter 15 of this publication. 
Abstracts of results for all SAND substudies are also available on the FMRC’s website 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
2.7 Statistical methods 
The analysis of the 2012–13 BEACH data was conducted with Statistical Analysis System 
(SAS) version 9.3,34 and the encounter is the primary unit of inference. Proportions are used 
only when describing the distribution of an event that can arise only once at a consultation 
(for example, patient or GP age and sex), or to describe the distribution of events within a 
class of events (for example, problem A as a percentage of total problems). Due to rounding, 
proportions may not always add to exactly 100%. 
Rates per 100 encounters are used when an event can occur more than once at the 
consultation (for example, RFEs, problems managed or medications). 
Rates per 100 problems are also used when a management event can occur more than once 
per problem managed. In general, the results present the number of observations (n), the rate 
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per 100 encounters, and (in the case of management actions) the rate per 100 problems 
managed, and the 95% confidence interval. 
BEACH is a single stage cluster sample study design, each 100 encounters forming a cluster 
around each GP participant. In cluster samples, variance needs to be adjusted to account for 
the correlation between observations within clusters. Procedures in SAS version 9.3 were 
used to calculate the intracluster correlation, and adjust the confidence intervals 
accordingly.34  
Post-stratification weighting of encounter data adjusts for: any difference in the age–sex 
distribution of the participating GPs and those GPs in the sample frame from which the 
samples were drawn; and for the varying activity level of each GP (measured by number of 
claims each has made in the previous 12 months from Medicare Australia) (see Chapter 3). 
Statistical significance is tested by chi square statistic for GP characteristics, but significance 
of differences in/for rates is judged by non-overlapping confidence intervals of the results 
being compared. The magnitude of this difference can be described as at least p < 0.05. 
Assessment using non-overlapping confidence intervals (CIs) is a conservative measure of 
significance,35-37 particularly when differences are assessed by comparing results from 
independent random samples, as is the case when changes over time are investigated using 
BEACH data. Due to the number of comparisons made in this and the companion 
publication, we believe a conservative approach is warranted. 
2.8 Classification of data 
The following data elements are classified according to the International Classification of 
Primary Care – Version 2 (ICPC-2), a product of the World Organization of Family Doctors 
(Wonca):8 
• patient reasons for encounter (RFEs) 
• problems managed 
• clinical treatments (for example, counselling, advice) 
• procedural treatments 
• referrals 
• investigations ordered (including pathology, imaging and other investigations). 
The ICPC-2 is used in more than 45 countries as the standard for data classification in 
primary care. It is accepted by the WHO in the WHO Family of International 
Classifications,38 and is the declared national standard in Australia for reporting of health 
data from general practice and patient self-reported health information.39  
The ICPC-2 has a biaxial structure, with 17 chapters on one axis (each with an alphabetic 
code) and seven components on the other (numeric codes) (Figure 2.2). Chapters are based 
on body systems, with additional chapters for psychological and social problems. 
Component 1 includes symptoms and complaints. Component 7 covers diagnoses – it can 
also be expanded to provide data about infections, injuries, neoplasms, congenital anomalies 
and ‘other’ diagnoses.  
Component 2 (diagnostic, screening and prevention) is often applied in describing the 
problem managed (for example, check-up, immunisation). Components 3 to 6 cover other 
processes of care, including referrals, other (non-pharmacological) treatments and orders for 
pathology and imaging. The components are standard and independent throughout all 
chapters. The updated component groupings of ICPC-2 codes, released by the Wonca 
International Classification Committee in 200440 have been used in this report. 
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The ICPC-2 is an excellent epidemiological tool. The diagnostic and symptom rubrics have 
been selected for inclusion on the basis of their relative frequency in primary care settings, or 
because of their relative importance in describing the health of the community. ICPC has 
about 1,370 rubrics and these are sufficient for meaningful analyses. However, reliability of 
data entry, using ICPC-2 alone, requires a thorough knowledge of the classification for 
correct classification of a concept to be ensured. 
In 1995, recognising a need for a coding and classification system for general practice 
electronic health records, the FMRC (then the Family Medicine Research Unit, FMRU) 
developed an extended clinical terminology classified according to the ICPC, now called 
ICPC-2 PLUS.41 This is an interface terminology, developed from all the terms used by GPs 
in studies such as the Australian Morbidity and Treatment Survey 1990–91 (113,468 
encounters),42 a comparison of country and metropolitan general practice 1990–91 
(51,277 encounters),43 the Morbidity and Therapeutic Index 1992–1998 (a clinical audit tool 
that was available to GPs) (approximately 400,000 encounters), and BEACH 1998–2012 
(about 1.4 million encounters). Together, these make up about 2 million encounter records, 
involving about 3 million free text descriptions of problems managed and a further 3 million 
for patient reasons for encounter. These terms are classified according to ICPC-2 to ensure 
data can be compared internationally. Readers interested in seeing how coding works can 
download the ICPC-2 PLUS Demonstrator at <sydney.edu.au/medicine/fmrc/icpc-2-
plus/demonstrator>. 
When the free-text data are received from the GPs, trained secondary coders (who are 
undergraduate students), code the data in specific terms using ICPC-2 PLUS. This ensures 
high coder reliability and automatic classification of the concept, and allows us to ‘ungroup’ 
such ICPC-2 rubrics as ‘other diseases of the circulatory system’ and select a specific disease 
from the terms within it. 
 
                    
 Components A B D F H K L N P R S T U W X Y Z  
 1. Symptoms, complaints                    
 2. Diagnostic, screening, prevention                   
 3. Treatment, procedures, medication                   
 4. Test results                   
 5. Administrative                   
 6. Other                   
 7. Diagnoses, disease                   
 A General and unspecified L Musculoskeletal U Urinary 
 B Blood & blood-forming organs N Neurological W Pregnancy, family planning 
 D Digestive P Psychological X Female genital  
 F Eye R Respiratory Y Male genital  
 H Ear S Skin Z Social  
 K Circulatory T Endocrine, nutritional & metabolic   
 
Figure 2.2: The structure of the International Classification of Primary Care – Version 2 (ICPC-2) 
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Presentation of data classified in ICPC-2 
Statistical reporting is usually at the level of the ICPC-2 classification (for example, acute 
otitis media/myringitis is ICPC-2 code H71). However, there are some exceptions where 
data are grouped either above the ICPC-2 level or across the ICPC-2 level. These grouped 
morbidity, pathology and imaging codes are defined in Appendix 4 available at: 
<purl.library.usyd.edu.au/sup/9781743323779>. 
Reporting morbidity with groups of ICPC-2 codes 
When recording problems managed, GPs may not always be very specific. For example, in 
recording the management of hypertension, they may simply record the problem as 
‘hypertension’. In ICPC-2, ‘hypertension, unspecified’ is classified as ‘uncomplicated 
hypertension’ (code K86). There is another code for ‘complicated hypertension’ (K87). In 
some cases the GP may simply have failed to specify that the patient had hypertension with 
complications. The research team therefore feels that for national data reporting, it is more 
reliable to group the codes K86 and K87 and label this ‘Hypertension*’ – the asterisk 
indicating that multiple ICPC-2 codes (as in this example), or ICPC-2 PLUS codes (see 
below), are included. Appendix 4, Table A4.1 lists the codes included in these groups.  
Reporting morbidity with groups of ICPC-2 PLUS codes 
In other cases, a concept can be classified within (but be only part of) multiple ICPC-2 codes. 
For example, osteoarthritis is classified in ICPC-2 in multiple broader codes according to site, 
such as L92 – shoulder syndrome (includes bursitis, frozen shoulder, osteoarthritis of 
shoulder, rotator cuff syndrome). When reporting osteoarthritis in this publication, all the 
more specific osteoarthritis ICPC-2 PLUS terms classified within all the appropriate ICPC-2 
codes are grouped. This group is labelled ‘Osteoarthritis*’ – the asterisk again indicating 
multiple codes, but in this case they are PLUS codes rather than ICPC-2 codes. Appendix 4, 
Table A4.1 lists the codes included in these groups. 
Reporting chronic morbidity 
Chronic conditions are medical conditions characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern of 
recurrence or deterioration, a poor prognosis, and consequences or sequelae that affect an 
individual’s quality of life.  
To identify chronic conditions, a chronic condition list44 classified according to ICPC-2 was 
applied to the BEACH data set. In general reporting, both chronic and non-chronic 
conditions (for example, diabetes and gestational diabetes) may have been grouped together 
when reporting (for example, diabetes – all*). When reporting chronic morbidity, only 
problems regarded as chronic have been included in the analysis. Where the group used for 
the chronic analysis differs from that used in other analyses in this report, they are marked 
with a double asterisk. Codes included in the chronic groups are provided in Appendix 4, 
Table A4.2. 
Reporting pathology and imaging test orders 
All the pathology and imaging tests are coded very specifically in ICPC-2 PLUS, but ICPC-2 
classifies pathology and imaging tests very broadly (for example, a test of cardiac enzymes is 
classified in K34 – Blood test associated with the cardiovascular system; a CT scan of the 
lumbar spine is classified as L41 – Diagnostic radiology/imaging of the musculoskeletal 
system). In Australia, the MBS classifies pathology and imaging tests in groups that are 
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relatively well recognised. The team therefore regrouped all pathology and imaging ICPC-2 
PLUS codes into MBS standard groups. This allows comparison of data between data 
sources. The groups are marked with an asterisk, and inclusions are provided in Appendix 4, 
Tables A4.8 and A4.9. 
Classification of pharmaceuticals 
Pharmaceuticals that are prescribed, provided by the GP or advised for over-the-counter 
purchase are coded and classified according to an in-house classification, the Coding Atlas 
for Pharmaceutical Substances (CAPS). 
This is a hierarchical structure that facilitates analysis of data at a variety of levels, such as 
medication class, medication group, generic name/composition, and brand name. 
The generic name of a medication is its non-proprietary name, which describes the 
pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
When strength and regimen are combined with the CAPS code, we can derive the prescribed 
daily dose for any prescribed medication or group of medications. 
CAPS is mapped to the Anatomical Therapeutic Chemical (ATC)45 classification, which is the 
Australian standard for classifying medications at the generic level.39 The ATC has a 
hierarchical structure with five levels. For example: 
• Level 1: C – Cardiovascular system 
• Level 2: C10 – Serum lipid reducing agents 
• Level 3: C10A – Cholesterol and triglyceride reducers 
• Level 4: C10AA – HMG CoA reductase inhibitors 
• Level 5: C10AA01 – Simvastatin (the generic drug). 
Use of the pharmaceutical classifications in reporting 
For pharmaceutical data, there is the choice of reporting in terms of the CAPS coding scheme 
or the ATC. They each have advantages in different circumstances. 
In the CAPS system, a new drug enters at the product and generic level, and is immediately 
allocated a generic code. Therefore, the CAPS classification uses a bottom-up approach. 
In the ATC, a new generic may initially enter the classification at any level (1 to 5), not 
always at the generic level. Reclassification to lower ATC levels may occur later. Therefore, 
the ATC uses a top-down approach. 
When analysing medications across time, a generic medication that is initially classified to a 
higher ATC level will not be identifiable in that data period and may result in 
under-enumeration of that drug during earlier data collection periods. 
There are some differences in the labels applied to generic medications in the two 
classifications. For example the medication combination of paracetamol and codeine is 
labelled as ‘Paracetamol/codeine’ in CAPS and as ‘Codeine combinations excluding 
psycholeptics’ in the ATC. 
• When reporting annual results for pharmaceutical data, the CAPS database is used in 
tables of the ‘most frequent medications’ (Tables 9.2 to 9.4). 
• When reporting the annual results for pharmaceuticals in terms of the ATC hierarchy 
(Table 9.1), ATC levels 1, 3, and 5 are used. The reader should be aware that the results 
reported at the generic level (Level 5) may differ slightly from those reported in the 
‘most frequent medication’ tables for the reasons described above.  
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Practice nurse and Aboriginal health worker activities associated with the 
encounter 
The BEACH form was changed in 2005–06 to capture ‘other treatments’ performed by 
practice nurses (PNs) following the introduction of MBS item numbers for defined PN 
activities. GPs were asked to tick the ‘practice nurse’ box if a treatment was provided by the 
PN. If not ticked, it was assumed that the GP provided the ‘other treatment’. 
Over the years, new PN item numbers were added to the MBS and some items were 
broadened to include work done by Aboriginal health workers (AHWs). From 2005–06 to 
2010–11 we reported the results referring to PNs alone. As some GPs indicated (of their own 
accord) that the recorded action was done by an AHW rather than a PN, this information is 
now included. In this report we refer to work undertaken at encounters by PNs and AHWs 
in conjunction with the GPs, though the vast majority will have been done by PNs. There is a 
limitation to this approach. Few GPs specifically indicated that the work was done by an 
AHW. Others may have thought that because the question referred specifically to PNs, and 
recording of work done by AHWs was not specifically requested. These results therefore 
have the potential to be an underestimate of the work undertaken at GP–patient encounters 
by PNs and AHWs. 
2.9 Quality assurance 
All morbidity and therapeutic data elements were secondarily coded by staff entering key 
words or word fragments, and selecting the required term or label from a pick list. This was 
then automatically coded and classified by the computer. To ensure reliability of data entry 
we use computer-aided error checks (‘locks’) at the data entry stage, and a physical check of 
samples of data entered versus those on the original recording form. Further logical data 
checks are conducted through SAS regularly. 
2.10 Validity and reliability 
A discussion of the reliability and validity of the BEACH program has been published 
elsewhere.46 This section touches on some aspects of reliability and validity of active data 
collection from general practice that should be considered by the reader.  
In the development of a database such as BEACH, data gathering moves through specific 
stages: GP sample selection, cluster sampling around each GP, GP data recording, secondary 
coding and data entry. At each stage the data can be invalidated by the application of 
inappropriate methods. The methods adopted to ensure maximum reliability of coding and 
data entry have been described above. The statistical techniques adopted to ensure valid 
analysis and reporting of recorded data are described in Section 2.7. Previous work has 
demonstrated the extent to which a random sample of GPs recording information about a 
cluster of patients represents all GPs and all patients attending GPs,47 the degree to which GP-
reported patient RFEs and problems managed accurately reflect those recalled by the patient,48 
and reliability of secondary coding of RFEs49 and problems managed.42 The validity of ICPC as 
a tool with which to classify the data has also been investigated in earlier work.50 
However, the question of the extent to which the GP-recorded data are a reliable and valid 
reflection of the content of the encounter must also be considered. In many primary care 
consultations, a clear pathophysiological diagnosis is not reached. Bentsen51 and Barsky52 
suggest that a firm and clear diagnosis is not apparent in about half of GPs’ consultations, 
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and others suggest the proportion may be even greater.53 Further, studies of general 
ambulatory medical practice have shown that a large number of patients presenting to a 
primary care practitioner are without a serious physical disorder.54,55 As a result, it is often 
necessary for a practitioner to record a problem in terms of symptoms, signs, patient 
concerns, or the service that is requested, such as immunisation. For this reason, this report 
refers to patient ‘problems’ rather than ‘diagnoses’. 
A number of studies have demonstrated wide variance in the way a GP perceives the patient’s 
RFE and the manner in which the GP describes the problem under management. Further, in a 
direct observational study of consultations via a one-way mirror, Bentsen demonstrated that 
practitioners differ in the way they labelled problems, and suggested that clinical experience 
may be an important influence on the identification of problems within the consultation.51 Two 
other factors that might affect GPs’ descriptions of patient RFEs have been identified: 
although individuals may select the same stimuli, some label each stimulus separately, 
whereas others cluster them under one label; and individuals differ in the number of stimuli 
they select (selective perception).56 
The extent to which therapeutic decisions may influence the diagnostic label selected has also 
been discussed. Howie57 and Anderson54 argue that, while it is assumed that the diagnostic 
process used in general practice is one of symptom  diagnosis  management, the 
therapeutic method may well be selected on the basis of the symptom, and the diagnostic label 
chosen last. They suggest that the selection of the diagnostic label is therefore influenced by the 
management decision already made. 
Alderson contends that to many practitioners ‘diagnostic accuracy is only important to the 
extent that it will assist them in helping the patient’. He further suggests that if major symptoms 
are readily treatable, some practitioners may feel no need to define the problem in diagnostic 
terms.58 Crombie identified ‘enormous variability in the rates at which doctors perceive and 
record illnesses’. He was unable to account statistically for this variation by the effect of 
geography, age, sex or class differences in the practice populations.59 Differences in the way 
male and female GPs label problems also appear to be independent of such influences.60 
These problems are inherent in the nature of general practice. Knottnerus argues that the GP 
is confronted with a fundamentally different pattern of problems from the medical specialist, 
and often has to draw up general diagnostic hypotheses related to probability, severity and 
consequences.61 Anderson suggests that morbidity statistics from family practice should be 
seen as ‘a reflection of the physician’s diagnostic opinions about the problems that patients 
bring to them rather than an unarguable statement of the problems managed’.54  
While these findings regarding limitations in the reliability and validity of 
practitioner-recorded morbidity should be kept in mind, they apply equally to data drawn 
from health records, whether paper or electronic, as they do to active data collection 
methods.62,63 There is as yet no more reliable method of gaining detailed data about 
morbidity and its management in general practice. Further, irrespective of the differences 
between individual GPs in labelling problems, morbidity data collected by GPs in active data 
collection methods have been shown to provide a reliable overview of the morbidity 
managed in general practice.64 
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2.11 Extrapolated national estimates 
A section at the end of each chapter highlights changes that have occurred over the decade 
2003–04 to 2012–13. These sections summarise results published in the companion 
publication, A decade of Australian general practice activity 2003–04 to 2012–13.1 Where the 
results demonstrate a significant change over time, the estimated national change across total 
GP Medicare services from 2003–04 to 2012–13 can be calculated using the method detailed 
below. Note that extrapolations are always based on rate per 100 encounters rather than rate 
per 100 problems because there is no independent measure of the total number of problems 
managed in Australian general practice. In contrast, the number of national encounters can 
be drawn from Medicare claims data. 
In this report, we also occasionally extrapolate data for the single year 2012–13 to give the 
reader some feeling of the real size of the issue across Australian general practice. 
When extrapolating from a single time point we: 
• divide the ‘rate per 100 encounters’ of the selected event by 100, and then multiply by the 
total number of GP service items claimed through Medicare in that year, 126.8 million in 
2012–13 (rounded to the nearest 100,000, see Table 2.1), to give the estimated number of 
the selected event across Australia in 2012–13.  
When extrapolating measured change over the decade to national estimates, we: 
• divide the ‘rate per 100 encounters’ of the selected event for 2003–04 by 100, and then 
multiply by the total number of GP service items claimed through Medicare in that year, 
96.3 million (rounded to the nearest 100,000, see Table 2.1), to give the estimated national 
number of events in 2003–04.  
• repeat the process using data for 2012–13.  
The difference between the two estimates gives the estimated national change in the 
frequency of that event over the decade. Estimates are rounded to the nearest 100,000 if more 
than a million and to the nearest 10,000 if below a million. 
Change is expressed as the estimated increase or decrease over the study period (from 
2003–04 to 2012–13), in the number of general practice contacts for that event (for example, 
an increase or decrease in the number of GP management contacts with problem X); or an 
increase or decrease in the number of times a particular medication type was prescribed in 
Australia in 2012–13, when compared with 2003–04. 
Table 2.1 provides the rounded number of GP service items claimed from Medicare in each 
financial year from 2003–04 to 2012–13.  
Table 2.1: Rounded number of general practice professional services claimed from Medicare 
Australia each financial year, 2003–04 to 2012–13 (million) 
 2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13(a) 
Rounded number of 
MBS GP items of 
service claimed 
96.3 98.2 101.1 103.4 109.5 113.0 116.6 119.2 123.9 126.8 
(a) Medicare data for the 2012–13 year included data from the April 2012 to March 2013 quarters because the 2012–13 financial year data 
were not available at the time of preparation of this report. 
Source: Medicare statistics4,6 
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Examples of extrapolation:  
1. Number of GP encounters at which hypertension was managed nationally in 2012–13 
Hypertension was managed at a rate of 8.6 per 100 GP encounters (95% CI: 8.1–9.1) in  
2012–13 (shown in Table 7.3). How many times does this suggest that hypertension was 
managed in GP encounters across Australia in 2012–13?  
Our best estimate is: 10.9 million times [(8.6/100) x 126.8 million], but we are 95% confident 
that the true number lies between 10.3 million [(8.1/100) x 126.8 million] and 11.5 million 
[(9.1/100) x 126.8 million]. 
2. National increase in the number of problems managed from 2003–04 to 2012–13 
There was a statistically significant increase in the number of problems managed at 
encounter, from 146.3 per 100 encounters in 2003–04 to 154.7 in 2012–13 (see Table 7.2 in A 
decade of Australian general practice activity 2003–04 to 2012–131). The calculation used to 
extrapolate the effect of this change across Australia is:  
 (146.3/100) x 96.3 million = 140.9 million problems managed nationally in 2003–04, and 
(154.7/100) x 126.8 million = 196.2 million problems managed nationally in 2012–13.  
This suggests there were 55.3 million (196.2 million minus 140.9 million) more problems 
managed at GP–patient encounters in Australia in 2012–13 than in 2003–04.  
This is the result of the compound effect of the increase in the number of problems managed 
by GPs at encounters plus the increased number of visits over the decade across Australia. 
Considerations and limitations in extrapolations 
The extrapolations to the total events occurring nationally in any one year are only estimates. 
They may provide: 
• an underestimate of the true ‘GP workload’ of a condition/treatment because the 
extrapolations are made to GP Medicare items claimed, not to the total number of GP 
encounters per year – an additional 5% or so of BEACH encounters annually include 
encounters paid by sources other than Medicare, such as DVA, state governments, 
workers compensation insurance, and employers, or not charged to anyone. 
• an underestimate of activities of relatively low frequency with a skewed distribution 
across individual GPs. Where activity is so skewed across the practising population, a 
national random sample will provide an underestimate of activity because the sample 
reflects the population rather than the minority. 
Further, the base numbers used in the extrapolations are rounded to the nearest 100,000, and 
extrapolation estimates are rounded to the nearest 100,000 if more than a million and to the 
nearest 10,000 if below a million, so can only be regarded as approximations. However, the 
rounding has been applied to all years, so the effect on measures of change will be very 
small. Therefore, the extrapolation still provides an indication of the size of the effect of 
measured change nationally.  
Extrapolations are based on the unit of the encounter because the number of national 
encounters is quantifiable using Medicare claims data. However, the reader should be aware 
that where an event can occur more than once per encounter, the extrapolation represents 
the number of occasions at which that event occurs in general practice encounters, rather 
than the number of encounters where that event occurs.  
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3 The sample 
This chapter describes the GP sample and sampling methods used in the BEACH program. 
The methods are only summarised in this chapter. A more detailed explanation of the 
BEACH methods are described in Chapter 2. 
A summary of the BEACH data sets is reported for each year from 2003–04 to 2012–13 in the 
companion report A decade of Australian general practice activity 2003–04 to 2012–13.1  
3.1 Response rate 
A random sample of GPs who claimed at least 375 general practice Medicare items of service 
in the previous three months is regularly drawn from Medicare claims data by the Australian 
Government Department of Health and Ageing (DoHA) (see Chapter 2). 
Contact was attempted with 4,852 GPs but 20.0% could not be contacted. More than one-
third (37.3%) of these had moved (and were untraceable), or had retired or died (Table 3.1), 
although more than half were those with whom contact could not be established after five 
calls. Younger GPs were harder to contact. Of the GPs approached who were aged less than 
35 years, 21.6% were no longer at that practice and could not be traced. These would largely 
be registrars moving through practices during training. In contrast, 5.7% of GPs aged 
35 years and over were not traceable (results not shown). 
The final participating sample consisted of 978 practitioners, representing 25.2% of those 
who were contacted and available, and 20.2% of those with whom contact was attempted 
(Table 3.1). 
Table 3.1: Recruitment and participation rates 
Type of contact Number 
Per cent of  
approached  
(n = 4,852) 
Per cent of contacts 
established  
(n = 3,874) 
Letter sent and phone contact attempted 4,852 100.0 — 
No contact  978 20.0 — 
 No phone number 33 0.7 — 
 Moved/retired/deceased 365 7.5 — 
 Unavailable (overseas, maternity leave, etc) 65 1.3 — 
 No contact after five calls 515 10.6 — 
Telephone contact established 3,874 79.8 100.0 
 Declined to participate 2,626 54.1 67.8 
 Agreed but withdrew 270 5.6 7.0 
 Agreed and completed 978 20.2 25.2 
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3.2 Representativeness of the GP sample 
Whenever possible, the study group of GPs should be compared with the population from 
which the GPs were drawn (the sample frame) to identify and, if necessary, adjust for any 
sample bias that may affect the findings of the study. Comparisons between characteristics of 
the final GP sample and those of the GPs in the sample frame are provided below. The 
methods by which weightings are generated as a result of these comparisons and applied to 
the data are described in Section 3.3.  
Statistical comparisons, using the chi-square statistic (χ2) (significant at the 5% level), were 
made between BEACH participants, and all recognised GPs in the sample frame during the 
study period (Table 3.2). The GP characteristics data for BEACH participants were drawn 
from their GP profile questionnaire. DoHA provided the grouped data for all GPs in the 
sample frame, drawn from Medicare claims data. 
Table 3.2 demonstrates that there were no significant differences in GP characteristics 
between the final sample of BEACH participants and all GPs in the sample frame, in terms of 
sex, place of graduation, state, or practice location as classified by the Australian Standard 
Geographical Classification. In the final BEACH GP sample, there was a slight under-
representation of GPs in the 35–44 year age group, and a slight over-representation in the  
45–54 year age group, compared with the Australian sample frame. 
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Table 3.2: Comparison of BEACH participants and all active recognised GPs in Australia (the 
sample frame) 
Variable 
BEACH(a)(b)  Australia(a)(c) 
Number 
Per cent of GPs 
(n = 978)  Number 
Per cent of GPs 
(n = 21,676)  
Sex (χ2 = 3.36, p = 0.067)      
 Males 556 56.9  12,960 59.8 
 Females 422 43.1  8,716 40.2 
Age (χ2 = 9.83, p = 0.02)      
 < 35 years 82 8.5  1,724 8.0 
 35–44 years 165 17.0  4,418 20.4 
 45–54 years 322 33.2  6,402 29.5 
 55+ years 401 41.3  9,132 42.1 
 Missing 8     
Place of graduation (χ2 = 2.6, p = 0.1)      
 Australia 645 66.2  13,786 63.6 
 Overseas 330 33.8  7,890 36.4 
 Missing 3     
State (χ2 = 10.7, p = 0.15)      
 New South Wales 341 34.9  7,091 32.7 
 Victoria 207 21.2  5,365 24.8 
 Queensland 203 20.8  4,350 20.1 
 South Australia 75 7.7  1,768 8.2 
 Western Australia 105 10.7  2,033 9.4 
 Tasmania 23 2.4  560 2.6 
 Australian Capital Territory 13 1.3  344 1.6 
 Northern Territory 11 1.1  165 0.8 
ASGC (χ2 = 8.48, p = 0.07)      
 Major Cities of Australia 673 68.8  15,348 70.8 
 Inner Regional Australia 188 19.2  4,106 18.9 
 Outer Regional Australia 103 10.5  1,784 8.2 
 Remote Australia 10 1.0  268 1.2 
 Very Remote Australia 4 0.4  167 0.8 
(a) Missing data removed. 
(b) Data drawn from the BEACH GP profile completed by each participating GP. 
(c) All GPs who claimed at least 375 MBS GP consultation services during the most recent three month Medicare Australia data period. 
Data provided by the Department of Health and Ageing. 
Note: ASGC – Australian Standard Geographical Classification.65 
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GP activity in the previous year 
Data on the number of MBS general practice service items claimed in the previous year were 
also provided by DoHA for each GP in the drawn samples, and for all GPs (as a group) in the 
sample frame. These data were used to determine the ‘activity level’ of each GP, and to 
compare the activity level of the final participants with that of GPs in the Australian sample 
frame.  
When comparing GP activity level in the previous 12 months, there was a smaller  
proportion of GPs in the final participant sample who had claimed fewer than 1,500 services 
in the previous year, and a larger proportion who had claimed 1,501–3,000 services. The  
3,001–6,000 and >6,000 claims categories were proportionally similar. However, comparison 
of the mean number of claims made by the participating GPs and those in the GP sample 
frame showed that the mean for the sample frame was included in the confidence intervals 
around the participant mean, indicating no significant different between the two measures 
(Table 3.3). 
The similarity of the BEACH participants to the national sample frame in terms of age, sex, 
place of graduation, state and practice location, and the marginal difference in activity level 
(equating to about half of one consultation per day), shows a final BEACH participant 
sample that is highly representative of GPs in the Australian sample frame. 
Table 3.3: Annual activity level of participating GPs and GPs in the sample frame 
Variable 
Participants(a)  
(n = 978)  
Australia  
(n = 21,676) 
Number of GPs Per cent  Number of GPs Per cent 
Activity (χ2 = 22.76, p < 0.0001)      
 1–1,500 services in previous year 59 6.0  1,901 9.0 
 1,501–3,000 services in previous year 236 24.1  4,105 19.4 
 3,001–6,000 services in previous year 400 40.9  8,361 39.6 
 > 6,000 services in previous year 283 28.9  6,739 31.9 
 Number of claims 95% CI  Number of claims  
Mean activity level  4,947.6 4,762.6–5,132.5  5,103.4 — 
Standard deviation 2,947.5 —  — — 
Median activity level 4,357.5 —  —  — 
(a) Missing data removed. 
3.3 Weighting the data 
Age–sex weights  
As described in Section 3.2, comparisons are made annually to test how representative 
BEACH participants are of the GPs in the original Australian sample frame. Occasionally, 
where participants in a particular age or sex group are over-represented or under-
represented, GP age–sex weights need to be applied to the data sets in post-stratification 
weighting to achieve comparable estimates and precision. The BEACH participants were 
representative in all age and sex categories, but because there are always marginal (even if 
not statistically significant) differences, post-stratification weighting was applied for 
consistency over recording years. 
25
  
Activity weights  
In BEACH, each GP provides details of 100 consecutive encounters. There is considerable 
variation among GPs in the number of services each provides in a given year. Encounters 
were therefore assigned an additional weight directly proportional to the activity level of the 
recording GP. GP activity level was measured as the number of MBS general practice service 
items claimed by the GP in the previous 12 months (data supplied by DoHA). 
Total weights  
The final weighted estimates were calculated by multiplying raw rates by the GP age–sex 
weight and the GP sampling fraction of services in the previous 12 months. Table 3.4 shows 
the precision ratio calculated before and after weighting the encounter data. 
3.4 Representativeness of the encounter sample 
BEACH aims to gain a representative sample of GP–patient encounters. To assess the 
representativeness of the final weighted sample of encounters, the age–sex distribution of 
patients at weighted BEACH encounters with GP consultation service items claimed 
(excluding those with Department of Veterans’ Affairs [DVA] patients) was compared with 
that of patients at all encounters claimed as GP consultation service items through Medicare 
in the 2012–13 study period (data provided by DoHA).  
As shown in Table 3.4, there is an excellent fit of the age–sex distribution of patients at the 
weighted BEACH encounters with that of the MBS claims distribution, with precision ratios 
all within the 0.91–1.09 range. Even prior to the weightings, the range of raw precision  
ratios (0.90–1.14) indicates that the BEACH sample is a good representation of Australian 
GP–patient encounters, as only one age–sex category varied by more than 10% from the 
population distribution. 
The age–sex distribution of patients at BEACH encounters and for MBS GP consultation 
service item claims, is shown graphically for all patients in Figure 3.1, for males in Figure 3.2, 
and for females in Figure 3.3. 
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Table 3.4: Age–sex distribution of patients at BEACH and MBS GP consultation service items 
 
BEACH–raw(a)  BEACH–weighted(b)  Australia(c)  
Precision ratios 
(Australia = 1.00) 
Sex/age 
Number 
Per cent  
(n = 81,099)  Number 
Per cent 
(n = 82,015)  
Per cent 
(n = 108,487,877)  Raw(a) Weighted(c) 
All           
 < 1 year 1,723  2.1   1,607  2.0   2.0  1.08 1.00 
 1–4 years 4,039  5.0   3,998  4.9   5.0  0.99 0.97 
 5–14 years 4,523  5.6   4,567  5.6   6.1  0.91 0.91 
 15–24 years 6,937  8.6   6,891  8.4   8.7  0.99 0.97 
 25–44 years 18,200  22.4   18,350  22.4   22.8  0.98 0.98 
 45–64 years 22,206  27.4   22,635 27.6   27.0  1.02 1.02 
 65–74 years 11,389  14.0   11,681  14.2   13.3  1.05 1.07 
 75+ years 12,082  14.9   12,286  15.0   15.1  0.99 0.99 
Male           
 < 1 year 907 1.1   864  1.1   1.1  1.06 1.00 
 1–4 years 2,137 2.6   2,129 2.6   2.7  0.99 0.97 
 5–14 years 2,310 2.8   2,357  2.9   3.1  0.91 0.92 
 15–24 years 2,314 2.9   2,492  3.0   3.2  0.90 0.96 
 25–44 years 6,344 7.8   7,079  8.6   8.6  0.91 1.00 
 45–64 years 8,865 10.9   9,835  12.0   11.6  0.94 1.03 
 65–74 years 4,758 5.9   5,269  6.4   6.2  0.95 1.04 
 75+ years 4,777 5.9   5,198  6.3   6.3  0.94 1.01 
Female           
 < 1 year 816 1.0   743  0.9   0.9  1.11 1.00 
 1–4 years 1,902 2.3   1,869 2.3   2.4  1.00 0.97 
 5–14 years 2,213 2.7   2,210  2.7   3.0  0.92 0.91 
 15–24 years 4,623 5.7   4,399 5.4   5.5  1.04 0.97 
 25–44 years 11,856 14.6   11,271  13.7   14.3  1.03 0.96 
 45–64 years 13,341 16.5   12,800  15.6   15.3  1.07 1.02 
 65–74 years 6,631 8.2   6,412  7.8   7.2  1.14 1.09 
 75+ years 7,305 9.0   7,089 8.6   8.8  1.02 0.98 
(a) Unweighted GP consultation Medicare service items only, excluding encounters with patients who hold a DVA Repatriation Health Card. 
(b) Calculated from BEACH weighted data, excluding encounters with patients who hold a DVA Repatriation Health Card. 
(c) MBS claims data provided by the Australian Government Department of Health and Ageing. 
Note: GP consultation Medicare services – see ‘Glossary’. Only encounters with a valid age and sex are included in the comparison. 
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 Figure 3.1: Age distribution of all patients at BEACH and MBS GP consultation service,s 2012–13 
 
 
 
 
 
 Figure 3.2: Age distribution of male patients at BEACH and MBS GP consultation services, 
2012–13 
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 Figure 3.3: Age distribution of female patients at BEACH and MBS GP consultation services, 
2012–13 
3.5 The weighted data set 
The final unweighted data set from the 15th year of collection contained encounters, reasons 
for encounters, problems and management/treatments. The apparent number of encounters 
and number of medications increased after weighting, and the number of reasons for 
encounter, problems managed, other treatments, referrals, imaging and pathology all 
decreased after weighting. Raw and weighted totals for each data element are shown in 
Table 3.5. The weighted data set is used for all analyses in the remainder of this report. 
Table 3.5: The BEACH data set, 2012–13 
Variable Raw Weighted 
General practitioners 978 978 
Encounters 97,800 98,564 
Reasons for encounter 152,319 152,278 
Problems managed 155,212 152,517 
Medications 99,439 101,065 
Other treatments(a) 55,636 53,163 
Referrals and admissions 16,491 15,417 
Pathology 50,442 46,398 
Imaging 10,432 10,163 
Other investigations 893 856 
(a) Other treatments excludes injections for immunisations/vaccinations (raw n = 3,844, weighted  
n = 3,636) (see Chapter 10). 
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4 The participating GPs 
This chapter reports data collected between April 2012 and March 2013 about the 
participating GPs and their practices from the 15th year of the BEACH program. Details of 
GP and practice characteristics are reported for each year from 2003–04 to 2012–13 in the ten-
year summary report A decade of Australian general practice activity 2003–04 to 2012–13.1  
4.1 Characteristics of the GP participants 
All participants returned a GP profile questionnaire, although some were incomplete. The 
results are provided in Tables 4.1 and 4.2. Of the 978 participants: 
• 56.9% were male, and 41.3% were aged 55 years and over (mean age 51.5 years) 
• 59.5% had been in general practice for more than 20 years 
• 66.2% had graduated in Australia and 11.7% in Asia 
• 33.0% spent more than 40 hours each week on direct patient care services (mean hours 
worked was 37.5; median was 38.0 hours)  
• 36.2% expected to decrease their hours spent on direct patient care in the next 5 years 
• more than 55% were Fellows of the RACGP, and 8.4% were Fellows of the ACRRM 
• 52.5% had provided care in a residential aged care facility in the previous month 
• 68.8% practised in Major cities (using Australian Standard Geographical Classification)65  
• 73.9% worked at only one practice location in a regular week, and 21.1% worked in two 
• 33.1% were in practices of fewer than five individual GPs, and 21% were in practices of 
ten or more individual GPs. On average, there were 6.5 individual GPs per practice, with 
a median of 6 per practice 
• 50.8% were in practices of fewer than five full-time equivalent (FTE) GPs. On average, 
there were 4.7 FTE GPs per practice, with a median of 4 FTE GPs per practice 
• 81.6% of the GPs worked in a practice that employed practice nursing staff—for more 
than one-third of these (35.3%) the practice employed less than two FTEs (35–45 hours 
per week). On average, there were 0.4 FTE practice nurses per FTE GP 
• nearly two-thirds (63.0%) had a co-located pathology laboratory or collection centre in or 
within 50 metres of the practice, and almost half (48.5%) a co-located psychologist  
• 43.5% worked in a practice that provided their own or cooperative after-hours care, and 
53.3% in a practice that used a deputising service for after-hours patient care (multiple 
responses allowed). 
Those interested in the clinical activity of overseas trained doctors will find more 
information in Bayram et al. (2007) Clinical activity of overseas trained doctors practising in 
general practice in Australia.66 Readers interested in the effects of GP age on clinical practice 
will find more information in Charles et al. (2006) The independent effect of age of general 
practitioner on clinical practice.67 For more information about the effect of the sex of the GP on 
clinical practice see Harrison et al. (2011) Sex of the GP.68  
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Table 4.1: Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
(n = 978) 
Sex (missing n = 0)   
 Male 556 56.9 
 Female 422 43.1 
Age (missing n = 8)   
 < 35 years 82 8.5 
 35–44 years 165 17.0 
 45–54 years 322 33.2 
 55+ years 401 41.3 
Years in general practice (missing n = 11)   
 < 2 years 25 2.6 
 2–5 years 105 10.9 
 6–10 years 96 9.9 
 11–19 years 166 17.2 
 20+ years 575 59.5 
Place of graduation (missing n = 3)   
 Australia 645 66.2 
 Overseas 330 33.8 
  Asia 114 11.7 
  United Kingdom/Ireland 90 9.2 
  Africa and Middle East 62 6.4 
  Europe 29 3.0 
  New Zealand 21 2.2 
  Other 14 1.4 
Direct patient care hours (worked) per week (missing n = 12)   
 ≤ 10 hours 14 1.5 
 11–20 hours 98 10.1 
 21–40 hours 535 55.4 
 41–60 hours 301 31.2 
 61+ hours 18 1.9 
Expectations for providing direct patient care in 5 yrs time (missing n = 13)   
 Increase number of working hours 98 10.2 
 No change to number of working hours 413 42.8 
 Decrease number of working hours 348 36.1 
 Stop working as a GP 72 7.5 
 Unsure about future work as a GP 34 3.5 
Currently in general practice training program (missing n = 8) 59 3.1 
Fellow of RACGP (missing n = 6) 541 55.7 
Fellow of ACRRM (missing n = 35) 79 8.4 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 978) 
Patient care provided in previous month(b)    
 In a residential aged care facility (missing n = 6) 510 52.5 
 As a salaried/sessional hospital medical officer (missing n = 7) 123 12.7 
Practice location by RRMA (missing n = 0)   
 Capital 617 63.1 
 Other metropolitan 76 7.8 
 Large rural 76 7.8 
 Small rural 63 6.4 
 Other rural 132 13.5 
 Remote central 7 0.7 
 Other remote, offshore 7 0.7 
Practice location by ASGC remoteness structure (missing n = 0)   
 Major cities 673 68.8 
 Inner regional 188 19.2 
 Outer regional 103 10.5 
 Remote 10 1.0 
 Very remote 4 0.4 
Number of practice locations worked at in a regular week (missing n = 12)   
 1 713 73.8 
 2 203 21.0 
 3 44 4.6 
 4 4 0.4 
 5 2 0.2 
Size of practice – number of individual GPs (missing n = 28)   
 Solo 93 9.8 
 2–4  221 23.3 
 5–9  367 38.6 
 10–14 192 20.2 
 15+  77 8.1 
Size of practice – full-time equivalent GPs (missing n = 136)   
 < 1 1 0.1 
 1.0– <2 99 11.8 
 2.0– <3 93 11.1 
 3.0– <4 105 12.5 
 4.0– <5 130 15.4 
 5.0– <10 322 38.2 
 10.0– <15 67 8.0 
 15+ 25 3.0 
(continued) 
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Table 4.1 (continued): Characteristics of participating GPs and their practices 
GP characteristic Number(a) 
Per cent of GPs(a) 
 (n = 978) 
Practice nurse at major practice address (missing n = 10) 790 81.6 
Number of individual practice nurses (missing n = 30)   
 0 178 18.8 
 1 127 13.4 
 2  202 21.3 
 3 141 14.9 
 4–5  192 20.1 
 6+ 108 11.4 
Number of full-time equivalent practice nurses (missing n = 168)   
 0 178 22.0 
 < 1 58 7.2 
 1.0– <2 228 28.2 
 2.0– <3 169 20.9 
 3.0– <4 100 12.4 
 4.0+ 77 9.5 
Co-located services(c) (missing n = 9)   
 Pathology laboratory/collection centre 610 63.0 
 Psychologist 470 48.5 
 Physiotherapist 337 34.8 
 Medical specialist 203 21.0 
 Imaging/radiology services 157 16.2 
After-hours arrangements(b) (missing n = 5)   
 Practice does own and/or cooperative with other practices 423 43.5 
  Practice does its own 299 30.7 
  Cooperative with other practices 145 14.9 
 Deputising service 519 53.3 
 Other arrangement 89 9.2 
(a) Missing data removed. 
(b) Multiple responses allowed. 
(c) Services located/available on the same premises, in the same building or within 50 metres, available on a daily or regular basis. 
Note: RRMA – Rural, Remote and Metropolitan Areas classification; ASGC – Australian Standard Geographical Classification;  
RACGP – Royal Australian College of General Practitioners; ACRRM – Australian College of Rural and Remote Medicine. 
Table 4.2: Means of selected characteristics of participating GPs and their practices 
Characteristic 
Mean 
(n = 978) 
95% 
LCL 
95% 
UCL 
Mean age of participating GPs (missing n = 8) 51.5  50.8 52.2 
Mean hours worked per week on direct patient care (missing n = 12) 37.6 36.7 38.4 
Mean number of individual GPs at major practice address (missing n = 16) 6.5 6.2 6.7 
Mean number of FTE GPs at major practice address (missing n = 108) 4.7 4.5 4.9 
FTE Practice nurse: FTE GP (missing n = 225) 0.4 0.3 0.4 
Note: LCL – lower confidence limit; UCL – upper confidence limit; FTE – full-time equivalent. 
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4.2 Computer use at GP practices 
As computers are increasingly being used by GPs in their clinical activity, the GP profile 
questionnaire was redesigned in 2012–13 so that more comprehensive information could be 
gained about the uses to which computers are put in a general practice clinical environment 
(see Appendix 2). In particular, more specific information was collected about electronic and 
other prescribing, and whether the medical records used were paper only, a mix of paper 
and electronic medical records, or whether the practice was completely paperless in this 
regard. 
Table 4.3 shows the proportion of individual participating GPs who used computers for each 
of the listed activities. 
• Only 3.8% of GPs did not use a computer at all for clinical purposes. 
• 95.7% of GPs were producing prescriptions electronically. 
• More than two-thirds (70.4%) reported they had electronic medical records exclusively 
(that is, were paperless). 
• More than one-quarter (25.8%) reported maintaining a hybrid record where some patient 
information is kept electronically and some on paper records. 
Table 4.3: Computer applications available/used at major practice address 
Computer use Number 
Per cent of GPs  
(n = 978) 
Computer not used for any clinical purposes (missing n = 4) 37 3.8 
 Not available  21 2.2 
 Available, not used 8 0.8 
 Internet/email only 8 0.8 
Clinical use   
Prescribing(a) (missing n = 24)   
 Electronic (ePrescribing online) 276 28.9 
  (*Electronic + print scripts) (62) (6.5) 
 Print scripts only 637 66.8 
 Paper only (handwritten) 41 4.3 
Internet (missing n = 4) 750 77.0 
Email (missing n = 4) 592 60.8 
Medical records (missing n = 10)   
 Complete (paperless) 681 70.4 
 Partial/hybrid records 250 25.8 
 Paper records only 37 3.8 
(a) Multiple responses allowed.  
* Sub-set of ePrescribing. 
 
Those interested in the effect of computerisation on quality of care in general practice will 
find more detailed information in Henderson (2007) The effect of computerisation on the quality 
of care in Australian general practice.69  
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4.3 Changes in characteristics of the GPs over the 
decade 2003–04 to 2012–13 
Changes over the decade 2003–04 to 2012–13 are described in detail in the accompanying 
report A decade of Australian general practice activity 2003–04 to 2012–13.1 Briefly, the major 
changes in the characteristics of the participating GPs were: 
• the proportion of GP participants who were female increased over time 
• the proportion of GPs who were younger than 45 years decreased, whereas the 
proportion aged 55 years or more increased over the decade 
• reflecting the increase in the age of GP participants, the proportion who had worked in 
general practice for more than 20 years also increased significantly over time 
• the proportion of GPs working 21–40 hours per week on direct patient care significantly 
increased, and the proportion working 41–60 hours, and the proportion working more 
than 60 hours, significantly decreased 
• the mean number of hours spent on direct patient care significantly decreased 
• the proportion of GPs who graduated from their primary medical degree in Australia 
decreased over the decade 
• the proportion of participants holding the Fellowship of the RACGP increased over the 
decade 
• the proportion of GPs in solo practice decreased over time, and the proportion in 
practices with 10 or more individual GPs more than doubled 
• fewer practices are providing after-hours care on their own, or in cooperation with other 
practices, but more practices are using deputising services for after-hours care 
• computers have become increasingly available at practices, as has their use for clinical 
activity.  
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5 The encounters 
This chapter describes the content and types of encounters recorded in the 2012–13 
BEACH year. Data about the encounters are reported for each year from 2003–04 to 2012–13 
in the 10-year report A decade of Australian general practice activity 2003–04 to 2012–13.1  
5.1 Content of the encounters 
In 2012–13, details of 98,564 encounters (weighted data) were available for 978 GPs. A 
summary of these encounters is provided in Table 5.1. Reasons for encounter (RFEs) and 
problems managed are expressed as rates per 100 encounters. Each management action is 
presented in terms of both a rate per 100 encounters and a rate per 100 problems managed, 
with 95% confidence limits. 
• On average, patients gave 155 RFEs, and GPs managed about 155 problems per 
100 encounters. 
• Chronic problems accounted for 36.0% of all problems managed, and an average of 55.7 
chronic problems were managed per 100 encounters. 
• New problems accounted for 37.0% of all problems, and on average 57.3 new problems 
were managed per 100 encounters. 
• Work-related problems were managed at a rate of 2.4 per 100 encounters. 
• Medications were the most common treatment choice (102.5 per 100 encounters), most of 
these being prescribed (83.3 per 100), rather than supplied by the GP (9.9 per 100) or 
advised for over-the-counter purchase (9.4 per 100). 
• For an ‘average’ 100 GP–patient encounters, GPs provided 103 medications and 
37 clinical treatments (such as advice and counselling), undertook 17 procedures, made 9 
referrals to medical specialists and 5 to allied health services, and placed 47 pathology 
test orders and 10 imaging test orders (Table 5.1). 
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Table 5.1: Summary of morbidity and management at GP–patient encounters 
Variable Number 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 152,517) 
95% 
LCL 
95% 
UCL 
General practitioners 978 — — — — — — 
Encounters 98,564 — — — — — — 
Reasons for encounter 152,278 154.5 152.7 156.3 — — — 
Problems managed 152,517 154.7 152.5 157.0 — — — 
 New problems 56,454 57.3 55.7 58.8 37.0 36.0 38.0 
 Chronic problems 54,944 55.7 53.7 57.8 36.0 35.0 37.0 
 Work-related 2,319 2.4 2.2 2.5 1.5 1.4 1.6 
Medications 101,065 102.5 100.2 104.9 66.3 64.9 67.6 
 Prescribed 82,079 83.3 81.0 85.5 53.8 52.5 55.1 
 GP-supplied 9,728 9.9 9.1 10.7 6.4 5.9 6.9 
 Advised OTC 9,258 9.4 8.4 10.3 6.1 5.5 6.7 
Other treatments(a) 53,163 53.9 51.2 56.7 34.9 33.2 36.5 
 Clinical* 36,023 36.5 34.2 38.9 23.6 22.2 25.1 
 Procedural* 17,140 17.4 16.5 18.3 11.2 10.7 11.8 
Referrals 14,561 14.8 14.2 15.4 9.5 9.2 9.9 
 Medical specialist* 8,750 8.9 8.5 9.3 5.7 5.5 6.0 
 Allied health services* 4,616 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 354 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 270 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 571 0.6 0.5 0.7 0.4 0.3 0.4 
Pathology 46,398 47.1 45.1 49.0 30.4 29.3 31.5 
Imaging 10,163 10.3 9.9 10.8 6.7 6.4 6.9 
Other investigations(b) 856 0.9 0.8 1.0 0.6 0.5 0.6 
(a) Other treatments includes treatment given by practice nurses in the context of the GP–patient encounter and treatment given by GPs. 
(b) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
5.2 Encounter type 
During the first 7 years of the BEACH program, where one (or more) Medicare Benefits 
Schedule/Department of Veterans’ Affairs (MBS/DVA) item number was claimable for the 
encounter, GP participants were asked to record only one item number. Where multiple item 
numbers (e.g. an A1 item such as ‘standard surgery consultation’ and a procedural item 
number) were claimable for an encounter, GPs were instructed to record the lower of the 
item numbers (usually an A1 item number). 
Changes to the BEACH form were made in the 2005–06 BEACH year to capture practice 
nurse activity associated with GP–patient consultations. One of these changes was to allow 
GPs to record up to three Medicare item numbers per encounter. For comparability with 
earlier years, in Tables 5.3, 5.4 and 5.5 only one item number per MBS/DVA-claimable 
encounter has been counted. Selection of one item number was undertaken on a priority 
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basis: consultation item numbers overrode incentive item numbers, which overrode 
procedural item numbers, which overrode other Medicare item numbers. Table 5.6 provides 
a breakdown of service item numbers recorded by the GPs.  
Table 5.2 provides an overview of the MBS/DVA item numbers recorded in BEACH in  
2012–13. At least one MBS/DVA item number was recorded at 85,885 encounters (87.1% of 
all BEACH encounters). A single item number was recorded at 96.3% of BEACH encounters 
said to be claimable from the MBS/DVA. 
Table 5.2: Overview of MBS items recorded 
Variable Number 
Per cent of MBS/DVA encounters 
(n = 85,885) 
Encounters at which one MBS item was recorded 82,666 96.3 
Encounters at which two MBS items were recorded 2,927 3.4 
Encounters at which three MBS items were recorded 291 0.3 
Total encounters at which at least one item was recorded 85,885 100.00 
Note: MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
In previous years we have reported the breakdown of MBS/DVA services into groups for 
GPs and practice nurses in Table 5.3. The MBS expanded, with some services provided by 
Aboriginal health workers and other allied health services (e.g. physiotherapists and speech 
pathologists) claimable through the MBS/DVA. To account for these changes, we modified 
Table 5.3 last year to group MBS/DVA items according to whether the service was provided 
by a GP or an ‘other health professional’. The group for other health professionals includes 
practice nurses, Aboriginal health workers and allied health services. Further changes in the 
MBS items available to other health professionals during the last year have significantly 
reduced the claimable items. 
Of the 90,077 encounters where a payment source was recorded (counting only one item 
number per encounter), 95.3% related to MBS/DVA GP items of service. Items with other 
health professionals not accompanied by a GP item of service were recorded at a negligible 
number of encounters as a result of changes to the practice nurse consultations items in the 
MBS. Direct encounters are defined as those where the patient was physically seen by the 
GP. At indirect encounters, the patient was not physically seen by the GP (Table 5.3). More 
detail about item numbers recorded for practice nurse items is given in Chapter 10. 
Table 5.3: Breakdown of MBS/DVA items of service according to provider (counting one item 
number per encounter) 
Type of encounter Number 
Per cent of encounters(a) 
(n = 90,077) 
95% 
LCL 
95% 
UCL 
MBS/DVA GP item of service  85,881 95.3 94.9 95.8 
MBS/DVA item of service with other health professional(b)  
(no related GP item) 4 0.0Ŧ 0.0 0.0 
Direct encounters  2 0.0Ŧ 0.0 0.0 
Indirect encounters  1 0.0Ŧ 0.0 0.0 
Unspecified as direct or indirect 2 0.0Ŧ 0.0 0.0 
MBS/DVA item of service (all encounters)(c) 85,885 95.3 94.9 95.8 
(a) Missing data removed from analysis (n = 8,487). 
(b) ‘Other health professional’ includes practice nurses, allied health services and Aboriginal health workers. 
(c) Includes direct encounters at which either a GP or a practice nurse item was recorded. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
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Table 5.4 reports the breakdown of encounter type by payment source, counting a single 
Medicare item number per encounter (where applicable).  
• Indirect encounters (where the patient was not seen by the GP) accounted for 1.7%, and 
direct encounters for 98.3% of encounters at which a payment source was recorded. 
• The vast majority of all direct encounters (95.3%) were claimable through Medicare or 
the DVA. 
• Direct encounters where the GP indicated that no charge was made were rare, 
accounting for 0.4% of encounters. 
• Encounters claimable through workers compensation accounted for 1.8% of encounters. 
• Encounters claimable through other sources (e.g. hospital-paid encounters) accounted 
for 0.9% of encounters. 
Table 5.4: Type of encounter at which a source of payment was recorded for the encounter 
(counting one item number per encounter) 
Type of encounter Number 
Per cent of 
encounters(a) 
(n = 90,077) 
95% 
LCL 
95% 
UCL 
Per cent of direct 
encounters 
(n = 88,586) 
Indirect encounters(b) 1,506 1.7 1.4 1.9  
Direct encounters 88,568 98.3 98.1 98.6 100.0 
 MBS/DVA items of service (direct encounters only)(c) 85,870 95.3 94.9 95.8 96.9 
 Workers compensation 1,580 1.8 1.6 1.9 1.8 
 Other paid (hospital, state, etc) 785 0.9 0.6 1.2 0.9 
 No charge 334 0.4 0.3 0.4 0.4 
Other health professional only items (unspecified as 
direct or indirect) 2 0.0Ŧ 0.0 0.0 — 
Total 90,077 100.0 — — — 
(a) Missing data removed from analysis (n = 8,487). 
(b) Five encounters involving chronic disease management or case conference items were recorded as indirect encounters. 
(c) Includes direct encounters at which either a GP or an item with an other health professional (or both) was recorded. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs. 
Table 5.5 provides a summary of the MBS items recorded in BEACH, counting one item 
number per encounter. This provides comparable results about item numbers recorded to 
those reported in previous years.  
• Standard surgery consultations accounted for 80.6% of MBS/DVA-claimable GP 
consultations, and for 76.9% of all encounters for which a payment source was recorded.  
• 10.0% of MBS/DVA claimable encounters were claimable as long or prolonged surgery 
consultations. 
• Home or institution visits, and visits at residential aged care facilities were all relatively 
rare, together accounting for 2.7% of MBS/DVA claimable encounters. 
• About 1.4% of encounters were claimable as GP mental health care items, 1.4% as 
chronic disease management items, 0.4% as health assessments and case conference 
items were rare. 
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Table 5.5: Summary of GP only MBS/DVA items recorded (counting one item number 
per encounter) 
MBS/DVA item Number 
Rate per 100 
encounters(a) 
(n = 90,077) 
95% 
LCL 
95% 
UCL 
Per cent of 
MBS/DVA 
recorded 
GP items  
(n = 85,881) 
Short surgery consultations 1,502  1.7 1.4 1.9 1.7 
Standard surgery consultations 69,260  76.9 75.8 78.0 80.6 
Long surgery consultations 8,071  9.0 8.4 9.6 9.4 
Prolonged surgery consultations  491  0.6 0.4 0.6 0.6 
Residential aged care facility (RACF) visits 1,490  1.7 1.2 2.1 1.7 
Home or institution visits (excluding RACF) 829 0.9 0.7 1.1 1.0 
GP mental health care  1,258  1.4 1.2 1.5 1.5 
Chronic disease management items 1,232  1.4 1.2 1.5 1.4 
Health assessments  346  0.4 0.3 0.4 0.4 
Case conferences 11  0.0Ŧ 0.0 0.0 0.0 
Attendances associated with Practice 
Incentives Program payments 
 187  0.2 0.2 0.3 0.2 
Other items 1,203  1.3 1.1 1.6 1.4 
 Therapeutic procedures  432  0.5 0.3 0.6 0.5 
 Surgical operations  307  0.3 0.3 0.4 0.4 
 Acupuncture  262  0.3 0.1 0.4 0.3 
 Other items  203  0.2 0.1 0.3 0.2 
Total MBS/DVA items of service (GPs only)  85,881  95.3 94.9 95.8 100.0 
(a) Encounters with missing payment source were removed from analysis (n = 8,487). Denominator used for analysis n = 90.077. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule; DVA – Department of Veterans’ Affairs; GP 
– general practitioner; RACF – residential aged care facility. 
Table 5.6 provides the distribution of all Medicare item numbers recorded across Medicare 
item number groups and the number of encounters at which at least one of each type of item 
number was recorded. Overall, there were 89,394 MBS item numbers recorded at 85,885 
Medicare/DVA claimable encounters in 2012–13, an average of 1.0 items per encounter 
claimable through Medicare/DVA.  
Surgery consultations (including short, standard, long and prolonged) were the most 
commonly recorded type of item number, accounting for 88.7% of all MBS items, one of these 
items being recorded at 92.4% of MBS claimable encounters.  
Items for hospital, residential aged care and home visits together accounted for 2.6% of all 
MBS items. Items for other practice nurse, Aboriginal health worker and allied health 
services accounted for 0.3% of all MBS items, and were recorded at 0.3% of claimable 
encounters at which at least one MBS item was recorded. A more detailed breakdown of 
practice nurse item numbers and related data on practice nurse activity is provided in 
Section 10.4. 
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Table 5.6: Distribution of MBS/DVA service item numbers recorded, across item number groups 
and encounters 
Items/encounters 
All MBS/DVA 
items(a) 
(n = 89,394)  
Encounters with at least one item 
recorded(b) 
(n = 85,885) 
Number Per cent  Number Per cent  
95% 
LCL 
95% 
UCL 
Surgery consultations  79,328  88.7  79,325  92.4 91.7 93.0 
Home, institution and residential aged care visits 2,319  2.6   2,319  2.7 2.2 3.2 
Chronic disease management items (including 
case conferences) 
 2,371  2.7  1,693  2.0 1.7 2.2 
Other practice nurse/Aboriginal health 
worker/allied health worker services 
 287  0.3   287  0.3 0.1 0.5 
GP mental health care items 1,530  1.7   1,530  1.8 1.6 2.0 
Surgical operations 1,166  1.3  1,105  1.3 1.1 1.5 
Diagnostic procedures and investigations  473  0.5   465  0.5 0.5 0.6 
Health assessments  488  0.5   488  0.6 0.5 0.7 
Therapeutic procedures  538  0.6   531  0.6 0.5 0.8 
Acupuncture  269  0.3   269  0.3 0.1 0.5 
Pathology services 148  0.2  144  0.2 0.1 0.2 
Attendances associated with Practice Incentives 
Program payments 
 236  0.3   236  0.3 0.2 0.3 
Diagnostic imaging services  4  0.0Ŧ   4  0.0Ŧ 0.0 0.0 
Other items  238  0.3   238  0.3 0.2 0.4 
Total items  89,394  100.0  — — — — 
(a) Up to three MBS/DVA items could be recorded at each encounter.  
(b) Identifies encounters where at least one item from the MBS group was recorded. 
Ŧ Rates are reported to one decimal place. This indicates that the rate is less than 0.05 per 100 encounters. 
Note: LCL – lower confidence limit; UCL – upper confidence limit; MBS – Medicare Benefits Schedule. 
5.3 Consultation length 
In a subsample of 34,928 BEACH MBS/DVA-claimable encounters at which start and finish 
times had been recorded by the GP, the mean length of consultation in 2012–13 was 
15.6 minutes (95% CI: 15.3–15.8). The median length was 14.0 minutes (results not tabled). 
For A1 MBS/DVA-claimable encounters, the mean length of consultation in 2012–13 was 
15.1 minutes (95% CI: 14.9–15.4), and the median length was 13.0 minutes (results not 
tabled). Methods describing the substudy from which data on consultation length are 
collected are described in Section 2.6. 
The determinants of consultation length were investigated by Britt et al. (2004) in 
Determinants of GP billing in Australia: content and time70 and Britt et al. (2005) in Determinants 
of consultation length in Australian general practice.71  
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5.4 Changes in the encounters over the decade 
2003–04 to 2012–13 
The companion report A decade of Australian general practice activity 2003–04 to 2012–13,1 
provides an overview of changes in general practice encounters over the past decade. The 
major changes between 2003–04 and 2012–13 are summarised below. 
• There was an increase in the average number of problems managed at encounter, from 
146 per 100 encounters in 2003–04 to 155 in 2012–13. This change was reflected in a 
marginal increase in the number of chronic problems managed per 100 encounters. 
However these changes did not result in an increase in the average length of GP–patient 
encounters which remained static over the decade. 
• The number of work-related problems managed significantly decreased over the past 9 
years from 3.1 to 2.4 per 100 encounters.  
Of the encounters claimable from Medicare/DVA: 
• short surgery consultations as a proportion of all Medicare/DVA claimed consultations 
increased over the study period 
• the proportion claimable as: chronic disease management items; health assessments; and 
GP mental health care, all increased significantly. 
The changes in management actions described below are measured in terms of rates per 100 
encounters. As there was a significant increase in the number of problems managed at 
encounters, it may therefore be more informative to consider changes in management actions 
in terms of rates per 100 problems managed as described in Section 8.1. 
• The number of procedures undertaken per 100 encounters rose significantly from 14.7 to 
17.4 per 100 encounters.  
• There was an increased rate of referrals, which was reflected in referrals to allied health 
services and (to a lesser degree) to medical specialists. 
• Pathology test/battery order rates increased by 34%. Orders for imaging tests also 
increased.  
5.5 Discussion 
The number of GP encounters with patients, measured by MBS attendance items for both 
GPs and other medical practitioners claiming primary care attendance items, increased from 
96.3 million in 2003–04 to 126.8 million in 2012–13 (see Section 2.11), an increase of 31.7% 
over the past decade. This is a great deal more than the increase in the Australian population 
during this period and may be driven by an ageing population with an increased number of 
chronic diseases requiring more frequent encounters. This is also reflected in the increase in 
the number of problems managed at encounter, from 146 to 155 per 100 encounters, and the 
increase in chronic problems managed from 51.9 to 55.7 per 100 encounters between 2003–04 
and 2012–13. 
A significant decrease in long surgery consultations occurred in 2008–09 and the rate has 
remained relatively low since. This coincided with concern being expressed by the Medicare 
Professional Services Review regarding the number of longer GP consultations being 
claimed from Medicare. A significant rise in chronic disease management items occurred in 
2008–09, (including GP management plans and team care arrangements) and these may be a 
partial substitute for long consultations for this group of patients. 
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The significant drop in clinical treatments given at GP encounters in 2005–06 coincided with 
the introduction of the MBS practice nurse items. This may represent a shift of some of this 
activity from GPs to practice nurses but undertaken by the nurse outside the encounter and 
therefore not recorded on the BEACH form. The rate of GP clinical treatments steadily 
increased since and is now back to 2003–04 levels. The recent removal of practice nurse 
Medicare items may alter this pattern further in the future. 
There was a decrease in home visits in the decade to 201072 and this has important 
implications for ageing patients wishing to be managed at home rather than in institutional 
care. The changes to the Medicare schedule in May 2010 mean that it is no longer possible to 
separate home visits from institutional visits using Medicare item numbers. The BEACH 
collection form has been altered from the 2012–13 BEACH data year onwards to ensure we 
can identify home visits in the future and provide information regarding this important 
aspect of GP care. 
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6 The patients 
This chapter reports data collected between April 2012 and March 2013 about the 
characteristics of patients at GP encounters and their reasons for encounter, from the 15th year 
of the BEACH program. Data on patient characteristics and reasons for encounter are 
reported for each year from 2003–04 to 2012–13 in the 10-year report A decade of Australian 
general practice activity 2003–04 to 2012–13.1  
6.1 Age–sex distribution of patients at encounter 
The age–sex distribution of patients at encounters is shown in Figure 6.1. Females accounted 
for the greater proportion (56.7%) of encounters (Table 6.1). This was reflected across all age 
groups except among children aged less than 15 years (Figure 6.1). 
Patients aged less than 25 years accounted for 19.7% of encounters, those aged 25–44 years 
for 22.2%, those aged 45–64 years accounted for 27.6% and those aged 65 years and over for 
30.5% of encounters (Table 6.1). 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Missing data removed. The distributions will not agree perfectly with those in Table 6.1 because of missing data in either age or  
sex fields. 
Figure 6.1: Age–sex distribution of patients at encounter, 2012–13 
 
The relationship between patient age, patient general practice attendance rates and the age 
distribution of the Australian population was reported in General practice activity in Australia, 
health priorities and policies 1998 to 2008.73  
Age group (years) 
Per cent of encounters 
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6.2 Other patient characteristics 
Table 6.1 presents other characteristics of the patients at GP encounters. In summary: 
• the patient was new to the practice at 7.2% of encounters 
• nearly half of the encounters were with patients who held a Commonwealth concession 
card (46.0%) and/or a Repatriation Health Card (2.3%) 
• at 12.0% of encounters the patient was from a non-English-speaking background 
• at 1.5% of encounters the patient identified themselves as an Aboriginal and/or Torres 
Strait Islander person. 
Table 6.1: Characteristics of the patients at encounters 
Patient characteristics Number 
Per cent of encounters 
(n = 98,564) 
95% 
LCL 
95%  
UCL 
Sex (missing)(a) (823)    
 Males 42,314 43.3 42.5 44.1 
 Females 55,427 56.7 55.9 57.5 
Age group (missing)(a) (825)    
 < 1 year 1,769 1.8 1.7 1.9 
 1–4 years 4,402 4.5 4.2 4.8 
 5–14 years 5,104 5.2 4.9 5.5 
 15–24 years 7,975 8.2 7.7 8.6 
 25–44 years 21,734 22.2 21.4 23.1 
 45–64 years 26,971 27.6 27.0 28.2 
 65–74 years 13,839 14.2 13.6 14.7 
 75+ years 15,946 16.3 15.4 17.3 
New patient to practice (missing)(a) (1,432)    
 New patient to practice 7,018 7.2 6.6 7.9 
 Patient seen previously 90,114 92.8 92.1 93.4 
Commonwealth concession card status (missing)(a) (7,935)    
 Has a Commonwealth concession card 42,624 46.0 44.4 47.6 
 No Commonwealth concession card 50,000 54.0 52.4 55.6 
Repatriation Health Card status (missing)(a) (9,996)    
 Has a Repatriation Health Card 2,095 2.3 2.1 2.5 
 No Repatriation Health Card 89,126 97.7 97.5 97.9 
Language status (missing)(a) (10,001)    
 Non-English-speaking background(b) 10,606 12.0 10.0 14.0 
 English-speaking background 77,956 88.0 86.0 90.0 
Indigenous status (missing)(a) (9,681)    
 Aboriginal and/or Torres Strait Islander(c) 1,373 1.5 1.2 1.9 
 Non-Indigenous 87,510 98.5 98.1 98.8 
(a) Missing data removed. 
(b) Speaks a language other than English as their primary language at home. 
(c) Self identified.  
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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6.3 Patient reasons for encounter 
Patient reasons for encounter (RFEs) reflect the patient’s demand for care and can provide an 
indication of service use patterns, which may benefit from intervention at a population 
level.74  
RFEs are those concerns and expectations that patients bring to the GP. Participating GPs 
were asked to record at least one and up to three patient RFEs in words as close as possible 
to those used by the patient, before the diagnostic or management process had begun. These 
reflect the patient’s view of their reasons for consulting the GP. RFEs can be expressed in 
terms of one or more symptoms (for example, ‘itchy eyes’, ‘chest pain’), in diagnostic terms 
(for example, ‘about my diabetes’, ‘for my hypertension’), a request for a service (‘I need 
more scripts’, ‘I want a referral’), an expressed fear of disease or a need for a check-up. 
Patient RFEs can have a one-to-one, one-to-many, many-to-one or many-to-many 
relationship to problems managed. That is, the patient may describe a single RFE that relates 
to a single problem managed at the encounter, a single RFE that relates to multiple problems, 
multiple RFEs that relate to a single problem managed, or multiple RFEs that relate to 
multiple problems managed at the encounter. GPs may also manage a problem that was 
unrelated to the patient’s RFE (e.g. a patient presents about their diabetes but while they are 
there the GP also provides a vaccination and performs a Pap smear). 
Number of reasons for encounter 
There were 152,278 RFEs recorded at 98,564 encounters in 2012–13 (Table 6.3). At 58.0% of 
encounters only one RFE was recorded, at 29.4% two RFEs were recorded and at 12.5% of 
encounters three RFEs were recorded (Table 6.2). On average patients presented with 154.5 
RFEs per 100 encounters, or about one and a half RFEs per encounter (Table 6.3). 
Table 6.2: Number of patient reasons for encounter  
Number of RFEs at encounter 
Number of encounters 
(n = 98,564) 
Per cent of 
encounters 
95% 
LCL 
95% 
UCL 
One RFE 57,209 58.0 56.8 59.3 
Two RFEs 28,996 29.4 28.7 30.1 
Three RFEs 12,359 12.5 11.9 13.2 
Total 98,564 100.0 — — 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
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Reasons for encounter by ICPC-2 component 
The distribution of patient RFEs by ICPC-2 component is presented in Table 6.3, expressed as 
a percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits. In the 
‘diagnosis, diseases’ group we provide data about infections, injuries, neoplasms, congenital 
anomalies and ‘other’ diagnoses.  
Approximately 4 out of 10 (41.6%) patient RFEs were expressed in terms of a symptom or 
complaint (for example, ‘tired’, ‘fever’). RFEs described in diagnostic terms (for example, 
‘about my diabetes’, ‘for my depression’) accounted for 19.3% of RFEs. The remaining 39.1% 
of RFEs were described in terms of processes of care, such as requests for a health check, 
requests for prescriptions, referrals, test results or medical certificates. 
On average at 100 encounters, patients described 64.3 ‘symptom or complaint’ RFEs, 
described 29.9 diagnosis/disease RFEs, made 24.6 requests for a procedure and made 15.4 
requests for treatment. 
Table 6.3: Patient reasons for encounter by ICPC-2 component 
ICPC-2 component Number 
Per cent of  
total RFEs 
(n = 152,278) 
Rate per 100 
encounters 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
Symptoms and complaints 63,341 41.6 64.3 62.4 66.2 
Diagnosis, diseases 29,442 19.3 29.9 28.4 31.4 
 Infections 7,473 4.9 7.6 7.1 8.1 
 Injuries 4,168 2.7 4.2 4.0 4.4 
 Neoplasms 1,021 0.7 1.0 0.9 1.2 
 Congenital anomalies 226 0.1 0.2 0.2 0.3 
 Other diagnoses, diseases 16,554 10.9 16.8 15.7 17.9 
Diagnostic and preventive procedures 24,293 16.0 24.6 23.7 25.6 
Medications, treatments and therapeutics 15,212 10.0 15.4 14.7 16.2 
Results 8,929 5.9 9.1 8.6 9.5 
Referrals and other RFEs 7,937 5.2 8.1 7.5 8.6 
Administrative 3,124 2.1 3.2 2.9 3.4 
Total RFEs 152,278 100.0 154.5 152.7 156.3 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit. 
Reasons for encounter by ICPC-2 chapter 
The distribution of patient RFEs by ICPC-2 chapter and the most common RFEs within each 
chapter are presented in Table 6.4. Each chapter and individual RFE is expressed as a 
percentage of all RFEs and as a rate per 100 encounters with 95% confidence limits.  
RFEs of a general and unspecified nature were presented at a rate of 44.4 per 100 encounters, 
with requests for prescriptions, general check-ups and test results the most frequently 
recorded of these. RFEs related to the respiratory system occurred at a rate of 20.8 per 100 
encounters, those related to the musculoskeletal system at a rate of 15.8 per 100, and those 
relating to skin at a rate of 15.0 per 100 encounters (Table 6.4).  
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Table 6.4: Patient reasons for encounter by ICPC-2 chapter and most frequent individual reasons 
for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 152,278) 
Rate per 100 
encounters 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
General and unspecified 43,809 28.8 44.4 43.2 45.7 
 Prescription NOS 9,336 6.1 9.5 8.9 10.1 
 General check-up* 4,584 3.0 4.7 4.3 5.0 
 Results tests/procedures NOS 7,627 5.0 7.7 7.3 8.2 
 Administrative procedure NOS 2,812 1.8 2.9 2.6 3.1 
 Immunisation/vaccination NOS 2,002 1.3 2.0 1.9 2.2 
 Fever 1,891 1.2 1.9 1.7 2.1 
 Weakness/tiredness 1,394 0.9 1.4 1.3 1.5 
 Other referrals NEC 1,310 0.9 1.3 1.2 1.5 
 Blood test NOS 1,195 0.8 1.2 1.0 1.4 
 Other reason for encounter NEC 1,005 0.7 1.0 0.7 1.3 
 Observation/health education/advice/diet NOS 977 0.6 1.0 0.9 1.1 
 Follow-up encounter unspecified 976 0.6 1.0 0.9 1.1 
 Chest pain NOS 880 0.6 0.9 0.8 1.0 
 Trauma/injury NOS 787 0.5 0.8 0.7 0.9 
 Clarify or discuss patient’s RFE 761 0.5 0.8 0.7 0.9 
Respiratory 20,492 13.5 20.8 19.9 21.7 
 Cough 6,201 4.1 6.3 5.8 6.8 
 Throat symptom/complaint 2,476 1.6 2.5 2.3 2.7 
 Immunisation/vaccination – respiratory 2,346 1.5 2.4 2.0 2.8 
 Upper respiratory tract infection 2,257 1.5 2.3 2.0 2.5 
 Sneezing/nasal congestion 1,229 0.8 1.2 1.1 1.4 
 Shortness of breath/dyspnoea 771 0.5 0.8 0.7 0.9 
 Asthma 730 0.5 0.7 0.7 0.8 
Musculoskeletal 15,547 10.2 15.8 15.2 16.3 
 Back complaint* 3,138 2.1 3.2 3.0 3.4 
 Knee symptom/complaint 1,439 0.9 1.5 1.4 1.6 
 Shoulder symptom/complaint 1,281 0.8 1.3 1.2 1.4 
 Foot/toe symptom/complaint 1,144 0.8 1.2 1.1 1.3 
 Leg/thigh symptom/complaint 975 0.6 1.0 0.9 1.1 
 Neck symptom/complaint 826 0.5 0.8 0.7 0.9 
 Musculoskeletal injury NOS 744 0.5 0.8 0.7 0.8 
Skin 14,822 9.7 15.0 14.4 15.6 
 Rash* 2,550 1.7 2.6 2.4 2.8 
 Skin symptom/complaint, other 1,510 1.0 1.5 1.4 1.7 
 Skin check-up* 1,477 1.0 1.5 1.2 1.8 
 Swelling (skin)* 1,032 0.7 1.0 1.0 1.1 
 Laceration/cut 686 0.5 0.7 0.6 0.8 
(continued) 
48
  
Table 6.4 (continued): Patient reasons for encounter by ICPC-2 chapter and most frequent 
individual reasons for encounter within chapter  
Reasons for encounter Number 
Per cent of 
total RFEs(a) 
(n = 152,278) 
Rate per 100 
encounters 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
Digestive 9,361 6.1 9.5 9.1 9.9 
 Abdominal pain* 2,002 1.3 2.0 1.9 2.2 
 Diarrhoea 1,165 0.8 1.2 1.1 1.3 
 Vomiting 727 0.5 0.7 0.7 0.8 
Psychological 9,180 6.0 9.3 8.8 9.8 
 Depression* 2,248 1.5 2.3 2.1 2.5 
 Anxiety* 1,340 0.9 1.4 1.2 1.5 
 Sleep disturbance 1,071 0.7 1.1 1.0 1.2 
 Acute stress reaction 700 0.5 0.7 0.6 0.8 
Cardiovascular 9,012 5.9 9.1 8.7 9.6 
 Cardiovascular check-up* 3,580 2.4 3.6 3.3 3.9 
 Hypertension/high blood pressure* 1,885 1.2 1.9 1.7 2.2 
 Prescription – cardiovascular 703 0.5 0.7 0.6 0.8 
Endocrine and metabolic 6,142 4.0 6.2 5.9 6.6 
 Diabetes (non-gestational)* 1,396 0.9 1.4 1.3 1.6 
 Prescription – endocrine/metabolic 935 0.6 0.9 0.8 1.1 
Neurological 4,325 2.8 4.4 4.2 4.6 
 Headache* 1,652 1.1 1.7 1.5 1.8 
 Vertigo/dizziness 1,002 0.7 1.0 0.9 1.1 
Female genital system 4,298 2.8 4.4 4.0 4.7 
 Female genital check-up/Pap smear* 1,556 1.0 1.6 1.4 1.8 
Ear 3,518 2.3 3.6 3.4 3.7 
 Ear pain/earache 1,290 0.8 1.3 1.2 1.4 
Pregnancy and family planning 3,216 2.1 3.3 3.0 3.5 
 Pre/post natal check-up* 708 0.5 0.7 0.6 0.8 
Urology 2,701 1.8 2.7 2.6 2.9 
Eye 1,998 1.3 2.0 1.9 2.2 
Blood and blood forming organs 1,673 1.1 1.7 1.5 1.9 
 Blood test – blood and blood forming organs 1,086 0.7 1.1 0.9 1.3 
Male genital system 1,144 0.8 1.2 1.1 1.3 
Social 1,041 0.7 1.1 1.0 1.2 
Total RFEs 152,278 100.0 154.5 152.7 156.3 
(a) Only individual RFEs accounting for ≥ 0.5% of total RFEs are included. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; NOS – not 
otherwise specified. 
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Most frequent patient reasons for encounter 
The 30 most commonly recorded RFEs (Table 6.5), accounted for more than half (58.6%) of all 
RFEs. In this analysis the specific ICPC-2 chapter to which an across-chapter concept belongs 
is disregarded, so that, for example, ‘check-up – all’ includes all check-ups from all ICPC-2 
chapters, irrespective of whether or not the body system was specified.  
Table 6.5: Thirty most frequent patient reasons for encounter 
Patient reason for encounter Number 
Per cent of  
total RFEs 
(n = 152,278) 
Rate per 100 
encounters 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
 Check-up – all* 12,899 8.5 13.1 12.4 13.7 
 Prescription – all* 12,545 8.2 12.7 12.0 13.4 
 Test results* 8,929 5.9 9.1 8.6 9.5 
 Cough 6,201 4.1 6.3 5.8 6.8 
 Immunisation/vaccination – all* 4,486 2.9 4.6 4.1 5.0 
 Back complaint* 3,138 2.1 3.2 3.0 3.4 
 Administrative procedure – all* 3,124 2.1 3.2 2.9 3.4 
 Blood test – all* 2,811 1.8 2.9 2.6 3.1 
 Rash* 2,550 1.7 2.6 2.4 2.8 
 Throat symptom/complaint 2,476 1.6 2.5 2.3 2.7 
 Upper respiratory tract infection 2,257 1.5 2.3 2.0 2.5 
 Depression* 2,248 1.5 2.3 2.1 2.5 
 Abdominal pain* 2,002 1.3 2.0 1.9 2.2 
 Fever 1,891 1.2 1.9 1.7 2.1 
 Hypertension/high blood pressure* 1,885 1.2 1.9 1.7 2.2 
 Headache* 1,652 1.1 1.7 1.5 1.8 
 Observation/health education/advice/diet – all* 1,591 1.0 1.6 1.5 1.8 
 Skin symptom/complaint, other 1,510 1.0 1.5 1.4 1.7 
 Knee symptom/complaint 1,439 0.9 1.5 1.4 1.6 
 Diabetes – all* 1,406 0.9 1.4 1.3 1.6 
 Weakness/tiredness 1,394 0.9 1.4 1.3 1.5 
 Anxiety* 1,340 0.9 1.4 1.2 1.5 
 Other referrals NEC 1,310 0.9 1.3 1.2 1.5 
 Ear pain/earache 1,290 0.8 1.3 1.2 1.4 
 Shoulder symptom/complaint 1,281 0.8 1.3 1.2 1.4 
 Sneezing/nasal congestion 1,229 0.8 1.2 1.1 1.4 
 Diarrhoea 1,165 0.8 1.2 1.1 1.3 
 Foot/toe symptom/complaint 1,144 0.8 1.2 1.1 1.3 
 Sleep disturbance 1,071 0.7 1.1 1.0 1.2 
 Swelling (skin)* 1,032 0.7 1.0 1.0 1.1 
Subtotal 89,298 58.6 — — — 
Total RFEs 152,278 100.0 154.5 152.7 156.3 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: RFEs – reasons for encounter; LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
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Of the top 30 RFEs (Table 6.5), most were either symptom or disease descriptions such as 
cough, throat complaint, back complaint and rash. However, four of the top five RFEs 
reflected requests for a process of care (that is, requests for check-up, prescription, test result 
and immunisation), and together accounted for about one-quarter of all RFEs (25.5%) 
6.4 Changes in patients and their reasons for 
encounter over the decade 2003–04 to 2012–13 
An overview of changes in the characteristics of patients at encounters and their reasons for 
encounter over the decade 2003–04 to 2012–13 can be found in Chapter 6 of the companion 
report A decade of Australian general practice activity 2003–04 to 2012–13.1 Major changes are 
summarised below.  
With the ageing of the Australian population, the proportion of the Australian population 
that was aged 45 years and over increased from 36.6% in 2003 to 39.0% in 2012.2 Over the 
same period the proportion of BEACH encounters with patients aged 45 years and over 
increased from 54.0% to 58.1%. When extrapolated, this change (in combination with the 
increased number of encounters nationally) means that in 2012–13 there were only about 
8.8 million more encounters with younger patients, but about 21.7 million more with older 
patients nationally than a decade earlier. 
The increase in the proportion of encounters with older patients was greater than the 
population increase in this age group, because older patients attend general practice more 
often than do younger patients.75 This change in the age distribution of patients at GP 
encounters will affect all aspects of general practice as older patients are more likely to have 
more problems managed at encounters (see Section 7.1), more chronic conditions managed 
and are more likely to have multimorbidity.24 
There was a significant decrease in the proportion of encounters with patients who were new 
to the practice (from 9.3% in 2003–04 to 7.2% in 2012–13). This may be due to the need for 
continuity of care for chronic conditions. The proportion of encounters with patients holding 
a Commonwealth concession card was relatively stable through the decade, but the 
proportion with patients holding a Repatriation Health Card decreased by over one-third, 
from 3.9% in 2003–04 to 2.3% in 2012–13. This is probably due to a decline in the number of 
World War 2 veterans and their partners in the population. 
Over the decade there was a significant increase in the number of reasons for encounter 
recorded per 100 encounters, from 150.2 in 2003–04 to 154.5 in 2012–13, with fewer patients 
giving a single RFE and more giving two or three RFEs. This increase in RFEs is also 
probably related to the increasing proportion of encounters with older people, who are more 
likely to visit for multiple chronic disease management. There was a significant decrease in 
the rate of RFEs described as symptoms and complaints, and increases in rates of patient 
presentations for tests and test results. This is also probably due to the increased proportion 
of encounters that are with older patients and the increase in chronic condition management 
which require regular attendance and monitoring. The increase in patients’ requests for tests 
and test results ties in with the increased use of pathology and imaging testing over the 
decade (see Chapter 12). One increase unrelated to the ageing of the population was a large 
increase in requests for administrative procedures such as sickness certificates. This is 
probably due to increasing number of policies forcing workers to provide such 
documentation to claim sick days. 
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7 Problems managed 
A ‘problem managed’ is a formal statement of the provider’s understanding of a health 
problem presented by the patient, family or community, and can be described in terms of a 
disease, symptom or complaint, social problem or ill-defined condition managed at the 
encounter. As GPs were instructed to record each problem at the most specific level possible 
from the information available, the problem managed may at times be limited to the level of 
a presenting symptom. 
At each patient encounter, up to four problems could be recorded by the GP. A minimum of 
one problem was compulsory. The status of each problem to the patient – new (first 
presentation to a medical practitioner) or old (follow-up of previous problem) – was also 
indicated. The concept of a principal diagnosis, which is often used in hospital statistics, is 
not adopted in studies of general practice where multiple problem management is the norm 
rather than the exception. Further, the range of problems managed at the encounter often 
crosses multiple body systems and may include undiagnosed symptoms, psychosocial 
problems or chronic disease, which makes the designation of a principal diagnosis difficult. 
Thus, the order in which the problems were recorded by the GP is not significant. All 
problems managed in general practice are included in this section, including those that 
involved management by a practice nurse at the recorded encounter. Problems that included 
management by a practice nurse are reported specifically in Chapter 10. 
There are two ways to describe the frequency of problems managed: as a percentage of all 
problems managed in the study or as a rate at which problems are managed per 
100 encounters. Where groups of problems are reported (for example, cardiovascular 
problems) it must be remembered that more than one of that type of problem (such as 
hypertension and heart failure) may have been managed at a single encounter. In 
considering these results, the reader must be mindful that although a rate per 100 encounters 
for a single ungrouped problem, for example, ‘asthma, 2.0 per 100 encounters’, can be 
regarded as equivalent to ‘asthma is managed at 2.0% of encounters’, such a statement 
cannot be made for grouped concepts (ICPC-2 chapters and those marked with asterisks in 
the tables). 
Data on problems managed in Australian general practice from the BEACH study are 
reported for each year from 2003–04 to 2012–13 in the 10-year report A decade of Australian 
general practice activity 2003–04 to 2012–13.1  
7.1 Number of problems managed at encounter 
In 2012–13 there were 152,517 problems managed, at a rate of 154.7 per 100 encounters 
(Table 7.2, total row). Table 7.1 shows the number of problems managed at each encounter. 
As described in Chapter 2, up to 4 problems managed can be recorded at each BEACH 
encounter. One problem was managed at 61.5% of encounters and two problems managed at 
one-quarter of encounters (25.7%). Nearly 10% of encounters involved the management of 
three problems (9.5%), and four problems were managed at only 3.3% of encounters. 
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Table 7.1: Number of problems managed at an encounter 
Number of problems managed at encounter Number of encounters Per cent 95% LCL 95% UCL 
One problem 60,572 61.5 60.2 62.8 
Two problems 25,331 25.7 25.0 26.4 
Three problems 9,359 9.5 9.0 10.0 
Four problems 3,301 3.3 3.0 3.7 
Total 98,564 100.0 — — 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Figure 7.1 shows the age–sex-specific rates of problems managed. The number of problems 
managed increased steadily with the age of the patient, from young adulthood onward.  
Significantly more problems were managed overall at encounters with female patients 
(157.5 per 100 encounters, 95% CI: 155.1–159.9) than at those with male patients (151.4 per 
100 encounters, 95% CI: 148.9–153.8) (results not tabled). Figure 7.1 demonstrates that this 
difference was particularly evident in the 15–24 and 25–44 year age groups. The number of 
problems managed at encounters significantly increased with each step in adult age, then 
levelled out in the oldest age groups (65–74 and 75 years and over). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Missing data removed.  
Figure 7.1: Age–sex-specific rates of problems managed per 100 encounters with 95% CI, 2012–13 
 
Rate per 100 encounters 
Age group (years) 
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7.2 Problems managed by ICPC-2 component 
A broader view of the types of problems managed in general practice can be seen by 
examining problems managed from the perspective of the component structure of the  
ICPC-2 classification (as described in Section 2.8). Table 7.2 lists the distribution of problems 
managed by ICPC-2 component.  
Two-thirds (66.5%) of problems were expressed as diagnoses or diseases. Of these, the 
majority were ‘other diagnoses’ (accounting for 43.1% of all problems managed), followed by 
infections (15.3%), injuries (4.7%) and neoplasms (3.0%). 
Nearly 1 in 5 problems (18.5%) were managed as a symptom or complaint. In some 
situations, rather than providing clinical descriptions of the problem under management, 
processes of care were recorded. The processes recorded most often were diagnostic and 
preventive procedures (e.g. check-ups), accounting for 9.3% of problems managed. 
At an ‘average’ 100 encounters GPs managed 103 diagnoses/diseases: 24 infections; 7 
injuries; and 5 neoplasms. They also managed 29 symptoms and complaints, and described 
the problem in terms of diagnostic and preventive procedures at 15 encounters.  
Table 7.2: Problems managed by ICPC-2 component 
ICPC-2 component Number 
Per cent of 
total problems 
(n = 152,517) 
Rate per 100 
encounters 
(n = 98,564) 
95% 
 LCL 
95% 
 UCL 
Diagnosis, diseases 101,388 66.5 102.9 100.9 104.9 
 Infections 23,318 15.3 23.7 22.8 24.5 
 Injuries 7,146 4.7 7.2 7.0 7.5 
 Neoplasms 4,581 3.0 4.6 4.3 5.0 
 Congenital anomalies 646 0.4 0.7 0.6 0.7 
 Other diagnoses 65,696 43.1 66.7 64.6 68.7 
Symptoms and complaints 28,280 18.5 28.7 27.8 29.6 
Diagnostic and preventive procedures 14,247 9.3 14.5 13.7 15.2 
Medications, treatments and therapeutics 3,866 2.5 3.9 3.6 4.3 
Results 2,019 1.3 2.0 1.8 2.2 
Referrals and other RFEs 1,303 0.9 1.3 1.2 1.5 
Administrative 1,414 0.9 1.4 1.3 1.6 
Total problems  152,517 100.0 154.7 152.5 157.0 
Note: LCL – lower confidence limit; UCL – upper confidence limit; RFE – reason for encounter.  
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7.3 Problems managed by ICPC-2 chapter 
The frequency and the distribution of problems managed, by ICPC-2 chapter, are presented 
in Table 7.3. Rates per 100 encounters and the proportion of total problems are provided at 
the ICPC-2 chapter level, and for frequent individual problems within each chapter. Only 
those individual problems accounting for at least 0.5% of all problems managed are listed in 
the table, in decreasing order of frequency. 
The most common problems managed were: 
• those classified to the respiratory system (20.1 per 100 encounters), in particular upper 
respiratory tract infection, respiratory immunisations, acute bronchitis and asthma 
• problems of a general and unspecified nature (19.3 per 100 encounters), particularly 
general check-ups, general immunisations and prescriptions 
• musculoskeletal problems (17.7 per 100 encounters), such as arthritis and back complaint 
• skin problems (16.9 per 100 encounters), contact dermatitis and malignant skin neoplasm 
being the most common 
• cardiovascular problems (16.5 per 100 encounters), led by hypertension and atrial 
fibrillation (Table 7.3). 
Table 7.3: Problems managed by ICPC-2 chapter and frequent individual problems within chapter  
Problem managed  Number 
Per cent total 
problems  
(n = 152,517) 
Rate per 100 
encounters(a) 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
Respiratory 19,774 13.0 20.1 19.4 20.8 
 Upper respiratory tract infection 5,716 3.7 5.8 5.3 6.3 
 Immunisation/vaccination – respiratory 2,730 1.8 2.8 2.3 3.2 
 Acute bronchitis/bronchiolitis 2,306 1.5 2.3 2.1 2.5 
 Asthma 2,124 1.4 2.2 2.0 2.3 
 Sinusitis acute/chronic  1,209 0.8 1.2 1.1 1.3 
 Chronic obstructive pulmonary disease 921 0.6 0.9 0.8 1.0 
General and unspecified 19,052 12.5 19.3 18.6 20.1 
 General check-up* 2,869 1.9 2.9 2.7 3.1 
 Immunisation/vaccination NOS 1,948 1.3 2.0 1.8 2.1 
 Prescription NOS 1,621 1.1 1.6 1.4 1.9 
 Results tests/procedures NOS 1,532 1.0 1.6 1.4 1.7 
 Administrative procedure NOS 1,243 0.8 1.3 1.1 1.4 
 Abnormal result/investigation NOS 1,043 0.7 1.1 1.0 1.2 
 Viral disease, other/NOS 971 0.6 1.0 0.9 1.1 
(continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 152,517) 
Rate per 100 
encounters(a) 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
Musculoskeletal 17,462 11.5 17.7 17.2 18.3 
 Arthritis – all* 3,225 2.1 3.3 3.1 3.5 
  Osteoarthritis* 2,789 1.8 2.8 2.6 3.0 
 Back complaint* 2,906 1.9 2.9 2.8 3.1 
 Sprain/strain* 1,357 0.9 1.4 1.2 1.5 
 Fracture* 896 0.6 0.9 0.8 1.0 
 Injury musculoskeletal NOS 880 0.6 0.9 0.8 1.0 
 Osteoporosis 834 0.5 0.8 0.7 0.9 
Skin 16,644 10.9 16.9 16.3 17.5 
 Contact dermatitis 1,764 1.2 1.8 1.7 1.9 
 Malignant neoplasm, skin 1,169 0.8 1.2 1.0 1.3 
 Solar keratosis/sunburn 1,102 0.7 1.1 1.0 1.3 
 Laceration/cut 961 0.6 1.0 0.9 1.1 
 Skin disease, other 802 0.5 0.8 0.7 0.9 
 Skin symptom/complaint, other 691 0.5 0.7 0.6 0.8 
Cardiovascular 16,271 10.7 16.5 15.8 17.3 
 Hypertension* 8,482 5.6 8.6 8.1 9.1 
 Atrial fibrillation/flutter 1,405 0.9 1.4 1.3 1.6 
 Ischaemic heart disease* 1,058 0.7 1.1 0.9 1.2 
 Cardiovascular check-up* 779 0.5 0.8 0.7 0.9 
Endocrine and metabolic 13,558 8.9 13.8 13.1 14.4 
 Diabetes (non-gestational)* 4,157 2.7 4.2 3.9 4.5 
 Lipid disorder 3,292 2.2 3.3 3.1 3.6 
 Vitamin/nutritional deficiency 1,466 1.0 1.5 1.3 1.6 
 Hypothyroidism/myxoedema  923 0.6 0.9 0.8 1.0 
Psychological 12,870 8.4 13.1 12.4 13.7 
 Depression* 4,084 2.7 4.1 3.9 4.4 
 Anxiety* 2,085 1.4 2.1 1.9 2.3 
 Sleep disturbance 1,534 1.0 1.6 1.4 1.7 
 Acute stress reaction 725 0.5 0.7 0.7 0.8 
Digestive 10,779 7.1 10.9 10.6 11.3 
 Oesophageal disease 2,538 1.7 2.6 2.4 2.8 
 Gastroenteritis* 1,294 0.8 1.3 1.2 1.4 
Female genital system 5,191 3.4 5.3 4.9 5.6 
 Female genital check-up/Pap smear* 1,546 1.0 1.6 1.4 1.7 
(continued) 
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Table 7.3 (continued): Problems managed by ICPC-2 chapter and frequent individual problems 
within chapter 
Problem managed  Number 
Per cent total 
problems  
(n = 152,517) 
Rate per 100 
encounters(a) 
(n = 98,564) 
95%  
LCL 
95%  
UCL 
Ear 3,740 2.5 3.8 3.6 4.0 
 Acute otitis media/myringitis 1,059 0.7 1.1 1.0 1.2 
 Excessive ear wax 733 0.5 0.7 0.7 0.8 
Pregnancy and family planning 3,629 2.4 3.7 3.4 4.0 
 Pregnancy* 1,281 0.8 1.3 1.1 1.5 
 Oral contraception* 1,045 0.7 1.1 1.0 1.2 
Neurological 3,594 2.4 3.7 3.5 3.8 
Urology 3,416 2.2 3.5 3.3 3.6 
 Urinary tract infection* 1,678 1.1 1.7 1.6 1.8 
Eye 2,226 1.5 2.3 2.1 2.4 
Male genital system 1,809 1.2 1.8 1.7 2.0 
Blood and blood forming organs 1,613 1.1 1.6 1.5 1.8 
Social 888 0.6 0.9 0.8 1.0 
Total problems 152,517 100.0 154.7 152.5 157.0 
(a) Only those individual problems accounting for ≥ 0.5% of total problems are included in the table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.4 Most frequently managed problems 
Table 7.4 shows the most frequently managed individual problems in general practice, in 
decreasing order of frequency. These problems accounted for 52.9% of all problems 
managed, and the top 10 problems accounted for 30.4%. 
In this analysis, the specific chapter to which ‘across chapter concepts’ (for example, 
check-ups, immunisation/vaccination and prescriptions) apply is ignored, and the concept is 
grouped with all similar concepts regardless of body system. For example, immunisation/ 
vaccination includes vaccinations for influenza, childhood diseases, hepatitis and many 
others. 
The most common problems managed were hypertension (8.6 per 100 encounters), 
check-ups (6.4 per 100), upper respiratory tract infection (URTI) (5.8 per 100), 
immunisation/vaccination (5.0 per 100), and diabetes (4.2 per 100) (Table 7.4).  
The far right-hand column in Table 7.4 lists the percentage of each problem that was new to 
the patient. The problem is considered new if it is a new problem or a new episode of a 
recurrent problem, and the patient has not been treated for that problem or episode by any 
medical practitioner before. This can provide a measure of general practice incidence. For 
example, only 5.3% of all contacts with diabetes were new diagnoses. In contrast, 77.4% of 
URTI problems were new to the patient, suggesting that the majority of people attend the GP 
for URTI only once per episode.  
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Table 7.4: Most frequently managed problems 
Problem managed Number 
Per cent of 
total problems 
(n = 152,517) 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Hypertension* 8,482 5.6 8.6 8.1 9.1 5.0 
Check-up – all* 6,304 4.1 6.4 6.0 6.8 45.1 
Upper respiratory tract infection 5,716 3.7 5.8 5.3 6.3 77.4 
Immunisation/vaccination – all* 4,922 3.2 5.0 4.5 5.5 61.3 
Diabetes – all* 4,186 2.7 4.2 4.0 4.5 5.3 
Depression* 4,084 2.7 4.1 3.9 4.4 14.6 
Arthritis – all* 3,743 2.5 3.8 3.6 4.0 18.2 
Lipid disorder 3,292 2.2 3.3 3.1 3.6 10.9 
Back complaint* 2,906 1.9 2.9 2.8 3.1 23.3 
Prescription – all* 2,677 1.8 2.7 2.4 3.0 5.8 
Gastro-oesophageal reflux 
disease* 
2,538 1.7 2.6 2.4 2.8 15.8 
Acute bronchitis/bronchiolitis 2,306 1.5 2.3 2.1 2.5 70.9 
Asthma 2,124 1.4 2.2 2.0 2.3 17.1 
Anxiety* 2,085 1.4 2.1 1.9 2.3 16.3 
Test results* 2,019 1.3 2.0 1.8 2.2 29.4 
Contact dermatitis 1,764 1.2 1.8 1.7 1.9 48.0 
Urinary tract infection* 1,678 1.1 1.7 1.6 1.8 63.7 
Sleep disturbance 1,534 1.0 1.6 1.4 1.7 18.8 
Vitamin/nutritional deficiency 1,466 1.0 1.5 1.3 1.6 32.5 
Administrative procedure – all* 1,414 0.9 1.4 1.3 1.6 42.2 
Atrial fibrillation/flutter 1,405 0.9 1.4 1.3 1.6 6.6 
Sprain/strain* 1,357 0.9 1.4 1.2 1.5 59.6 
Gastroenteritis* 1,294 0.8 1.3 1.2 1.4 75.9 
Pregnancy* 1,281 0.8 1.3 1.1 1.5 36.4 
Abnormal test results* 1,265 0.8 1.3 1.2 1.4 45.8 
Sinusitis acute/chronic 1,209 0.8 1.2 1.1 1.3 64.4 
Malignant neoplasm, skin 1,169 0.8 1.2 1.0 1.3 54.9 
Bursitis/tendonitis/synovitis NOS 1,110 0.7 1.1 1.0 1.2 56.2 
Solar keratosis/sunburn 1,102 0.7 1.1 1.0 1.3 48.3 
Headache* 1,073 0.7 1.1 1.0 1.2 34.3 
Acute otitis media/myringitis 1,059 0.7 1.1 1.0 1.2 71.7 
Ischaemic heart disease* 1,058 0.7 1.1 0.9 1.2 7.2 
Oral contraception* 1,045 0.7 1.1 1.0 1.2 17.6 
Subtotal  80,667 52.9 — — — — 
Total problems 152,517 100.0 154.7 152.5 157.0 37.0 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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7.5 Most common new problems 
For each problem managed, participating GPs are asked to indicate whether the problem 
under management was a new problem for the patient (see definition in Section 7.4). 
Table 7.5 lists the most common new problems managed in general practice, in decreasing 
order of frequency. Overall, 56,454 problems (37.0% of all problems) were specified as being 
new, being managed at a rate of 57.3 per 100 encounters. 
New problems were often acute in nature, such as upper respiratory tract infections (4.5 
per 100 encounters), acute bronchitis/bronchiolitis (1.7 per 100) and urinary tract infection 
(1.1 per 100). Preventive activities were also frequently recorded, including immunisation/ 
vaccination (3.1 per 100 encounters) and check-ups (2.9 per 100) (Table 7.5). 
The far right-hand column of this table shows the new cases of this problem as a proportion 
of total contacts with this problem. This provides an indication of the incidence of each 
problem. For example, the 681 new cases of arthritis represented only 18% of all GP contacts 
with diagnosed arthritis, suggesting that by far the majority of contacts for arthritis were for 
ongoing management. In contrast, 71% of acute bronchitis contacts were first consultations to 
a medical practitioner for this episode, the balance (29%) being follow-up consultations for 
this episode. This indicates that most patients only require one visit to a GP for the 
management of an episode of acute bronchitis. 
Table 7.5: Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 56,454) 
Rate per 100 
 encounters 
(n = 98,564) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Upper respiratory tract infection 4,424 7.8 4.5 4.1 4.9 77.4 
Immunisation/vaccination – all* 3,016 5.3 3.1 2.7 3.4 61.3 
Check-up – all* 2,843 5.0 2.9 2.7 3.1 45.1 
Acute bronchitis/bronchiolitis 1,635 2.9 1.7 1.5 1.8 70.9 
Urinary tract infection* 1,069 1.9 1.1 1.0 1.2 63.7 
Gastroenteritis* 982 1.7 1.0 0.9 1.1 75.9 
Contact dermatitis  846 1.5 0.9 0.8 0.9 48.0 
Sprain/strain* 809 1.4 0.8 0.7 0.9 59.6 
Sinusitis acute/chronic  778 1.4 0.8 0.7 0.9 64.4 
Acute otitis media/myringitis 759 1.3 0.8 0.7 0.9 71.7 
Viral disease, other/NOS 743 1.3 0.8 0.6 0.9 76.5 
Arthritis – all* 681 1.2 0.7 0.6 0.8 18.2 
Back complaint* 676 1.2 0.7 0.6 0.8 23.3 
Malignant neoplasm, skin 641 1.1 0.7 0.6 0.7 54.9 
Bursitis/tendonitis/synovitis NOS 624 1.1 0.6 0.6 0.7 56.2 
Depression* 598 1.1 0.6 0.5 0.7 14.6 
Administrative procedure – all* 596 1.1 0.6 0.5 0.7 42.2 
Test results* 594 1.1 0.6 0.5 0.7 29.4 
Tonsillitis* 590 1.0 0.6 0.5 0.7 73.2 
Abnormal test results* 580 1.0 0.6 0.5 0.7 45.8 
(continued) 
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Table 7.5 (continued): Most frequently managed new problems 
New problem managed Number 
Per cent of total 
 new problems 
(n = 56,454) 
Rate per 100 
 encounters 
(n = 98,564) 
95% 
 LCL 
95% 
UCL 
New as per 
cent of all 
problems(a) 
Solar keratosis/sunburn 532 0.9 0.5 0.5 0.6 48.3 
Vitamin/nutritional deficiency 476 0.8 0.5 0.4 0.6 32.5 
Pregnancy* 466 0.8 0.5 0.4 0.5 36.4 
Laceration/cut 461 0.8 0.5 0.4 0.5 48.0 
Excessive ear wax 437 0.8 0.4 0.4 0.5 59.7 
Fracture* 427 0.8 0.4 0.4 0.5 47.7 
Hypertension* 427 0.8 0.4 0.4 0.5 5.0 
Observation/health education/ 
advice/diet – all* 426 0.8 0.4 0.4 0.5 53.1 
Subtotal 27,136 47.9 — — — — 
Total new problems 56,454 100.0 57.3 55.7 58.8 — 
(a) The proportion of total contacts with this problem that were accounted for by new problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
7.6 Most frequently managed chronic problems 
To identify chronic conditions, a list classified according to ICPC-2, based on work 
undertaken by O’Halloran et al. in 200444 and regularly updated by O’Halloran (see  
‘Chronic conditions’ grouper G84 <sydney.edu.au/medicine/fmrc/icpc-2-plus/ 
demonstrator>), was applied to the BEACH data set. More than one-third (36.0%) of the 
problems managed in general practice were chronic. At least one chronic problem was 
managed at 41.8% of encounters (95% CI: 40.7–42.9) (results not tabled), and chronic 
problems were managed at an average rate of 55.7 per 100 encounters (Table 7.6). 
In other parts of this chapter, both chronic and non-chronic conditions (for example, diabetes 
and gestational diabetes) may have been grouped together when reporting (for example, 
diabetes – all*, Table 7.4). In this section, only problems regarded as chronic have been 
included in the analysis. For this reason, the condition labels and figures in this analysis may 
differ from those in Table 7.4. Where the group used for the chronic analysis differs from that 
used in other analyses in this report, they are marked with a double asterisk (for example, 
Diabetes [non-gestational]**). Codes included can be found in Appendix 4, Table A4.2. 
Table 7.6 shows the most frequently managed chronic problems in decreasing order of 
frequency. Together, these 30 chronic problems accounted for 79.1% of all chronic problems 
managed, and for 28.5% of all problems managed. Just over half (51.7%) of all chronic 
problems managed were accounted for by the top seven chronic problems: non-gestational 
hypertension (15.4% of chronic conditions), non-gestational diabetes (7.6%), depressive 
disorder (7.3%), chronic arthritis (6.8%), lipid disorder (6.0%), oesophageal disease (4.7%) 
and asthma (3.9%) (Table 7.6).  
Extrapolation of these results suggests that, across Australia in 2012–13, there were 
10.9 million encounters involving non-gestational hypertension, 5.3 million involving non-
gestational diabetes and 5.2 million involving depression.  
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Table 7.6: Most frequently managed chronic problems 
Chronic problem managed Number 
Per cent of total 
chronic problems 
(n = 54,944) 
Rate per 100 
encounters 
(n = 98,564) 
95% 
 LCL 
95% 
UCL 
Hypertension (non-gestational)** 8,474 15.4 8.6 8.1 9.1 
Diabetes (non-gestational)** 4,157 7.6 4.2 3.9 4.5 
Depressive disorder** 4,038 7.3 4.1 3.9 4.3 
Chronic arthritis** 3,728 6.8 3.8 3.5 4.0 
Lipid disorder 3,292 6.0 3.3 3.1 3.6 
Oesophageal disease 2,568 4.7 2.6 2.4 2.8 
Asthma 2,124 3.9 2.2 2.0 2.3 
Atrial fibrillation/flutter 1,405 2.6 1.4 1.3 1.6 
Malignant neoplasm, skin 1,169 2.1 1.2 1.0 1.3 
Ischaemic heart disease** 1,058 1.9 1.1 0.9 1.2 
Back syndrome with radiating pain** 936 1.7 0.9 0.8 1.1 
Hypothyroidism/myxoedema 923 1.7 0.9 0.8 1.0 
Chronic obstructive pulmonary disease 921 1.7 0.9 0.8 1.0 
Osteoporosis 834 1.5 0.8 0.7 0.9 
Shoulder syndrome (excluding arthritis)** 616 1.1 0.6 0.5 0.7 
Migraine 604 1.1 0.6 0.5 0.7 
Dementia (including senile, Alzheimer’s) 592 1.1 0.6 0.5 0.7 
Obesity (BMI > 30) 584 1.1 0.6 0.5 0.7 
Chronic skin ulcer (including varicose ulcer) 581 1.1 0.6 0.5 0.7 
Gout 578 1.1 0.6 0.5 0.7 
Heart failure 571 1.0 0.6 0.5 0.7 
Chronic pain NOS 497 0.9 0.5 0.4 0.6 
Anxiety disorder** 474 0.9 0.5 0.4 0.6 
Schizophrenia 450 0.8 0.5 0.4 0.5 
Chronic back pain** 448 0.8 0.5 0.4 0.5 
Chronic kidney disease** 441 0.8 0.4 0.4 0.5 
Chronic acne** 392 0.7 0.4 0.3 0.4 
Malignant neoplasm prostate 364 0.7 0.4 0.3 0.4 
Vertiginous syndrome 338 0.6 0.3 0.3 0.4 
Back syndrome without radiating pain 
(excluding arthritis, sprains and strains)** 326 0.6 0.3 0.3 0.4 
Subtotal 43,483 79.1 — — — 
Total chronic problems 54,944 100.0 55.7 53.7 57.8 
** Includes multiple ICPC-2 or ICPC-2 PLUS codes and indicates that this group differs from that used for analysis in other sections of this 
chapter, as only chronic conditions have been included in this analysis (see Appendix 4, Table A4.2 
<purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; BMI – body mass index; NOS – not otherwise specified. 
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7.7 Work-related problems managed 
The work-related status of a problem under management was determined by the GP, and is 
defined as any problem that is (in the GP’s view) likely to have resulted from work-related 
activity or workplace exposure, or that has been significantly exacerbated by work activity or 
workplace exposure. Work-related problems accounted for 1.5% of problems and were 
managed at a rate of 2.4 per 100 encounters in 2012–13 (Table 7.7). This suggests that 
nationally 3 million problems managed in general practice were likely to be work related.  
Table 7.7: Work-related problems, by type and most frequently managed individual problems 
Work-related problem managed Number 
Per cent of total 
WR problems 
(n = 2,319) 
Rate per 100 
encounters 
(n = 98,564) 
95% 
 LCL 
95% 
UCL 
WR as per 
cent of all 
problems(a)  
Musculoskeletal problems 1,272 54.9 1.3 1.2 1.4 7.3 
 Back complaint* 319 13.8 0.3 0.3 0.4 11.0 
 Injury musculoskeletal NOS 203 8.8 0.2 0.2 0.3 23.1 
 Sprain/strain* 202 8.7 0.2 0.2 0.2 14.9 
 Bursitis/tendonitis/synovitis NOS 47 2.0 0.0 0.0 0.1 4.2 
 Fracture* 61 2.6 0.1 0.0 0.1 6.8 
 Shoulder syndrome 58 2.5 0.1 0.0 0.1 9.4 
 Acute internal knee damage 57 2.4 0.1 0.0 0.1 18.2 
 Shoulder symptom/complaint 43 1.8 0.0 0.0 0.1 15.7 
 Neck syndrome 39 1.7 0.0 0.0 0.1 12.3 
Psychological problems 291 12.5 0.3 0.2 0.3 2.3 
 Depression* 97 4.2 0.1 0.1 0.1 2.4 
 Acute stress reaction 76 3.3 0.1 0.1 0.1 10.4 
 Anxiety* 53 2.3 0.1 0.0 0.1 2.5 
 Post traumatic stress disorder 45 1.9 0.0 0.0 0.1 32.7 
Other work-related problems 756 32.6 0.8 0.7 0.9 0.6 
 General check-up* 109 4.7 0.1 0.1 0.2 1.7 
 Injury skin, other 82 3.5 0.1 0.1 0.1 14.4 
 Administrative procedure – all* 58 2.5 0.1 0.0 0.1 4.1 
 Pain, general/multiple sites 41 1.8 0.0 0.0 0.1 8.0 
Total work-related problems 2,319 100.0 2.4 2.2 2.5 — 
(a) The proportion of total contacts with this problem that was accounted for by work-related problems. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: WR – work-related; LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. Only the most frequent 
individual work-related problems accounting for ≥ 1.4% of total work-related problems are reported. 
The most common work-related problems were musculoskeletal problems, accounting for 
54.9% of work-related problems and managed at a rate of 1.3 per 100 general practice 
encounters. Of all musculoskeletal problems managed in general practice, 7.3% were work 
related. The most common musculoskeletal work-related problems were back complaint 
(13.8% of work-related problems), unspecified musculoskeletal injury (8.8%), sprain and 
strain (8.7%), and bursitis/tendonitis/synovitis (2.0%). 
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Work-related psychological problems accounted for 12.5% of total work-related problems, 
and were managed at a rate of 0.3 per 100 encounters. The most common were depression 
(4.2% of work-related problems), acute stress reaction (3.3%), anxiety (2.3%) and post-
traumatic stress disorder (1.9%). Psychological work-related problems accounted for only 
2.3% of total psychological problems managed in general practice.  
7.8 Changes in problems managed over the 
decade 2003–04 to 2012–13 
Data about the problems managed in general practice from each of the past 10 years of the 
BEACH study, 2003–04 to 2012–13 are reported in the companion report A decade of 
Australian general practice activity 2003–04 to 2012–13.1 Major changes that occurred over the 
decade are summarised below. 
Overall, the number of problems managed at general practice encounters increased from 
146.3 per 100 encounters in 2003–04 to 154.7 per 100 encounters in 2012–13. When this result 
is extrapolated to estimate national figures this represents an additional 55.3 million 
problems managed at general practice encounters in 2012–13 than in 2003–04. A rise in GP 
attendances over the decade (see Chapter 2 Methods) also contributed to this increase. This 
was reflected in a significant increase in the management of chronic conditions (from 51.9 to 
55.7 per 100 encounters) over the decade. 
Changes in the most common individual problems managed in general practice are 
summarised below. 
• The management rate of diabetes increased significantly from 3.3 per 100 encounters in 
2003–04 to 4.2 per 100 encounters in 2012–13, an estimated 2.1 million more occasions of 
diabetes management in 2012–13 than in 2003–04.  
• The management rate of gastro-oesophageal reflux disease increased from 2.2 per 100 
encounters to 2.6 per 100 between 2003–04 and 2012–13, suggesting about 1.2 million 
more occasions where oesophageal disease was managed in 2012–13 than in 2003–04. 
• Vitamin/nutritional deficiency was managed more often in 2012–13 than in 2003–04, 
increasing from 0.5 per 100 encounters in 2003–04 to 1.5 per 100 encounters in 2012–13. 
This represents an additional 1.4 million occasions at which vitamin/nutritional 
deficiency was managed in 2012–13 than in 2003–04. 
• The management of asthma decreased from 2.6 per 100 encounters in 2003–04 to 2.2 per 
100 encounters in 2012–13. However, due to a rise in the number of general practice 
attendances nationally, there was an estimated national increase of 290,000 occasions of 
asthma management in 2012–13 compared with 2003–04.  
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8 Overview of management 
The BEACH survey form allows GPs to record several aspects of patient management for 
each problem managed at each encounter. Pharmaceutical management is recorded in detail. 
Other modes of treatment, including clinical treatments (for example, counselling) and 
procedures, recorded briefly in the GP’s own words, are also related to a single problem. The 
form allows for referrals, hospital admissions, pathology and imaging test orders to be 
related to a single problem or to multiple problems (see Appendix 1). 
A summary of management at general practice encounters from 2003–04 to 2012–13 is 
reported for each year in the 10-year report A decade of Australian general practice activity  
2003–04 to 2012–13.1 
At the 98,564 encounters, GPs undertook 226,206 management activities in total. The most 
common management form was medication, either prescribed, GP-supplied, or advised for 
over-the-counter purchase. ‘Other treatments’ were the second most common management 
activity, with clinical treatments more frequent than procedural treatments (Table 8.1). 
For an ‘average’ 100 patient problems managed, GPs provided 54 prescriptions and 
24 clinical treatments, undertook 11 procedures, made 6 referrals to medical specialists and 3 
to allied health services, and placed 30 pathology test orders and 7 imaging test orders. 
Table 8.1: Summary of management 
Management type Number 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems  
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Medications 101,065 102.5 100.2 104.9 66.3 64.9 67.6 
 Prescribed 82,079 83.2 81.0 85.5 53.8 52.5 55.1 
 GP-supplied 9,728 9.9 9.1 10.7 6.4 5.9 6.9 
 Advised OTC 9,258 9.4 8.4 10.3 6.1 5.5 6.7 
Other treatments 53,163 53.9 51.2 56.7 34.9 33.2 36.5 
 Clinical* 36,023 36.5 34.2 38.9 23.6 22.2 25.1 
 Procedural* 17,140 17.4 16.5 18.3 11.2 10.7 11.8 
Referrals and admissions 14,561 14.8 14.2 15.4 9.5 9.2 9.9 
 Medical specialist* 8,750 8.9 8.5 9.3 5.7 5.5 6.0 
 Allied health services* 4,616 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 354 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 270 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 571 0.6 0.5 0.7 0.4 0.3 0.4 
Pathology 46,398 47.1 45.1 49.0 30.4 29.3 31.5 
Imaging 10,163 10.3 9.9 10.8 6.7 6.4 6.9 
Other investigations(a) 856 0.9 0.8 1.0 0.6 0.5 0.6 
Total management activities 226,206 229.5 — — 148.4 — — 
(a) Other investigations reported here include only those ordered by the GP. Other investigations in Chapter 12 include those ordered by the GP 
and those done by the GP or practice staff. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; OTC – over-the-counter. 
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The number of encounters or problems for which at least one form of management was 
recorded by the GPs gives us another perspective (Table 8.2). At least one management 
action was recorded at 90.7% of encounters, for 85.1% of problems managed. 
• At least one medication or other treatment was given for nearly three-quarters (71.2%) of 
the problems managed. 
• At least one medication (most commonly prescribed) was prescribed, supplied or 
advised for more than half (52.2%) of the problems managed. 
• At least one other treatment (most commonly clinical) was provided for nearly one-third 
(30.6%) of problems managed. 
• At least one referral (most commonly to a medical specialist) was made for 9.5% of 
problems managed. 
• At least one investigation (most commonly pathology) was requested for 18.6% of 
problems managed (Table 8.2). 
Table 8.2: Encounters and problems for which management was recorded 
Management type 
Number of 
encounters 
Per cent of all 
encounters 
(n = 98,564) 
Number of 
problems 
Per cent of all 
problems 
(n = 152,517) 
At least one management type 89,393 90.7 129,789 85.1 
 At least one medication or other treatment 79,308 80.5 108,658 71.2 
  At least one medication  61,912 62.8 79,620 52.2 
  At least one prescription 51,994 52.8 66,077 43.3 
  At least one GP-supplied 7,567 7.7 7.807 5.1 
  At least one OTC advised 8,128 8.2 8,335 5.5 
  At least one other treatment 40,098 40.7 46,684 30.6 
  At least one clinical treatment 27,940 28.3 32,089 21.0 
  At least one procedural treatment 15,349 15.6 16,034 10.5 
 At least one referral or admission 13,331 13.5 14,431 9.5 
  At least one referral to a medical specialist 8,346 8.5 8,855 5.8 
  At least one referral to allied health services 4,270 4.3 4,587 3.0 
  At least one referral to hospital 354 0.4 371 0.2 
  At least one referral to emergency department 270 0.3 287 0.2 
  At least one other referral 570 0.6 597 0.4 
 At least one investigation 24,371 24.7 28,381 18.6 
  At least one pathology order 17,821 18.1 20,655 13.5 
  At least one imaging order 8,678 8.8 20,655 13.5 
  At least one other investigation(a) 811 0.8 837 0.5 
(a) Other investigations reported here only include those ordered by the GP. Other investigations in Chapter 12 include those ordered by the 
GP and those done by the GP or practice staff. 
Note: OTC – over-the-counter. 
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The combinations of management types related to each problem were investigated. The 
majority of treatments occurred as a single component, or in combination with one other 
component. Management was provided: 
• as a single component for almost two-thirds (61.1%) of the problems managed 
• as a double component for 19.2% of problems managed (Table 8.3) 
• less often (18.9%) with more than two components (results not tabled). 
Table 8.3 lists the most common management combinations. Medication alone was the most 
common management, followed by a clinical treatment alone, and the combination of a 
medication and a clinical treatment. When a problem was referred it was most likely that no 
other treatments were given for the problem at the encounter.  
Table 8.3: Most common management combinations 
1+ 
medication 
1+ clinical 
treatment 
1+ procedural  
treatment 
1+  
referral 
1+ imaging 
order 
1+ pathology 
order 
Per cent of 
total 
problems  
(n = 152,517) 
Per cent  
of total 
encounters 
 (n = 98,564) 
No recorded management 14.9 9.3 
1+ management recorded 85.1 90.7 
      34.6 28.6 
      9.4 6.8 
      6.5 10.3 
      5.1 3.0 
      4.8 3.5 
      4.5 3.9 
      2.9 4.4 
      2.7 4.4 
      2.4 1.8 
      1.3 3.0 
      1.2 1.3 
      1.2 1.2 
      1.1 1.9 
      1.0 1.3 
      0.6 1.8 
      0.6 0.7 
      0.4 1.2 
      0.4 0.0 
      0.3 1.1 
      0.3 1.0 
      0.0 0.0 
Note: 1+ – at least one specified management type. 
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8.1 Changes in management over the decade 
2003–04 to 2012–13 
Changes in management over the decade 2003–04 to 2012–13 are described in detail in the 
accompanying report A decade of Australian general practice activity 2003–04 to 2012–13.1 In that 
publication, changes over time are largely reported in terms of changes in management 
actions as a rate per 100 problems. This reflects change in how GPs are managing problems 
after accounting for the significant increase in the number of problems managed per 
encounter over the decade. 
The major changes over the 10 years to 2012–13 are summarised below. 
• There was a significant decrease in the rate of medications being prescribed/supplied by 
the GP/advised for over-the-counter purchase, from 71.3 per 100 problems in 2003–04 to 
66.3 per 100 problems in 2012–13. 
• The major contributor to the above change was a significant decrease in the rate of 
prescribed medications over the time period, from 58.8 to 53.8 per 100 problems. GP 
supplied medications had significantly increased in 2008–09 and 2009–10, but decreased 
again in 2010–11 to a rate not significantly different to the 2003–04 result. 
• The introduction of MBS item numbers for practice nurse activity in 2005–06 led to a 
significant decrease in the rate of clinical treatments given by GPs, from a peak of 27.0  
in 2004–05 to a low point of 19.9 per 100 problems managed in 2006–07. However, since 
then, the rate of GP-provided clinical treatments gradually increased again such that 
there was no significant difference between the start and end of the decade. The original 
impact of practice nurses on this area of GP workload was no longer observed, 
suggesting that by 2012–13 GPs were again performing clinical treatments at a similar 
rate to that prior to the introduction of practice nurse item numbers. 
• There was a significant increase in the rate at which procedural treatments were 
undertaken, from 10.1 per 100 problems managed in 2003–04 to 11.2 per 100 problems  
in 2012–13.  
• The rate of referrals to other health providers significantly increased, from 8.0 to 9.5 per 
100 problems between 2003–04 and 2012–13, influenced by referrals to allied health 
services, which almost doubled over the period (1.8 to 3.0 per 100 problems managed). It 
was further influenced by a marginal increase in referrals to emergency departments (0.1 
to 0.2), and in ‘other referrals’ (0.3 to 0.4 per 100 problems managed). Conversely, the 
rate of referrals to hospital halved between 2003–04 and 2012–13. 
• The rate at which pathology tests/batteries of tests were ordered significantly increased 
by 26%, from 24.1 tests/batteries of tests per 100 problems managed in 2003–04, to 30.4 
in 2012–13.  
• The rate at which imaging was ordered increased significantly, from 5.6 imaging orders 
per 100 problems managed in 2003–04 to 6.7 per 100 in 2012–13. 
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9 Medications 
GPs could record up to four medications for each of four problems – a maximum of 
16 medications per encounter. Each medication could be recorded as prescribed (the default), 
supplied by the GP, or recommended for over-the-counter (OTC) purchase. The generic 
name of a medication is its non-proprietary name, which describes the pharmaceutical 
substance(s) or active pharmaceutical ingredient(s). 
• GPs were asked to: 
– record the generic or brand name, the strength, regimen and number of repeats 
ordered for each medication 
– designate this as a new or continued medication for this patient for this problem. 
• Generic or brand names were entered in the database in the manner recorded by the GP. 
• Medications were coded using the Coding Atlas of Pharmaceutical Substances (CAPS) 
system (developed by the FMRC) which is able to capture details of products at the 
brand and generic level. Every medication in the CAPS coding system is mapped to the 
international Anatomical Therapeutic Chemical (ATC) classification index.76 
• The reporting of results at drug group, subgroup and generic level uses 
ATC levels 1, 3 and 5. The most frequently prescribed, supplied or advised individual 
medications are reported at the CAPS generic level (the equivalent of ATC level 5) 
because ATC does not include many over-the-counter medications that arise in BEACH. 
Further, some ATC level 5 labels are not sufficiently specific for clarity. 
Data on medications are reported for each year from 2003–04 to 2012–13 in the 10-year 
summary report, A decade of Australian general practice activity 2003–04 to 2012–13.1 
Readers interested in adverse drug events will find more detailed information from the 
BEACH program in Miller et al. (2006) Adverse drug events in general practice patients in 
Australia.77 
9.1 Source of medications 
As reported in Chapter 8, a total of 101,065 medications were recorded, at rates of 103 per 
100 encounters and 66 per 100 problems managed. We can derive from Table 8.1 that: 
• 4 out of 5 medications (81.2%) were prescribed 
• less than 1 in 10 (9.6%) medications was supplied to the patient by the GP 
• 9.2% of medications were recommended by the GP for over-the-counter purchase. 
When medication rates per 100 encounters are extrapolated to the 126.8 million general 
practice Medicare-claimed encounters in Australia April 2012 – March 2013, we estimate that 
GPs in Australia: 
• wrote a prescription (with/without repeats) for more than 105.5 million medications 
• supplied 12.6 million medications directly to the patient 
• recommended medications for OTC purchase 11.9 million times. 
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9.2 Prescribed medications 
There were 82,079 prescriptions recorded, at rates of 83 per 100 encounters and 
54 per 100 problems managed (Table 8.1). GPs recorded 82.4% of prescribed medications by 
brand (proprietary) name and 17.6% by their generic (non-proprietary) name. Some of the 
medications most likely to be recorded as a generic were amoxycillin, warfarin and 
prednisolone (results not tabled). 
On a per problem basis: 
• no prescription was given for 56.7% of all problems managed 
• one prescription was given for 35.4% of problems managed 
• two prescriptions were given for 6.0% of problems managed 
• three or four prescriptions were given for 1.9% of problems managed (Figure 9.1). 
 
 
 
 
Figure 9.1: Number of medications prescribed per problem, 2012–13 
Number of repeats 
For 63,538 prescriptions (77.4% of all prescriptions) the GPs recorded ‘number of repeats’. 
The distribution of the specified number of repeats (from nil to more than five) is provided in 
Figure 9.2. For 34.5% of these prescriptions, the GP specified that no repeats had been 
prescribed, and for 36.6% five repeats were ordered. The latter proportion reflects the PBS 
provision of one month’s supply and five repeats for many medications used for chronic 
conditions such as hypertension. The ordering of one repeat was also quite common (15.8%). 
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Figure 9.2: Number of repeats ordered per prescription, 2012–13 
Age–sex-specific rates of prescribed medications 
Age–sex-specific analysis found similar prescription rates for male (84 per 100 encounters) 
and female patients (83 per 100). It also showed the well-described tendency for the number 
of prescriptions written at each encounter to rise with the advancing age of the patient. The 
rate of prescribing almost doubled from 54 per 100 encounters for patients aged less than 
25 years to 94 per 100 encounters for patients aged 65 years and over (results not tabled). 
 
 
 
 
Figure 9.3: Age–sex-specific prescription rates per 100 problems managed, 2012–13 
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However, Figure 9.3 demonstrates that this age-based increase lessens if the prescription rate 
is considered in terms of the number of problems being managed in each age group. This 
suggests that a substantial part of the higher prescription rate for older patients is due to the 
increased number of health problems they have managed at an encounter. The remaining 
increase in prescription rate associated with patient age is probably a reflection of the 
problems under management, as rate of chronic problem management increases with patient 
age.78  
Types of medications prescribed 
Table 9.1 shows the distribution of prescribed medications using the WHO ATC 
classification index.76 This allows comparison with other data sources such as those 
produced by Medicare Australia for PBS data. The table lists medications in frequency order 
within ATC levels 1, 3 and 5. Prescriptions are presented as a percentage of total 
prescriptions, as a rate per 100 encounters, and as a rate per 100 problems managed, each 
with 95% confidence intervals.  
The high number of opioids shown in this table (compared with BEACH data published 
before 2010) is due to our re-classification of some medications in 2010. We re-coded codeine 
combinations which contained 30 mg of codeine as opioids in the ATC index, whereas pre-
2010 they were coded as ‘other analgesics and antipyretics’. In the ATC classification, either 
grouping is correct. We decided to place high-dose codeine products in the opioid group in 
accordance with MIMS grouping79 and following the Poisons Regulations of the Therapeutic 
Goods Administration,80 which stipulates that high-dose codeine combinations are Schedule 
4 (prescription only) medications. However, a few combination analgesics containing less 
than 30 mg of codeine but classified as Schedule 4, will not be counted in this group because 
there are other criteria which form part of the scheduling of prescription-only codeine. One 
of them is pack-size, which is not recorded in BEACH. 
Similarly, before 2010 all aspirin (acetylsalicylic acid) was classified in the analgesic group of 
neurological medications. In 2010 we split aspirin into two different codes depending on 
dosage. We reclassified low-dose (100 mg) plain aspirin as an antithrombotic medication in 
the blood medications group, while higher doses and combinations with other 
analgesic/antipyretics remain in the neurological group. 
If readers are making comparisons with previous BEACH publications, they should note that 
this change has caused the opioid and antithrombotic groups to increase, and ‘other 
analgesics and antipyretics’ to decrease.  
In the companion report to this publication, A decade of Australian general practice activity 
2003–04 to 2012–13,1 medications have been re-analysed across all 10 years, and the results 
incorporate these adjustments.  
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Table 9.1: Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 82,079) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 1 3 5 
Nervous system  19,170 23.4 19.4 (18.5–20.4) 12.6 (12.0–13.1) 
  Opioids 5,870 7.2 6.0 (5.6–6.3) 3.8 (3.6–4.1) 
  Codeine, combinations excluding psycholeptics 1,760 2.1 1.8 (1.6–1.9) 1.2 (1.1–1.3) 
  Oxycodone 1,607 2.0 1.6 (1.5–1.8) 1.1 (1.0–1.1) 
  Tramadol 863 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
 Buprenorphine 537 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
  Antidepressants 3,923 4.8 4.0 (3.8–4.2) 2.6 (2.4–2.7) 
  Sertraline 547 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
  Escitalopram 536 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
  Other analgesics and antipyretics 2,548 3.1 2.6 (2.3–2.9) 1.7 (1.5–1.8) 
  Paracetamol, plain 2,423 3.0 2.5 (2.2–2.7) 1.6 (1.4–1.8) 
  Anxiolytics 2,036 2.5 2.1 (1.8–2.3) 1.3 (1.2–1.5) 
  Diazepam 1,244 1.5 1.3 (1.1–1.4) 0.8 (0.7–0.9) 
  Hypnotics and sedatives 1,507 1.8 1.5 (1.4–1.7) 1.0 (0.9–1.1) 
  Temazepam 994 1.2 1.0 (0.9–1.1) 0.7 (0.6–0.7) 
  Antipsychotics 1,090 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
  Drugs used in addictive disorders 799 1.0 0.8 (0.6–1.0) 0.5 (0.4–0.7) 
  Antiepileptics 714 0.9 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
Cardiovascular system 15,675 19.1 15.9 (15.9–16.8) 10.3 (9.8–10.8) 
 Lipid modifying agents, plain 3,508 4.3 3.6 (3.3–3.8) 2.3 (2.2–2.4) 
 Atorvastatin 1,440 1.8 1.5 (1.3–1.6) 0.9 (0.9–1.0) 
 Rosuvastatin 1,195 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
 Angiotensin II antagonists, plain 2,211 2.7 2.2 (2.1–2.4) 1.4 (1.3–1.6) 
 Irbesartan 817 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Telmisartan 664 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Candesartan 540 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 ACE inhibitors, plain 1,922 2.3 2.0 (1.8–2.1) 1.3 (1.2–1.4) 
 Perindopril 1,065 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
 Ramipril 545 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Beta blocking agents 1,651 2.0 1.7 (1.5–1.8) 1.1 (1.0–1.2) 
 Atenolol 653 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
 Angiotensin II antagonists, combinations 1,524 1.9 1.5 (1.4–1.7) 1.0 (0.9–1.1) 
 Irbesartan and diuretics 549 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Selective calcium channel blockers with mainly 
vascular effects 
1,272 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Amlodipine 541 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 (continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 82,079) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 1 3 5 
 ACE inhibitors, combinations 715 0.9 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 High-ceiling diuretics 614 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
 Frusemide 612 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
Anti-infective for systemic use 15,156 18.5 15.4 (14.8–16.0) 9.9 (9.5–10.4) 
  Beta-lactam antibacterials, penicillins 5,823 7.1 5.9 (5.6–6.2) 3.8 (3.6–4.1) 
 Amoxycillin 2,993 3.6 3.0 (2.8–3.3) 2.0 (1.8–2.1) 
 Amoxycillin and enzyme inhibitor 1,931 2.4 2.0 (1.8–2.1) 1.3 (1.1–1.4) 
 Other beta-lactam antibacterials 3,069 3.7 3.1 (2.9–3.3) 2.0 (1.9–2.2) 
 Cephalexin 2,597 3.2 2.6 (2.4–2.8) 1.7 (1.6–1.8) 
 Macrolides, lincosamides and streptogramins 1,030 1.3 1.0 (2.2–2.6) 1.5 (1.4–1.7) 
 Roxithromycin 639 0.8 0.6 (0.9–1.2) 0.7 (0.6–0.8) 
 Clarithromycin 1,030 1.3 1.0 (0.5–0.8) 0.4 (0.3–0.5) 
 Tetracyclines 831 1.0 0.8 (0.8–0.9) 0.5 (0.5–0.6) 
 Doxycycline 758 0.9 0.8 (0.7–0.9) 0.5 (0.4–0.6) 
 Sulfonamides and trimethoprim 711 0.9 0.7 (0.6–0.8) 0.5 (0.4–0.5) 
 Viral vaccines 624 0.8 0.6 (0.5–0.7) 0.4 (0.3–0.5) 
Alimentary tract and metabolism 8,440 10.3 8.6 (8.1–9.0) 5.5 (5.3–5.8) 
 Drugs for peptic ulcer and gastro-oesophageal reflux 3,374 4.1 3.4 (3.2–3.6) 2.2 (2.1–2.3) 
 Esomeprazole 1,566 1.9 1.6 (1.5–1.7) 1.0 (1.0–1.1) 
 Pantoprazole 681 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
 Blood glucose lowering drugs, excluding insulins 2,189 2.7 2.2 (2.0–2.4) 1.4 (1.3–1.6) 
 Metformin 1,280 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Propulsives 584 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Insulins and analogues 498 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Respiratory system 4,972 6.1 5.0 (4.8–5.3) 3.3 (3.1–3.4) 
 Adrenergics, inhalants 2,663 3.2 2.7 (2.5–2.9) 1.7 (1.6–1.9) 
 Salbutamol 1,283 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
 Salmeterol and other drugs for obstructive airways 
disease 
770 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Formoterol and other drugs for obstructive airways 
disease 
500 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
 Decongestants and other nasal preparations for topical 
use 
873 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
 Other drugs for obstructive airway diseases, inhalants 816 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
(continued) 
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Table 9.1 (continued): Prescribed medications by ATC levels 1, 3 and 5  
 
ATC Classification level 
Number 
Per cent of 
prescribed 
medications 
(n = 82,079) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 1 3 5 
Musculoskeletal system 4,092 5.0 4.2 (3.9–4.4) 2.7 (2.5–2.8) 
 Anti-inflammatory and antirheumatic products,  
non-steroid 
2,908 3.5 3.0 (2.8–3.1) 1.9 (1.8–2.0) 
 Meloxicam 826 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
 Diclofenac 558 0.7 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
 Celecoxib 545 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
 Antigout preparations 534 0.7 0.5 (0.5–0.6) 0.4 (0.3–0.4) 
 Drugs affecting bone structure and mineralization 504 0.6 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Dermatologicals 3,553 4.3 3.6 (3.4–3.8) 2.3 (2.2–2.4) 
 Corticosteroids, plain 2,128 2.6 2.2 (2.0–2.3) 1.4 (1.3–1.5) 
 Betamethasone 744 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
 Mometasone 598 0.7 0.6 (0.5–0.7) 0.4 (0.4–0.4) 
Genitourinary system and sex hormones 2,951 3.6 3.0 (2.8–3.2) 1.9 (1.8–2.0) 
 Hormonal contraceptives for systemic use 1,306 1.6 1.3 (1.2–1.4) 0.9 (0.8–0.9) 
 Levonorgestrel and ethinyloestradiol 742 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Blood and blood forming organs 2,625 3.2 2.7 (2.5–2.9) 1.7 (1.6–1.8) 
 Antithrombotic agents 2,079 2.5 2.1 (1.9–2.3) 1.4 (1.3–1.5) 
 Warfarin 1,134 1.4 1.2 (1.0–1.3) 0.7 (0.7–0.8) 
Systemic hormonal preparations, excluding sex 
hormones  
2,570 3.1 2.6 (2.4–2.8) 1.7 (1.6–1.8) 
  Corticosteroids for systemic use, plain  1,513 1.8 1.5 (1.4–1.7) 1.0 (0.9–1.1) 
  Prednisolone 954 1.2 1.0 (0.9–1.1) 0.6 (0.6–0.7) 
  Thyroid preparations  827 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
  Levothyroxine sodium 818 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Sensory organs  2,062 2.5 2.1 (1.9–2.2) 1.4 (1.3–1.4) 
  Anti-infectives ophthalmological  742 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
  Chloramphenicol ophthalmological 665 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
  Corticosteroids and anti-infective in combination 
otological  
557 0.7 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
Antineoplastic and immunomodulating agents  397 0.5 0.4 (0.3–0.5) 0.3 (0.2–0.3) 
Various  189 0.2 0.2 (0.2–0.2) 0.1 (0.1–0.1) 
Antiparasitic products, insecticides and repellent 226 0.3 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Total prescribed medications 82,079 100.0 83.3 (81.0–85.5) 53.8 (52.5–55.1) 
Note: ATC – Anatomical Therapeutic Chemical classification; CI – confidence interval; ACE – angiotensin-converting enzyme. 
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Most frequently prescribed medications 
The most frequently prescribed individual medications are reported at the CAPS generic 
level (ATC level 5 equivalent) in Table 9.2. Together these 30 medications made up 43.6% of 
all prescribed medications.  
Table 9.2: Most frequently prescribed medications  
Generic medication Number 
Per cent of 
prescribed 
medications 
(n = 82,079) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 
Amoxycillin 2,993 3.6 3.0 (2.8–3.3) 2.0 (1.8–2.1) 
Cephalexin 2,597 3.2 2.6 (2.4–2.8) 1.7 (1.6–1.8) 
Paracetamol 2,423 3.0 2.5 (2.2–2.7) 1.6 (1.4–1.8) 
Amoxycillin/potassium clavulanate 1,931 2.4 2.0 (1.8–2.1) 1.3 (1.1–1.4) 
Paracetamol/codeine 1,730 2.1 1.8 (1.6–1.9) 1.1 (1.0–1.2) 
Oxycodone 1,607 2.0 1.6(1.5–1.8) 1.1 (1.0–1.1) 
Esomeprazole 1,566 1.9 1.6 (1.5–1.7) 1.0 (1.0–1.1) 
Atorvastatin 1,440 1.8 1.5 (1.3–1.6) 0.9 (0.9–1.0) 
Salbutamol 1,290 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
Metformin 1,280 1.6 1.3 (1.2–1.4) 0.8 (0.8–0.9) 
Diazepam 1,244 1.5 1.3 (1.1–1.4) 0.8 (0.7–0.9) 
Rosuvastatin 1,195 1.5 1.2 (1.1–1.3) 0.8 (0.7–0.9) 
Warfarin sodium 1,134 1.4 1.2 (1.0–1.3) 0.7 (0.7–0.8) 
Perindopril 1,065 1.3 1.1 (1.0–1.2) 0.7 (0.6–0.8) 
Roxithromycin 1,030 1.3 1.0 (0.9–1.2) 0.7 (0.6–0.8) 
Temazepam 994 1.2 1.0 (0.9–1.1) 0.7 (0.6–0.7) 
Tramadol 863 1.1 0.9 (0.8–1.0) 0.6 (0.5–0.6) 
Meloxicam 826 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Thyroxine 818 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Irbesartan 817 1.0 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Fluticasone/salmeterol 770 0.9 0.8 (0.7–0.9) 0.5 (0.5–0.6) 
Doxycycline 758 0.9 0.8 (0.7–0.9) 0.5 (0.4–0.6) 
Betamethasone topical 744 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Levonorgestrel/ethinyloestradiol 741 0.9 0.8 (0.7–0.8) 0.5 (0.4–0.5) 
Pantoprazole 681 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Chloramphenicol eye 665 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Telmisartan 664 0.8 0.7 (0.6–0.8) 0.4 (0.4–0.5) 
Atenolol 653 0.8 0.7 (0.6–0.7) 0.4 (0.4–0.5) 
Clarithromycin 639 0.8 0.6 (0.5–0.8) 0.4 (0.3–0.5) 
Prednisolone 623 0.8 0.6 (0.5–0.7) 0.4 (0.4–0.5) 
Subtotal 35,778 43.6 — — 
Total prescribed medications 82,079 100.0 83.3 (81.0–85.5) 53.8 (52.5–55.1) 
Note: CI – confidence interval. 
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9.3 Medications supplied by GPs 
GPs supplied 9,728 medications in 2012–13, at a rate of 9.9 medications per 100 encounters. 
At least one medication was supplied at 7.7% of encounters for 5.1% of problems (Table 8.2). 
Table 9.3 shows the top medications supplied at CAPS generic level (ATC level 5). 
Table 9.3: Medications most frequently supplied by GPs  
Generic medication Number 
Per cent of GP 
supplied 
medications 
(n = 9,728) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 
Influenza virus vaccine 2,308 23.7 2.3 (1.9–2.7) 1.5 (1.3–1.8) 
Pneumococcal vaccine 570 5.9 0.6 (0.5–0.6) 0.4 (0.3–0.4) 
Vitamin B12 (cobalamin) 464 4.8 0.5 (0.4–0.6) 0.3 (0.3–0.4) 
Diphtheria/pertussis/tetanus/hepatitis B/polio/Hib 
vaccine 
423 4.3 0.4 (0.4–0.5) 0.3 (0.2–0.3) 
Mumps/measles/rubella vaccine 316 3.2 0.3 (0.3–0.4) 0.2 (0.2–0.2) 
Rotavirus vaccine 306 3.2 0.3 (0.3–0.4) 0.2 (0.2–0.2) 
Triple antigen (diphtheria/pertussis/tetanus) 238 2.4 0.2 (0.2–0.3) 0.2 (0.1–0.2) 
Chickenpox (varicella zoster) vaccine 157 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
ADT/CDT (diphtheria/tetanus) vaccine 146 1.5 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Meningitis vaccine 145 1.5 0.1 0.1–0.2) 0.1 (0.1–0.1) 
Haemophilus B vaccine 141 1.5 0.1 (0.1–0.2) 0.1 (0.1–0.1) 
Methylprednisolone 123 1.3 0.1 (0.0–0.3) 0.1 (0.0–0.2) 
Betamethasone systemic 121 1.2 0.1 (0.0–0.3) 0.1 (0.0–0.2) 
Allergen treatment 112 1.1 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Diphtheria/pertussis/tetanus/polio vaccine 108 1.1 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Hepatitis B vaccine 106 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Lignocaine 104 1.1 0.1 (0.0–0.3) 0.1 (0.0–0.2) 
Typhoid vaccine (Salmonella typhi) 98 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hepatitis A vaccine 94 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hepatitis A/typhoid vaccine (Salmonella typhi) 90 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Esomeprazole 84 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Celecoxib 79 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Medroxyprogesterone 79 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Metoclopramide 76 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Steroid injection NEC 76 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Salbutamol 75 0.8 0.1 (0.1–0.1) 0.0 (0.0–0.1) 
Meloxicam 72 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Local anaesthetic injection 61 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Immunisation NEC 58 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Budesonide/eformoterol 53 0.5 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Subtotal 6,885 70.8 — — 
Total supplied medications 9,728 100.0 9.9 (9.1–10.7) 6.4 (5.9–6.9) 
Note: CI – confidence interval; NEC – not elsewhere classified. 
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9.4 Medications advised for over-the-counter 
purchase 
The GPs recorded 9,258 medications as recommended for OTC purchase, at rates of 9.4 per 
100 encounters and 6.1 per 100 problems managed. At least one OTC medication was 
advised at 8.2% of encounters and for 5.5% of problems (Table 8.2). Table 9.4 shows the top 
30 advised medications at the CAPS generic level (ATC level 5 equivalent). A wide range of 
medications was recorded in this group, the most common being paracetamol, which 
accounted for 26.3% of these medications. The re-classification of aspirin described in Section 
9.2 also affected rates of advised OTC medications, as higher-dose analgesic aspirin and low-
dose aspirin for antithrombotic purposes are presented separately here. 
Table 9.4: Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 9,258) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 
Paracetamol, plain 2,437 26.3 2.5 (2.0–3.0) 1.6 (1.3–1.9) 
Ibuprofen 580 6.3 0.6 (0.5–0.7) 0.4 (0.3–0.4) 
Saline bath/solution/gargle 272 2.9 0.3 (0.2–0.4) 0.2 (0.1–0.2) 
Vitamin D3 (cholecalciferol) 267 2.9 0.3 (0.2–0.3) 0.2 (0.1–0.2) 
Simple analgesics NEC 210 2.3 0.2 (0.1–0.3) 0.1 (0.1–0.2) 
Sodium chloride topical nasal 206 2.2 0.2 (0.2–0.3) 0.1 (0.1–0.2) 
Diclofenac topical 161 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Cream/ointment/lotion NEC 161 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Sodium/potassium/citric acid/glucose 156 1.7 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Loratadine 145 1.6 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Hydrocortisone/clotrimazole 120 1.3 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Fexofenadine 115 1.2 0.2 (0.1–0.2) 0.1 (0.1–0.1) 
Vitamin D NEC 108 1.2 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Clotrimazole topical 103 1.1 0.1 (0.1–0.1) 0.1 (0.1–0.1) 
Cetirizine 102 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Paracetamol/codeine 101 1.1 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hydrocortisone topical 96 1.0 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Hyoscine butylbromide 80 0.9 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Bromhexine 76 0.8 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Fish oil 74 0.8 0.1 (0.1–0.1) 0.1 (0.0–0.1) 
Docusate otic 69 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Loperamide 69 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Cold and flu medication NEC 69 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Sorbolene/glycerol/cetomacrogol 68 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Sodium bicarbonate/citrate/tartrate 66 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Clotrimazole vaginal 65 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
(continued) 
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Table 9.4 (continued): Most frequently advised over-the-counter medications  
Generic medication Number 
Per cent of OTC 
medications 
(n = 9,258) 
Rate per 100 
encounters 
 (95% CI) 
(n = 98,564) 
Rate per 100 
problems 
 (95% CI)  
(n = 152,517) 
Multivitamins with minerals 64 0.7 0.1 (0.0–0.1) 0.1 (0.0–0.1) 
Aspirin analgesic 61 0.7 0.1 (0.0–0.1) 0.0 (0.0–0.1) 
Psyllium hydrophilic mucilloid (ispaghula) 57 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Aspirin cardiovascular 55 0.6 0.1 (0.0–0.1) 0.0 (0.0–0.0) 
Subtotal 6,211 67.1 — — 
Total advised medications 9,258 100.0 9.4 (8.4–10.3) 6.1 (5.5–6.7) 
Note: OTC – over-the-counter medication; CI – confidence interval; NEC – not elsewhere classified. 
9.5 Changes in medications over the decade 
2003–04 to 2012–13  
Data on medications are reported for each year from 2003–04 to 2012–13 in Chapter 9 of the 
companion report entitled A decade of Australian general practice activity 2003–04 to 2012–13.1 
In that report, changes over time are measured as change in the management of problems 
(that is, as a rate per 100 problems). This reflects change in how GPs are managing problems, 
and takes into account the significant increase in the number of problems managed per 
encounter over the decade to 2012–13 (see Section 7.9). 
The rate at which medications were prescribed decreased significantly from 2003–04 (58.8 
per 100 problems; 95% CI: 57.3–60.3) to 2012–13 (53.8 per 100; 95% CI: 52.5–55.1). Among the 
prescribed drug groups that decreased significantly were drugs for obstructive airways 
disease, systemic anti-inflammatory medications, corticosteroid dermatological preparations 
and sex hormones. At the same time, prescribing rates of several drug groups increased 
significantly, including agents acting on the renin-angiotensin system, psychoanaleptics, 
lipid modifying agents, and corticosteroids for systemic use.  
At the individual generic level, significant increases were found in the prescribing rates of a 
number of medications. Among them were cephalexin, oxycodone, esomeprazole, 
rosuvastatin and meloxicam. On the other hand, salbutamol, levonorgoestrel/ 
ethinyloestradiol, diclofenac sodium systemic and simvastatin were among the medications 
for which significant decreases in prescribing rates occurred over time.  
Other changes that occurred over the 10-year period were a steady rise in the proportion of 
prescriptions for which five repeats were recorded, and a corresponding decrease in those 
for which two, three or four repeats were recorded. There was a significant increase in the 
rate of vaccines supplied to the patient by GPs, and an increase in the rate of vitamin D3 
advised for over-the-counter purchase. 
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10 Other treatments  
The BEACH survey form allows GPs to record up to two other (non-pharmacological) 
treatments for each problem managed at the encounter. Other treatments include all clinical 
and procedural treatments provided. These groups are defined in Appendix 4, Tables A4.4 
and A4.5.  
Routine clinical measurements or observations, such as measurements of blood pressure and 
physical examinations, were not recorded if they were undertaken by the GP. However GPs 
were instructed to record clinical measurements or observations if these were undertaken by 
the practice nurse (PN) or Aboriginal health worker (AHW) in conjunction with the GP at the 
encounter. 
In Sections 10.1–10.3 inclusive, ‘other treatments’ have been counted irrespective of whether 
they were done by the GP or by the PN/AHW. That is, the non-pharmacological 
management provided in general practice patient encounters is described, rather than 
management provided specifically by the GP. However in the analysis of procedural 
treatments, injections given in provision of vaccines were removed, as this action has already 
been counted and reported in Section 9.3 Medications supplied by the GPs.  
In Section 10.4 treatments provided by the PN/AHW (including the injections given for 
vaccination) are reported separately, to provide a picture of the work they undertake in 
association with GP–patient encounters. 
Data on other treatments are reported for each year from 2003–04 to 2012–13 in the 10-year 
report, A decade of Australian general practice activity 2003–04 to 2012–13.1  
10.1 Number of other treatments 
In 2012–13, a total of 53,163 other treatments were recorded, at a rate of 53.9 per 100 
encounters (Table 10.1). More than two-thirds (67.7%) of these were clinical treatments. At 
least one other treatment was provided at 40.7% of all encounters, and for 30.6% of all 
problems managed. For every 100 problems managed, 24 clinical treatments and 11 
procedures were provided by a GP or PN/AHW (Table 10.1).  
Table 10.1: Summary of other treatments 
Variable Number 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
At least one other treatment 40,098 40.7 39.0 42.3 30.6 29.3 31.9 
Other treatments 53,163 53.9 51.2 56.7 34.9 33.2 36.5 
 Clinical treatments 36,023 36.5 34.2 38.9 23.6 22.2 25.1 
 Procedural treatments 17,140 17.4 16.5 18.3 11.2 10.7 11.8 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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Table 10.2 shows the relationship between other treatments and pharmacological treatments 
given for problems managed.  
• For 62.2% of the problems that were managed with an ‘other treatment’, no medication 
was prescribed, supplied or advised for that problem at that encounter. 
• 1 in 5 problems (21.0%) were managed with at least one clinical treatment. For 60.8% of 
these problems, no concurrent pharmacological treatment was provided. 
• 1 in 10 problems (10.5%) were managed with at least one procedural treatment, with no 
pharmacological management given for 64.4% of these problems. 
Table 10.2: Relationship between other treatments and pharmacological treatments 
Co-management of problems with other treatments 
Number of 
problems  
Per cent  
within class 
Per cent of  
problems 
(n = 152,517) 
95%  
LCL 
95%  
UCL 
At least one other treatment  46,684 100.0 30.6 29.3 31.9 
 Without pharmacological treatment 29,039 62.2 19.0 18.3 19.8 
At least one clinical treatment  32,089 100.0 21.0 19.8 22.2 
 Without pharmacological treatment 19,523 60.8 12.8 12.1 13.5 
At least one procedural treatment 16,034 100.0 10.5 10.0 11.0 
 Without pharmacological treatment  10,331 64.4 6.8 6.4 7.1 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.2 Clinical treatments 
Clinical treatments include general and specific advice, counselling or education, and 
administrative processes. During 2012–13, there were 36,023 clinical treatments recorded, at a 
rate of 36.5 per 100 encounters, or 23.6 per 100 problems managed (Table 10.1). 
Most frequent clinical treatments 
Table 10.3 lists the most common clinical treatments provided. Each clinical treatment is 
expressed as a percentage of all clinical treatments, as a rate per 100 encounters with 95% 
confidence limits and as a rate per 100 problems with 95% confidence limits. 
General advice and education was the most frequently recorded clinical treatment in  
2012–13 (5.8 per 100 encounters), accounting for 15.8% of all clinical treatments, followed by 
counselling about the problem under management (5.0 per 100 encounters) (Table 10.3). The 
10 most commonly provided clinical treatments accounted for 85.9% of all clinical 
treatments. 
Several recorded clinical treatments related to preventive activities. The most common was 
counselling and advice about nutrition and weight (3.8 per 100 encounters), followed by 
counselling/advice for: exercise; lifestyle; smoking; prevention; and alcohol. Together, these 
preventive treatments accounted for 19.2% of clinical treatments, provided at a rate of 7.7 per 
100 encounters (Table 10.3). 
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Table 10.3: Most frequent clinical treatments 
Clinical treatment Number 
Per cent of 
clinical 
treatments 
(n = 36,023) 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Advice/education NEC* 5,706 15.8 5.8 4.9 6.6 3.7 3.2 4.3 
Counselling – problem* 4,905 13.6 5.0 4.3 5.7 3.2 2.8 3.7 
Counselling/advice – nutrition/weight* 3,730 10.4 3.8 3.3 4.2 2.4 2.2 2.7 
Advice/education – treatment* 3,675 10.2 3.7 3.3 4.1 2.4 2.2 2.7 
Advice/education – medication* 3,146 8.7 3.2 2.9 3.5 2.1 1.9 2.3 
Counselling – psychological* 3,103 8.6 3.1 2.9 3.4 2.0 1.9 2.2 
Other administrative procedure/ 
document (excluding sickness 
certificate)* 
2,433 6.8 2.5 2.2 2.7 1.6 1.5 1.7 
Sickness certificate* 1,792 5.0 1.8 1.5 2.1 1.2 1.0 1.4 
Reassurance, support*  1,314 3.6 1.3 1.1 1.5 0.9 0.7 1.0 
Counselling/advice – exercise* 1,130 3.1 1.1 0.9 1.3 0.7 0.6 0.9 
Counselling/advice – lifestyle* 651 1.8 0.7 0.5 0.8 0.4 0.3 0.5 
Counselling/advice – smoking* 649 1.8 0.7 0.6 0.7 0.4 0.4 0.5 
Counselling/advice – health/body* 460 1.3 0.5 0.3 0.6 0.3 0.2 0.4 
Counselling/advice – prevention* 406 1.1 0.4 0.3 0.5 0.3 0.2 0.3 
Counselling/advice – alcohol* 346 1.0 0.4 0.3 0.4 0.2 0.2 0.3 
Family planning* 313 0.9 0.3 0.3 0.4 0.2 0.2 0.2 
Consultation with primary care 
provider* 239 0.7 0.2 0.2 0.3 0.2 0.1 0.2 
Observe/wait* 234 0.6 0.2 0.2 0.3 0.2 0.1 0.2 
Counselling/advice – pregnancy* 228 0.6 0.2 0.2 0.3 0.1 0.1 0.2 
Counselling/advice – relaxation* 202 0.6 0.2 0.2 0.2 0.1 0.1 0.2 
Advice/education – sun protection 201 0.6 0.2 0.0 0.4 0.1 0.0 0.3 
Counselling/advice – other* 197 0.5 0.2 0.2 0.3 0.1 0.1 0.2 
Subtotal  33,761 97.3 — — — — — — 
Total clinical treatments 36,023 100.0 36.5 34.2 38.9 23.6 22.2 25.1 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.4 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified. 
Problems managed with a clinical treatment 
Table 10.4 lists the top 10 problems managed with a clinical treatment. It also shows the 
extent to which clinical treatments were used for each problem, and the relationship between 
the use of a clinical treatment and the provision of medication for individual problems at 
that encounter.  
• A total of 32,089 problems (21.0% of all problems) involved one or more clinical 
treatments in their management (Table 8.2). 
• There was a very broad range of problems managed with clinical treatments. However, 
the 10 most common problems managed with a clinical treatment accounted for 30% of 
all problems for which clinical treatments were provided. 
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• Upper respiratory tract infection represented the largest proportion of problems 
managed with a clinical treatment (6.0%), followed by depression (5.1%). 
• A clinical treatment was provided at one-third (33.9%) of contacts with upper respiratory 
tract infection, with no concurrent pharmacological treatment provided for half (50.3%) 
of these contacts where a clinical treatment was provided. 
• Of the top 10 problems, acute stress reaction was the problem most likely to be managed 
with a clinical treatment (at 70.6% of contacts). Of the contacts with acute stress reaction 
where a clinical treatment was provided, 87.6% did not result in concurrent medication 
prescribed/supplied or advised for that problem. 
Table 10.4: The 10 most common problems managed with a clinical treatment 
Problem managed Number 
Per cent of 
problems with 
clinical treatment  
(n = 32,089) 
Rate per 100 
encounters(a) 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Per cent 
 of this 
problem(b) 
Per cent of 
treated 
 problems no 
medications(c) 
Upper respiratory tract infection  1,937 6.0 2.0 1.6 2.3 33.9 50.3 
Depression* 1,648 5.1 1.7 1.5 1.8 40.3 50.9 
Diabetes – all* 1,156 3.6 1.2 1.0 1.3 27.6 64.3 
Hypertension* 1,028 3.2 1.0 0.9 1.2 12.1 44.4 
Anxiety* 853 2.7 0.9 0.8 1.0 40.9 62.0 
Lipid disorder 800 2.5 0.8 0.7 0.9 24.3 66.8 
Gastroenteritis* 592 1.8 0.6 0.5 0.7 45.8 57.8 
Back complaint* 564 1.8 0.6 0.5 0.6 19.4 47.4 
Test results* 541 1.7 0.5 0.5 0.6 26.8 94.1 
Acute stress reaction 512 1.6 0.5 0.5 0.6 70.6 87.6 
Subtotal  9,631 30.0 — — — — — 
Total problems with clinical 
treatments 32,089 100.0 32.6 30.6 34.5 — — 
(a) Rate of provision of clinical treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one clinical treatment. 
(c) The numerator is the number of contacts with this problem that generated at least one clinical treatment but generated no medications.  
The denominator is the total number of contacts for this problem that generated at least one clinical treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.3 Procedural treatments 
Procedural treatments include therapeutic actions and diagnostic procedures undertaken at 
the encounter. Injections for immunisations (n = 3,636) are not counted here as these have 
been counted as medications (see Chapter 9). There were 17,140 other procedures recorded at 
a rate of 17.4 per 100 encounters, and 11.2 per 100 problems managed (Table 10.1). 
Most frequent procedures 
Table 10.5 lists the most common procedural treatments recorded. Each procedural 
treatment is expressed as a percentage of all procedural treatments, as a rate per 100 
encounters and as a rate per 100 problems, both with 95% confidence limits. Some of the 
procedures (for example international normalised ratio [INR] test, electrical tracings, 
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physical function test) are investigations undertaken at the encounter. These results do not 
include investigations that were ordered by the GP to be performed by an external provider. 
A summary of all investigations (both undertaken and ordered) is provided in Table 12.6. 
The most frequently recorded group of procedures was excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation (3.0 per 100 encounters), accounting for 17.4% of 
recorded procedures, followed by dressing/pressure/compression/tamponade (2.4 per 100 
encounters). The top five procedural treatments, accounting for almost 60% of all procedural 
treatments, were provided at a rate of 10.3 per 100 encounters. 
Table 10.5: Most frequent procedural treatments 
Procedural treatment Number 
Per cent of 
procedural 
treatments 
(n = 17,140) 
Rate per 
100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Excision/removal tissue/biopsy/ 
destruction/debridement/cauterisation* 2,983 17.4 3.0 2.7 3.3 2.0 1.8 2.1 
Dressing/pressure/compression/ 
tamponade* 2,370 13.8 2.4 2.2 2.6 1.6 1.4 1.7 
Local injection/infiltration*(a) 2,302 13.4 2.3 2.1 2.6 1.5 1.4 1.7 
Physical medicine/rehabilitation – all* 1,422 8.3 1.4 1.2 1.7 0.9 0.8 1.1 
Incision/drainage/flushing/aspiration/ 
removal body fluid* 1,105 6.4 1.1 1.0 1.2 0.7 0.6 0.8 
Other therapeutic procedures/minor 
surgery*  889 5.2 0.9 0.7 1.1 0.6 0.5 0.7 
Repair/fixation – suture/cast/prosthetic 
device (apply/remove)* 854 5.0 0.9 0.8 1.0 0.6 0.5 0.6 
Pap smear* 818 4.8 0.8 0.7 0.9 0.5 0.5 0.6 
INR test*  744 4.3 0.8 0.6 0.9 0.5 0.4 0.6 
Other preventive procedures/high-risk 
medication* 719 4.2 0.7 0.6 0.8 0.5 0.4 0.5 
Check-up – PN/AHW* 647 3.8 0.7 0.5 0.8 0.4 0.3 0.5 
Electrical tracings* 544 3.2 0.6 0.5 0.6 0.4 0.3 0.4 
Physical function test* 474 2.8 0.5 0.4 0.6 0.3 0.3 0.4 
Subtotal  16,984 99.1 — — — — — — 
Total procedural treatments  17,140 100.0 17.4 16.5 18.3 11.2 10.7 11.8 
(a) Excludes all local injection/infiltrations performed for immunisations/vaccinations. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.5 and A4.6, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NEC – not elsewhere classified; INR – international normalised ratio;  
PN/AHW – practice nurse/Aboriginal health worker. 
Problems managed with a procedural treatment 
Table 10.6 lists the top 10 problems managed with a procedural treatment. It also shows the 
proportion of contacts with each problem that was managed with a procedure, and the 
proportion of problems managed with a procedure without medication given concurrently. 
• One or more procedural treatments were provided in the management of 16,034 
problems (10.5% of all problems) (Table 8.2). 
• The top 10 problems accounted for more than one-third (34.1%) of all problems for 
which a procedure was used. 
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• Female genital check-up/Pap smear accounted for 5.0% of all problems managed with 
procedures, followed by laceration/cut (4.7%). 
• Of the top 10 problems, warts was the problem most likely to be managed with a 
procedural treatment with a procedure being undertaken at 4 out of 5 (79.1%) contacts. 
Of these contacts where warts were managed with a procedural treatment, no 
medication was prescribed/supplied or advised for that problem at 96.0% of contacts. 
Table 10.6: The 10 most common problems managed with a procedural treatment 
Problem managed Number 
Per cent of 
problems with 
procedure 
(n = 16,034)  
Rate per 100 
encounters(a) 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Per cent of 
this 
problem(b) 
Per cent of 
treated problems 
no medications(c) 
Female genital check-up/ 
Pap smear*  802 5.0 0.8 0.7 0.9 51.9 98.0 
Laceration/cut 758 4.7 0.8 0.7 0.9 78.9 79.9 
Solar keratosis/sunburn 745 4.6 0.8 0.6 0.9 67.6 96.4 
Excessive ear wax 518 3.2 0.5 0.5 0.6 70.7 93.0 
Malignant neoplasm, skin  503 3.1 0.5 0.4 0.6 43.1 94.4 
Warts  495 3.1 0.5 0.4 0.6 79.1 96.0 
General check-up* 483 3.0 0.5 0.4 0.6 16.8 82.4 
Chronic ulcer skin 
(including varicose ulcer) 415 2.6 0.4 0.4 0.5 71.3 79.3 
Atrial fibrillation/flutter 405 2.5 0.4 0.3 0.5 28.8 70.8 
Vitamin/nutritional deficiency 336 2.1 0.3 0.3 0.4 22.9 1.0 
Subtotal  5,461 34.1 — — — — — 
Total problems with 
procedural treatments 16,034 100.0 16.3 15.5 17.0 — — 
(a) Rate of provision of procedural treatment for selected problem per 100 total encounters. 
(b) Percentage of contacts with this problem that generated at least one procedural treatment. 
(c) The numerator is the number of cases of this problem that generated at least one procedural treatment but generated no medications. The 
denominator is the total number of contacts (for this problem) that generated at least one procedural treatment (with or without medications). 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
10.4 Practice nurse/Aboriginal health worker activity 
This section describes the activities of practice nurses (PNs) and Aboriginal health workers 
(AHWs) recorded in association with the GP–patient encounters detailed by the GP BEACH 
participants. 
In 2004, four Medicare item numbers were introduced into the MBS that allowed GPs to 
claim for specified tasks done by a PN under the direction of the GP.81 In 2005–06 the 
BEACH recording form was amended to capture this information. 
• GPs were allowed to record up to three Medicare item numbers where appropriate, 
rather than be limited to one item number as had been the case prior to 2005–06. 
• In the ‘other treatments’ section for each problem managed, GPs were asked to tick the 
‘practice nurse’ box if the treatment recorded was provided by the PN rather than by the 
GP. If the box was not ticked it was assumed the GP gave the treatment. 
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The survey form allows GPs to record up to two other treatments for each problem managed 
at the encounter (i.e. up to eight per encounter). Other treatments include all clinical and 
procedural treatments provided at the encounters. These groups are defined in Appendix 4, 
Tables A4.4 and A4.5. 
Over the years new PN item numbers were added to the MBS and some items were 
broadened, to cover work done by AHWs. In January 2012 the Australian Government 
significantly altered the payment structure for practice nurse and AHW activities in general 
practice, such that the range of claimable MBS item numbers was reduced and the Practice 
Nurse Incentive Program (PNIP) introduced. The PNIP “provides incentive payments to 
practices…by consolidating funding arrangements under the Practice Incentive Program 
(PIP) Practice Nurse Incentive”. Six of the Medicare Benefits Schedule (MBS) PN/AHW 
items were removed and the funds redirected into a single payment to eligible general 
practices.82 
The following section investigates: the proportion of encounters involving the PN/AHW; the 
proportion of encounters claimable with a Medicare item number; the distribution of the 
PN/AHW items recorded; treatments provided by PNs/AHWs in association with the GP- 
encounters; and the problems for which these treatments were provided.  
Remember that these results will not include PN/AHW activities undertaken during the 
GP’s BEACH recording period that were not associated with the recorded encounter. Such 
activities could include Medicare-claimable activities (for example, chronic disease 
management) provided under instruction from the GP but not at the time of the encounter 
recorded in BEACH, or provision of other services not claimable from Medicare (for 
example, dietary advice on a one-to-one basis, or in a group situation). 
Practice nurse/Aboriginal health worker Medicare claims 
There were 7,318 GP–patient encounters (7.4% of all encounters) for which at least one 
practice nurse item and/or nurse activity was recorded. However, for 84 of these their 
activity was not described. At the remaining 7,234 encounters a PN/AHW was involved in 
the management of 7,607 problems (5.0% of all problems managed at all encounters) 
(Table 10.7). Extrapolation of these results suggests that during 2012–13 practice nurses were 
involved in about 9 million GP–patient consultations across Australia.  
A PN/AHW Medicare item was recorded at only 287 encounters: 0.3% of the 85,885 with one 
or more MBS item number(s) (Table 5.2) and 3.9% of the 7,234 encounters involving a 
PN/AHW (Table 10.7). 
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Table 10.7: Summary of PN or AHW involvement at encounters 
Variable Number 
Total encounters  98,564 
Encounters involving PN/AHW 7,318 
 Encounters at which PN/AHW activity described 7,234 
 Encounters with PN/AHW item number(s) recorded but activity not described  84 
Encounters at which one or more MBS PN/AHW item numbers were recorded as claimable  287 
Total problems managed 152,517 
Problems managed with PN/AHW involvement 7,607 
 Per cent  (95% CI) 
Encounters involving the PN/AHW as a proportion of total encounters  7.4 (6.8–8.0) 
PN/AHW claimable encounters as a proportion of total encounters  0.3 (0.1–0.5) 
Proportion of PN/AHW involved encounters for which one or more PN/AHW item numbers were 
claimed from Medicare  
3.9 
(1.7–6.1) 
Problems involving the PN/AHW as a proportion of total problems (95% CI) 5.0 (4.6–5.4) 
Note: PN/AHW – practice nurse/Aboriginal health worker; MBS – Medicare Benefits Schedule; CI – confidence interval. 
Distribution of practice nurse/Aboriginal health worker items claimed  
Only 287 PN/AHW item numbers were recorded, one at each of 287 encounters. The vast 
majority (91.8%) were item 10997—practice nurse services to a person with chronic disease. 
These were followed by item 10986 (4.7%) and 10987 (3.5%) (Table 10.8).  
The distribution of recorded PN/AHW item numbers and that of the (approximately) 
0.8 million claims made for such items from Medicare demonstrated a relatively good fit.  
Table 10.8: Distribution of PN/AHW worker item numbers recorded  
Medicare 
item 
number Short descriptor Number 
Per cent 
 of total 
(95% CI) 
Per cent of Medicare 
PN/AHW item 
claims(a) 
(n = 0.8 million) 
10997 Service provided to a person with a chronic disease by a 
practice PN or registered AHW 
264 91.8  
(85.8–97.7) 
89.3 
10986 Provision of a health assessment for a patient who is 
receiving or has received their 4-year-old immunisation by 
a PN or AHW 
14 4.7 
(0.1–9.4) 
3.4 
10987 Follow up service provided by a PN/AHW for an 
Indigenous person who has received a health assessment 
10 3.5  
(0.3–6.6) 
7.0 
10988 Immunisation provided to a person by an AHW 0 0.1  
(0.0–0.2) 
0.6 
Total All Medicare practice nurse item numbers 287 100.0 — 
(a) Total Medicare claims for practice nurse and AHW activities July 2012 – June 2013.  
Source: https://www.medicareaustralia.gov.au/statistics/mbs_item.shtml 
Note: PN/AHW – practice nurse/Aboriginal health worker; CI – confidence interval. 
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Treatments provided by practice nurses or Aboriginal health worker 
at GP–patient encounters 
As shown in Section 10.1, GPs reported 53,163 other treatments at encounters. A further 
1,649 local injections in administration of vaccine were given by a PN/AHW and 1,987 by 
the recording GP (these were not reported in Section 10.2). So, in total 56,799 other 
treatments were recorded, PNs/AHWs accounting for 8,188 of these (representing 14.4% of 
all other treatments recorded at BEACH encounters) at a rate of 8.3 per 100 recorded 
encounters.  
By far the majority (86.2%) of the PN/AHW recorded activity was procedural, and these 
procedures represented 34.0% of all procedures recorded. In contrast, clinical treatments 
accounted for 13.8% of PN/AHW recorded activity at encounters, but PNs/AHWs provided 
only 3.1% of all recorded clinical treatments. PNs/AHWs did 45.4% of the recorded 
immunisation injections at GPs encounters (Table 10.9).  
Table 10.9: Summary of treatments given by GPs, and by PN or AHW at GP–patient encounters 
Treatment 
Performed/assisted by PN/AHW  Performed by the GP 
Total number 
recorded(a) 
Number Row per cent  
of total 
 Number Row per cent  
of total 
Procedures(a) 7,060 34.0  13,716 66.0 20,776 
(Immunisation injections) (1,649) (45.4)  (1,987) (54.6) (3,636) 
Clinical treatments 1,127 3.1  34,896 96.9 36,023 
All other treatments 8,188 14.4  48,611 85.6 56,799 
(a)  Procedural treatments here include all injections given by a PN/AHW or the GP for immunisations/vaccinations (n = 3,636).  
These are not included in the summary of the content of encounter in Table 5.1, summary of management in Table 8.1 or in the analyses of 
other treatments in Chapter 10, because the immunisation/vaccination is already counted as a prescription or GP-supplied medication. 
Note: PN/AHW – practice nurse/Aboriginal health worker. 
Of the 7,060 procedures performed by a PN/AHW 33.9% were injections (Table 10.10) and 
69.0% of these were for immunisations (Table 10.9). A further 18.8% were 
dressing/pressure/compression/tamponade. Together these accounted for 52.6% of all 
procedures undertaken by PNs/AHWs in association with the recorded GP–patient 
encounters. Check-ups made up 9.2% of the procedures undertaken by a PN/AHW followed 
by INR tests (7.4%), and incision/drainage/aspirations (6.0%). PNs/AHWs also undertook a 
wide range of other procedural activities in association with the GP–patient encounters 
(Table 10.10). 
Other administrative procedure (which includes administrative/documentation work but 
excludes provision of sickness certificates) was the most frequently recorded clinical activity, 
accounting for more than one-third (36.9%) of the 1,127 clinical treatments provided by 
PNs/AHWs, followed by counselling/advice about nutrition/weight (9.1%), 
advice/education about medication (8.2%) and about treatment (7.7%) (Table 10.10).  
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Table 10.10: Most frequent activities done by a PN or AHW at GP encounters 
Activity Number 
Per cent of 
group(a) 
Rate per 100 
encounters where 
PN/AHW activity 
described(a) 
 (n = 7,234) 
95% 
LCL 
95% 
UCL 
Procedural treatments 7,060 100.0 97.6 95.7 99.5 
 Local injection/infiltration* 2,391 33.9 33.0 30.2 35.7 
 Dressing/pressure/compression/tamponade* 1,324 18.8 18.3 16.4 20.2 
 Check-up – PN/AHW* 647 9.2 9.2 7.6 10.3 
 INR test* 522 7.4 7.4 5.9 8.5 
 Incision/drainage/flushing/aspiration/removal 
 body fluid* 
424 6.0 6.0 4.5 7.2 
 Repair/fixation – suture/cast/prosthetic device  
 (apply/remove)* 
352 5.0 5.0 4.2 5.6 
 Electrical tracings* 331 4.7 4.7 3.9 5.2 
 Excision/removal tissue/biopsy/destruction/ 
 debridement/cauterisation* 
257 3.6 3.6 2.8 4.3 
 Physical function test* 185 2.6 2.6 2.0 3.1 
 Urine test* 166 2.4 2.4 1.6 3.0 
 Glucose test* 84 0.9 0.9 0.4 1.3 
 Assist at operation 62 0.9 0.8 0.6 1.1 
 Other diagnostic procedures* 61 0.6 0.6 0.2 1.0 
 Pap smear* 44 0.5 0.5 0.2  0.7 
Clinical treatments 1,127 100.0 15.6 13.3 17.9 
 Other administrative procedure/document 
 (excluding sickness certificate)* 
416 36.9 5.8 4.6 7.0 
 Counselling/advice – nutrition/weight*  103 9.1 1.4 0.8 2.0 
 Advice/education – medication* 92 8.2 1.3 0.9 1.7 
 Advice/education – treatment* 87 7.7 1.2 0.7 1.7 
 Advice/education NEC* 83 7.4 1.2 0.7 1.6 
 Counselling – problem*  80 7.1 1.1 0.7 1.5 
 Consultation with primary care provider* 73 6.5 1.0 0.7 1.4 
 Counselling/advice – lifestyle* 34 3.0 0.5 0.2 0.7 
(a) Only the most common individual treatments provided by practice nurses/Aboriginal health workers are included in this table. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Tables A4.4–A4.6 purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; INR – international normalised ratio; PN/AHW – practice nurse/Aboriginal health 
worker; NEC – not elsewhere classified. 
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Problems managed with practice nurse or Aboriginal health 
workers involvement at encounter 
PNs and AHWs were involved in management of a wide range of problems in association 
with the GP encounters. The problems managed most often were immunisation/vaccination 
(22.0% of all problems managed with the involvement of a PN or AHW), check-ups (6.5%), 
laceration/cut (6.0%) and diabetes (4.4%). Other common problems for which PNs or AHWs 
were involved at the GP–patient consultations are listed in Table 10.11. 
Table 10.11: The most common problems managed with involvement of PNs or AHWs at 
GP–patient encounters 
Problem managed Number 
Per cent  
of problems 
involving  
PN/AHW(a) 
(n = 7,607) 
Rate per 100 
encounters with 
recorded PN/AHW 
activity(b) 
(n = 7,234) 
95% 
LCL 
95% 
UCL 
Immunisation/vaccination – all* 1,671 22.0 23.1 20.4 25.8 
Check-up – all* 497 6.5 6.9 5.9 7.8 
Laceration/cut 453 6.0 6.3 5.4 7.2 
Diabetes – all* 334 4.4 4.6 3.8 5.4 
Chronic ulcer skin (including varicose ulcer) 303 4.0 4.2 3.5 4.9 
Atrial fibrillation/flutter  301 4.0 4.2 3.2 5.1 
Excessive ear wax  186 2.4 2.6 2.1 3.1 
Malignant neoplasm, skin 167 2.2 2.3 1.8 2.8 
Blood test – all* 144 1.9 2.0 1.0 3.0 
Administrative procedure – all* 119 1.6 1.7 1.1 2.2 
Vitamin/nutritional deficiency 112 1.5 1.5 1.2 1.9 
Repair/fixation – suture/cast/prosthetic device 
(apply/remove)* 
107 1.4 1.5 1.2 1.8 
Hypertension* 103 1.4 1.4 1.0 1.8 
Asthma 98 1.3 1.3 1.0 1.7 
Skin symptom/complaint, other 83 1.1 1.1 0.8 1.5 
Prescription – all* 82 1.1 1.1 0.8 1.5 
Skin infection, other 76 1.0 1.1 0.8 1.3 
Pregnancy* 75 1.0 1.0 0.5 1.5 
Contraception, other 61 0.8 0.8 0.6 1.1 
Burns/scalds 58 0.8 0.8 0.5 1.1 
Other preventive procedures/high risk 
medication* 
55 0.7 0.8 0.4 1.1 
Subtotal 5,350 70.3 — — — 
Total problems involving practice nurse 7,607 100.0 105.2 104.4 105.9 
(a) Only those problems accounting for >0.5% of all problems managed at GP–patient encounters with involvement of a PN or AHW are 
included in this table.  
(b) Rate of nurse provision of treatment at encounter for selected problem per 100 total encounters in which a practice nurse or Aboriginal 
health worker was involved. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.3, <purl.library.usyd.edu.au/sup/9781743323779>).  
Note: LCL – lower confidence limit; UCL – upper confidence limit; PN/AHW – practice nurse/Aboriginal health worker. 
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10.5 Changes in other treatments over the decade 
2003–04 to 2012–13 
An overview of changes in other treatments provided in general practice over the decade can 
be found in Chapter 10 of the companion report A decade of Australian general practice activity 
2003–04 to 2012–13.1 A summary of the results is provided below. 
Clinical treatments 
There was no statistically significant difference in the rate at which clinical treatments were 
provided in the management of patient problems in 2003–04 and 2012–13, but there were 
major changes within the decade.  
The rate at which clinical treatments were provided remained steady from 2003–04 to  
2004–05. Following the introduction of PN and AHW Medicare item numbers in 2004, there 
was a sudden and significant decrease in the rate at which clinical treatments were provided 
in 2005–06. From 2006–07 onwards, rates slowly increased to reach 23.6 clinical treatments 
per 100 problems in 2012–13, nearing the level provided 10 years earlier.  
There were significant changes in some specific types of clinical treatments. 
• The rate at which other administrative procedure/document and sick certificates were 
provided significantly increased from 2003–04 to 2012–13, however the changes were not 
linear.  
• The rate at which counselling/advice about nutrition/weight was provided significantly 
decreased over the decade. Considering the rise in the prevalence of overweight and 
obesity among Australian general practice patients it is hoped that the decrease since 
2005–06 reflects a shift of this role to practice nurses.  
Based on the rate at which clinical treatments were provided per 100 encounters, we estimate 
that 11 million more clinical treatments were provided at GP–patient encounters nationally 
in 2012–13 than 10 years earlier. 
Procedural treatments 
The rate at which procedures were performed per 100 encounters increased significantly 
from 14.7 per 100 encounters in 2003–04 to 17.4 per 100 in 2012–13. The extrapolated effect of 
this change is that nationally in 2012–13 there were an estimated 7.9 million more procedures 
undertaken than a decade earlier.  
This increase was reflected in some specific types of procedures.  
• The provision of local injections/infiltration (excluding local injection performed for 
immunisations) significantly increased over the decade. When extrapolated, the increase 
from 1.6 per 100 encounters in 2003–04 to 2.3 per 100 encounters in 2012–13 equates to 
provision of 1.4 million more local injections/infiltrations nationally in 2012–13 than in 
2003–04.  
• There were also significant increases in the provision of the INR test, other preventive 
procedures/high risk medication and PN/AHW check-ups per 100 problems managed. 
There was an overall increase in the proportion of problems that were managed with a 
procedure, rising from 13.7 per 100 encounters in 2003–04 to 16.3 per 100 in 2012–13. 
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Practice nurse/Aboriginal health worker activity  
A comparison of PN/AHW activity from 2005–06 to 2012–13 is provided in Chapter 10 of the 
10-year report A decade of Australian general practice activity 2003–04 to 2012–13.1 Changes over 
the decade are summarised below. 
As a proportion of all encounters, those involving a PN/AHW doubled from 4.2% in 2005–06 
to 9.0% in 2009–10, then significantly decreased to 7.4% in 2011–12, and remained steady in 
2012–13. The proportion of problems managed with a PN/AHW involvement also increased 
from 2.8% in 2005–06 to 6.1% in 2009–10, with no change by 2012–13 (5.0%).  
In 2005–06, GPs recorded at least one PN/AHW Medicare item number at 39% of encounters 
with recorded PN/AHW activity. This increased to 46% by 2009–10, and then decreased to 
27% in 2012–12. In 2012–13, after the change in practice nurse funding structure, the 
PN/AHW item number was claimed at only 4%.  
The change in practice nurse funding structure had a huge impact on the distribution of 
PN/AHW item claims in 2012–13 for their activity associated with GP-encounters: 91% of 
items claimed were for PN/AHW management of chronic diseases, compared with only 
3.6% the previous year. 
The rate at which procedures (including tests) were undertaken by PNs/AHWs at  
GP–patient encounters more than doubled from 4.0 per 100 encounters in 2005–06 to 9.2 per 
100 in 2009–10, but decreased in 2011–12 to 7.2 per 100 encounters, remaining steady in  
2012–13. PNs/AHWs also took over an increasing proportion of the procedural work, 
increasing from 23% in 2005–06 to 38% in 2010–11, and remaining steady in 2012–13. 
While their provision of clinical treatments (such as advice and health education) remained 
infrequent at GP–patient encounters, there was a significant increase over the study period, 
from 0.2 clinical treatments per 100 encounters in 2005–06 to 1.1 per 100 in 2012–13.  
With the removal of a rebate for injections for immunisation, the rate at which PNs/AHWs 
provided injections in association with GP–patient encounters dropped to its lowest level 
(33.0 per 100 PN/AHW involved encounters), since first recorded in 2005–06. Check-ups by 
PNs/AHWs at GP–patient encounters doubled over the study period. INR blood testing 
frequency more than tripled.  
In clinical treatments, PNs/AHWs carried out administrative procedures (excluding sickness 
certificates) at an ever increasing rate, rising from 0.7 per 100 PN/AHW-involved encounters 
in 2005–06, to 5.8 per 100 in 2012–13. Most of this growth occurred over the last two years. 
Their provision of advice/education about medication also increased. 
There were significant increases in the rate at which PNs/AHWs were involved in 
management of check-ups, diabetes, and atrial fibrillation/flutter. These increases may have 
been stimulated by the introduction of MBS item 10997 for services provided to a person 
with a chronic disease, in 2007–08.  
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11 Referrals and admissions 
A referral is defined as the process by which the responsibility for part, or all, of the care of a 
patient is temporarily transferred to another health care provider. GPs were instructed only 
to record new referrals at the encounter (that is, not to record continuations). For each 
encounter, GPs could record up to two referrals, and each referral was linked by the GP to 
the problem(s) for which the patient was referred. Referrals included those to medical 
specialists, allied health services, hospitals for admission, emergency departments, and those 
to other services (including those to outpatient clinics and to other GPs). 
Data on referrals and admissions are reported for each of the most recent BEACH years from 
2003–04 to 2012–13 in the 10-year report A decade of Australian general practice activity 2003–04 
to 2012–13.1  
11.1 Number of referrals and admissions 
Table 11.1 provides a summary of referrals and admissions, and the rates per 100 encounters 
and per 100 problems managed. The patient was given at least one referral at 13.5% of all 
encounters, for 9.5% of all problems managed. 
There were 14,561 referrals made at a rate of 14.8 per 100 encounters, most often to medical 
specialists (8.9 per 100 encounters, 5.7 per 100 problems managed), followed by referrals to 
allied health services (4.7 per 100 encounters, 3.0 per 100 problems). Few patients were 
referred/admitted to hospital, or referred to the emergency department. 
Table 11.1: Summary of referrals and admissions 
Variable Number 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
At least one referral(a) 13,331 13.5 13.0 14.1 9.5 9.1 9.8 
Referrals  14,561 14.8 14.2 15.4 9.5 9.2 9.9 
 Medical specialist* 8,750 8.9 8.5 9.3 5.7 5.5 6.0 
 Allied health services* 4,616 4.7 4.4 5.0 3.0 2.8 3.2 
 Hospital* 354 0.4 0.3 0.4 0.2 0.2 0.3 
 Emergency department* 270 0.3 0.2 0.3 0.2 0.1 0.2 
 Other referrals* 571 0.6 0.5 0.7 0.4 0.3 0.4 
Total referrals 14,561 14.8 14.2 15.4 9.5 9.2 9.9 
(a) At least one referral was given in the management of 14,431 problems at the 13,331 encounters.  
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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11.2 Most frequent referrals 
Table 11.2 shows the medical specialists and allied health service groups to whom GPs most 
often referred patients. Referrals to medical specialists were most often to orthopaedic 
surgeons (9.3% of specialist referrals), surgeons (8.7%), and dermatologists (7.8%). The top 10 
specialists accounted for 64.9% of specialist referrals and for 42.5% of all referrals. 
Referrals to allied health services were most often to physiotherapists (25.9% of allied health 
services referrals), psychologists (21.6%), podiatrists/chiropodists (12.1%), 
dietitians/nutritionists (7.3%) and dentists (5.8%). The top 10 allied health services accounted 
for 83.1% of allied health referrals and 28.7% of all referrals. 
Table 11.2: Most frequent referrals, by type 
Professional/organisation Number 
Per cent 
of all 
referrals  
Per cent of 
referral 
group 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Medical specialist* 8,750 65.5 100.0 8.9 8.5 9.3 5.7 5.5 6.0 
 Orthopaedic surgeon  813 6.1 9.3 0.8 0.7 0.9 0.5 0.5 0.6 
 Surgeon 759 5.7 8.7 0.8 0.7 0.9 0.5 0.4 0.5 
 Dermatologist 679 5.1 7.8 0.7 0.6 0.8 0.4 0.4 0.5 
 Ophthalmologist 668 5.0 7.6 0.7 0.6 0.8 0.4 0.4 0.5 
 Cardiologist 634 4.7 7.2 0.6 0.6 0.7 0.4 0.4 0.5 
 Gastroenterologist 578 4.3 6.6 0.6 0.5 0.7 0.4 0.3 0.4 
 Ear, nose and throat 528 4.0 6.0 0.5 0.5 0.6 0.3 0.3 0.4 
 Gynaecologist  461 3.4 5.3 0.5 0.4 0.5 0.3 0.3 0.3 
 Urologist  305 2.3 3.5 0.3 0.3 0.4 0.2 0.2 0.2 
 Psychiatrist  255 1.9 2.9 0.3 0.2 0.3 0.2 0.1 0.2 
 Subtotal: top 10 medical  
 specialist referrals  
5,681 42.5 64.9 — — — — — — 
Allied health services* 4,616 34.5 100.0 4.7 4.4 5.0 3.0 2.8 3.2 
 Physiotherapist  1,197 9.0 25.9 1.2 1.1 1.3 0.8 0.7 0.9 
 Psychologist  999 7.5 21.6 1.0 0.9 1.1 0.7 0.6 0.7 
 Podiatrist/chiropodist  557 4.2 12.1 0.6 0.5 0.6 0.4 0.3 0.4 
 Dietitian/nutritionist  339 2.5 7.3 0.3 0.3 0.4 0.2 0.2 0.3 
 Dentist  266 2.0 5.8 0.3 0.2 0.3 0.2 0.1 0.2 
 Optometrist  116 0.9 2.5 0.1 0.1 0.1 0.1 0.1 0.1 
 Audiologist 113 0.8 2.4 0.1 0.1 0.1 0.1 0.1 0.1 
 Diabetes educator  104 0.8 2.2 0.1 0.1 0.1 0.1 0.1 0.1 
 Exercise physiologist  74 0.6 1.6 0.1 0.1 0.1 0.0 0.0 0.1 
 Nurse  69 0.5 1.5 0.1 0.1 0.1 0.0 0.0 0.1 
 Subtotal: top 10 allied  
 health referrals 
3,834 28.7 83.1 — — — — — — 
Subtotal: all referrals listed 9,515 71.2 — — — — — — — 
Total allied health and 
medical specialist referrals 13,366 100.0 — 13.6 13.0 14.2 8.8 8.4 9.1 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.7, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit.  
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11.3 Problems most frequently referred to a 
specialist 
The GP could link a single referral to multiple problems being managed at the encounter. 
Therefore, there are more problem–referral links than referrals. Table 11.3 shows the most 
common problems referred to a medical specialist, in decreasing frequency order of 
problem-referral links. 
The 8,750 referrals to a medical specialist were provided in management of 8,968 problems. 
The 10 problems most often referred to a specialist accounted for only 18.8% of all problem–
referral links, reflecting the breadth of problems referred to specialists. Malignant skin 
neoplasm accounted for 2.5% of problem-referral links, diabetes 2.4%, osteoarthritis 2.3% and 
pregnancy 2.0% (Table 11.3). The far right column of Table 11.3 shows the likelihood of 
referral to a medical specialist when each problem is managed. Malignant skin neoplasm 
resulted in a specialist referral at almost 1 in 5 (19.0%) GP contacts with this problem. This 
was followed by pregnancy (14.3%) and ischaemic heart disease (12.9%).  
Table 11.3: The 10 problems most frequently referred to a medical specialist 
Problem managed Number 
Per cent of 
problem–referral 
links  
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with this 
problem(a) 
Malignant neoplasm, skin 222 2.5 0.2 0.2 0.3 19.0 
Diabetes – all* 211 2.4 0.2 0.2 0.3 5.0 
Osteoarthritis* 203 2.3 0.2 0.2 0.2 7.3 
Pregnancy* 184 2.0 0.2 0.2 0.2 14.3 
Sleep disturbance 176 2.0 0.2 0.1 0.2 11.5 
Back complaint* 173 1.9 0.2 0.1 0.2 5.9 
Depression* 138 1.5 0.1 0.1 0.2 3.4 
Ischaemic heart disease* 136 1.5 0.1 0.1 0.2 12.9 
Gastro-oesophageal reflux disease* 125 1.4 0.1 0.1 0.2 4.9 
Abnormal test results* 117 1.3 0.1 0.1 0.1 9.3 
Subtotal: top 10 problems referred to 
a medical specialist 1,686 18.8 — — — — 
Total problems referred to medical 
specialist  8,968 100.0 9.1 8.7 9.5 — 
(a) The proportion of GP contacts with this problem that was referred to a medical specialist. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
At a meeting of senior academic researchers at the 2011 North American Primary Care 
Research Group meeting in Canada, we identified an international paucity of information 
about what problems are referred by GPs to particular types of specialists. The following 
analyses go some way to redressing this deficiency. 
Table 11.4 shows the five problems accounting for the greatest proportion of referrals to each 
of the 10 most common medical specialty types. The top five problems may represent a small 
or large proportion of all problems referred to a particular specialty. For example, the top 
five problems accounted for 25.5% of all referrals to general/unspecified surgeons 
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(indicative of the broad range of conditions referred to them), and for 76.2% of all referrals to 
psychiatrists, consistent with a more defined range.  
Orthopaedic surgeon: The two problems accounting for the most referrals were 
osteoarthritis (21.5% of orthopaedic surgeon referrals) and acute internal knee damage 
(11.9%). Of the five problems most frequently referred to an orthopaedic surgeon, those most 
likely to be referred at each GP contact with that problem were acute internal knee damage 
(referred at 31.5% of contacts) and knee symptom/complaint (15.5%).  
General/unspecified surgeon: The two problems accounting for the most referrals were 
inguinal hernia (7.3% of referrals) and malignant skin neoplasm (5.7%). Of the five problems 
most frequently referred, those most likely to be referred were inguinal hernia (referred at 
45.1% of GP contacts) and other abdominal hernia (23.7%).  
Dermatologist: The two problems accounting for the most referrals were malignant 
neoplasm of skin (14.4% of referrals) and solar keratosis/sunburn (9.9%). Of the five 
problems most frequently referred to a dermatologist, those most likely to be referred were 
acne (referred at 14.3% of GP contacts) and malignant skin neoplasm (8.5%).  
Ophthalmologist: The two problems accounting for the most referrals were diabetes (14.8% 
of referrals) and cataract (12.4%). Of the five problems most frequently referred to an 
ophthalmologist, those most likely to be referred were cataract (referred at 54.6% of GP 
contacts) and glaucoma (30.1%) (apart from GP contact specifically for referral).  
Cardiologist: The two problems accounting for the most referrals were ischaemic heart 
disease (19.0% of referrals) and atrial fibrillation/flutter (10.1%). Of the five problems most 
frequently referred, those most likely to be referred were palpitations (referred at 22.2% of 
GP contacts) and chest pain (not otherwise specified) (15.4%). 
Gastroenterologist: The two problems accounting for the most referrals were gastro-
oesophageal reflux disease (14.2% of referrals) and abdominal pain (7.1%). Of the five 
problems most frequently referred to a gastroenterologist, those most likely to be referred 
were rectal bleeding (referred at 22.4% of GP contacts) and digestive neoplasm (benign or 
uncertain) (20.8%).  
Ear, nose, and throat (ENT) specialist: The two problems accounting for the most referrals 
were acute otitis media/myringitis (8.3% of referrals) and tonsillitis (7.4%). Of the five 
problems most frequently referred to an ENT specialist, those most likely to be referred were 
tinnitus (referred at 29.4% of GP contacts) and tonsillitis (5.0%).  
Gynaecologist: The two problems accounting for the most referrals were menstrual 
problems (14.5% of referrals) and ‘other’ female genital disease (8.7%). Of the five problems 
most frequently referred to a gynaecologist, those most likely to be referred were 
uterovaginal prolapse (referred at 42.3% of GP contacts) and female infertility/subfertility 
(26.5%).  
Urologist: The two problems accounting for the most referrals were benign prostatic 
hypertrophy (17.5% of referrals) and abnormal test results (13.8%). Of the five problems most 
frequently referred, those most likely to be referred were benign prostatic hypertrophy 
(referred at 20.2% of GP contacts) and malignant neoplasm of prostate (11.7%).  
Psychiatrist: The two problems accounting for the most referrals were depression (44.1% of 
referrals) and affective psychosis (11.3%). Of the five problems most frequently referred to a 
psychiatrist, those most likely to be referred at each GP contact with that problem were 
hyperkinetic disorder (referred at 15.0% of GP contacts) and affective psychosis (9.3%) 
(Table 11.4). 
  
95
  
Table 11.4: The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of 
problems referred 
to each specialist 
Rate per 100 
contacts with  
this problem(a) 
Orthopaedic surgeon Total 824 100.0 — 
 Osteoarthritis* 177 21.5 6.3 
 Acute internal knee damage  98 11.9 31.5 
 Injury musculoskeletal NOS 64 7.8 7.3 
 Fracture* 51 6.2 5.7 
 Knee symptom/complaint 46 5.6 15.5 
 Subtotal: top five problems  436 52.9  — 
General/unspecified 
surgeon 
Total 776 100.0 — 
Inguinal hernia 56 7.3 45.1 
 Malignant neoplasm, skin 44 5.7 3.8 
 Cholecystitis/cholelithiasis 38 5.0 19.4 
 Haemorrhoids 31 4.0 12.3 
 Abdominal hernia, other 29 3.7 23.7 
 Subtotal: top five problems  198 25.5  — 
Dermatologist Total 693 100.0 — 
 Malignant neoplasm, skin 100 14.4 8.5 
 Solar keratosis/sunburn 69 9.9 6.2 
 Contact dermatitis 68 9.9 3.9 
 Acne 58 8.4 14.3 
 Skin symptom/complaint, other 51 7.4 7.4 
 Subtotal: top five problems 346 49.9  — 
Ophthalmologist  Total 678 100.0 — 
 Diabetes – all* 101 14.8 2.4 
 Cataract 84 12.4 54.6 
 Glaucoma 57 8.4 30.1 
 Eye/adnexa disease, other 55 8.1 29.2 
 Refer physician/specialist/clinic/hospital eye 36 5.3 80.4 
 Subtotal: top five problems 333 49.1  — 
Cardiologist Total 656 100.0 — 
 Ischaemic heart disease* 124 19.0 11.8 
 Atrial fibrillation/flutter 66 10.1 4.7 
 Hypertension* 55 8.4 0.7 
 Palpitations/awareness of heart 49 7.5 22.2 
 Chest pain NOS 48 7.2 15.4 
 Subtotal: top five problems 342 52.1  — 
(continued) 
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Table 11.4 (continued): The top problems most frequently referred, by type of medical specialist 
Specialist Problem managed Number 
Per cent of 
problems referred 
to each specialist 
Rate per 100 
contacts with this 
problem(a) 
Gastroenterologist Total 595 100.0 — 
 Gastro-oesophageal reflux disease* 85 14.2 3.3 
 Abdominal pain* 42 7.1 5.9 
 Chronic enteritis/ulcerative colitis 34 5.7 20.6 
 Rectal bleeding 33 5.5 22.4 
 Benign/uncertain neoplasm, digestive 32 5.4 20.8 
 Subtotal: top five problems 226 38.0  — 
Ear, nose, and throat 
(ENT) specialist 
Total 538 100.0 — 
Acute otitis media/myringitis 45 8.3 4.2 
 Tonsillitis* 40 7.4 5.0 
 Sinusitis acute/chronic 28 5.2 2.3 
 Tinnitus, ringing/buzzing ear 28 5.2 29.4 
 Otitis externa 24 4.5 4.8 
 Subtotal: top five problems 165 30.7  — 
Gynaecologist  Total 473 100.0 — 
 Menstrual problems* 69 14.5 11.5 
 Genital disease, other (female) 41 8.7 19.9 
 Uterovaginal prolapse 35 7.4 42.3 
 Abnormal test results* 27 5.6 2.1 
 Infertility/subfertility (female) 19 4.0 26.5 
 Subtotal: top five problems 191 40.4  — 
Urologist  Total 311 100.0 — 
 Benign prostatic hypertrophy 54 17.5 20.2 
 Abnormal test results* 43 13.8 3.4 
 Malignant neoplasm prostate 42 13.6 11.7 
 Urinary tract infection* 16 5.2 1.0 
 Haematuria 11 3.7 7.0 
 Subtotal: top five problems 166 53.4  — 
Psychiatrist Total 265 100.0 — 
 Depression* 117 44.1 2.9 
 Affective psychosis 30 11.3 9.3 
 Anxiety* 25 9.5 1.2 
 Hyperkinetic disorder 16 6.1 15.0 
 Schizophrenia 14 5.1 3.0 
 Subtotal: top five problems 202 76.2  — 
(a) The proportion of GP contacts with this problem that was referred to each type of medical specialist.  
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: NOS – not otherwise specified. 
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11.4 Problems most frequently referred to allied 
health services and hospitals  
The 4,616 referrals to an allied health service were provided in the management of 4,844 
problems. The 10 most commonly referred problems accounted for 45.6% of all problem–
referral links. Depression was the problem accounting for the largest proportion of allied 
health referrals (12.0%), followed by diabetes (8.7%), back complaints (6.0%) and anxiety 
(4.4%). However, of the 10 most commonly referred problems, the most likely to be referred 
to an allied health service was teeth/gum disease, referred at 27.9% of all GP contacts with 
this problem (Table 11.5).  
Table 11.5: The 10 problems most frequently referred to allied health services 
Problem managed Number 
Per cent of 
problem–
referral links  
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Depression* 582 12.0 0.6 0.5 0.7 14.3 
Diabetes – all*  420 8.7 0.4 0.4 0.5 10.0 
Back complaint* 291 6.0 0.3 0.2 0.3 10.0 
Anxiety* 214 4.4 0.2 0.2 0.3 10.3 
Osteoarthritis* 161 3.3 0.2 0.1 0.2 5.8 
Sprain/strain* 126 2.6 0.1 0.1 0.2 9.3 
Teeth/gum disease 123 2.5 0.1 0.1 0.2 27.9 
Administrative procedure NOS 119 2.5 0.1 0.1 0.2 9.6 
Bursitis/tendonitis/synovitis NOS 97 2.0 0.1 0.1 0.1 8.7 
Acute stress reaction 76 1.6 0.1 0.1 0.1 10.4 
Subtotal: top 10 problems referred to AHS 2,211 45.6 — — — — 
Total problems referred to AHS 4,844 100.0 4.9 4.6 5.2 — 
(a) The proportion of GP contacts with this problem that was referred to allied health services. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified; AHS – allied health service. 
The 354 referrals to a hospital were provided in the management of 371 problems.  
The 10 problems most frequently referred to hospital are shown in Table 11.6. Pregnancy 
accounted for the highest proportion (9.1%) of these referrals, but dehydration was the 
problem most likely to be referred (26.3%).  
The 270 referrals to an emergency department were associated with the management of 
287 problems. The 10 problems most frequently referred to an emergency department are 
shown in Table 11.7. Abdominal pain accounted for the highest proportion (4.5%) of these 
referrals, but appendicitis was the problem most likely to be referred (24.4%).  
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Table 11.6: The 10 problems most frequently referred to hospital 
Problem managed Number 
Per cent of 
problems 
referred 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Pregnancy* 34 9.1 0.03 0.02 0.05 2.6 
Fracture* 12 3.3 0.01 0.01 0.02 1.4 
Anaemia* 11 3.0 0.01 0.00 0.02 2.0 
Acute bronchitis/bronchiolitis 10 2.7 0.01 0.00 0.02 0.4 
Dehydration 9 2.4 0.01 0.00 0.02 26.3 
Chest pain NOS 9 2.4 0.01 0.00 0.02 2.8 
Skin infection, other 8 2.2 0.01 0.00 0.02 2.5 
Pneumonia 8 2.0 0.01 0.00 0.01 3.1 
Gastroenteritis* 8 2.0 0.01 0.00 0.02 0.6 
Appendicitis 7 1.9 0.01 0.00 0.01 16.3 
Subtotal: top 10 problems referred for 
admission 115 31.0 — — — — 
Total problems referred to hospital 371 100.0 0.38 0.32 0.43 — 
(a) The proportion of GP contacts with this problem that was referred to hospital. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
Table 11.7: The 10 problems most frequently referred to an emergency department 
Problem managed Number 
Per cent of 
problems 
referred 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
contacts with 
this problem(a) 
Abdominal pain* 13 4.5 0.01 0.01 0.02 1.8 
Ischaemic heart disease* 11 4.0 0.01 0.00 0.02 1.1 
Pneumonia 11 3.7 0.01 0.00 0.02 4.4 
Appendicitis 11 3.7 0.01 0.00 0.02 24.4 
Atrial fibrillation/flutter 10 3.6 0.01 0.00 0.02 0.7 
Fracture* 10 3.5 0.01 0.00 0.02 1.1 
Chest pain NOS 10 3.3 0.01 0.00 0.02 3.1 
Acute bronchitis/bronchiolitis 8 2.9 0.01 0.00 0.02 0.4 
Skin infection, other 8 2.8 0.01 0.00 0.02 2.4 
Boil/carbuncle 7 2.5 0.01 0.00 0.01 1.2 
Subtotal: top 10 problems referred to 
emergency department 99 34.5 — — — — 
Total problems referred to emergency 
department 287 100.0 0.29 0.24 0.34 — 
(a) The proportion of GP contacts with this problem that was referred to an emergency department. 
* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; NOS – not otherwise specified. 
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11.5 Changes in referrals over the decade 
2003–04 to 2012–13 
An overview of changes in referrals over the decade can be found in Chapter 11 of the 
companion report A decade of Australian general practice activity 2003–04 to 2012–13.1 In that 
report, changes over time are discussed in terms of change in the management of problems 
(that is, as a rate per 100 problems managed). This reflects change in how GPs are managing 
problems, and accounts for the significant increase in the number of problems managed per 
encounter over the decade (see Section 7.9).  
In summary, over the 10 years there was a significant increase in the proportion of problems 
that were referred: in 2003–04 at least one referral was made in the management of 8.0% of 
problems and this increased to 9.5% of problems managed in 2012–13.  
The overall rate of referral per 100 problems managed increased from 7.9 in 2003–04 to 9.5 in 
2012–13, and per 100 encounters from 11.6 to 14.8. This suggests that there were 7.6 million 
more referrals nationally in 2012–13 than a decade earlier.  
Referrals to medical specialists remained almost stable across the decade. However, there 
were marginally significant increases in the rate of referrals per 100 problems to orthopaedic 
surgeons, cardiologists and gastroenterologists, and marginal decreases in referrals to 
surgeons and ophthalmologists. In contrast, referrals to allied health services increased from 
1.8 per 100 problems managed in 2003–04 to 3.0 in 2012–13. This was reflected in significant 
increases in referral rates per 100 problems to psychologists and podiatrists/chiropodists, 
and a marginally significant increase in referral rates to dietitians/nutritionists.  
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12 Investigations 
The GP participants were asked to record (in free text) any pathology, imaging or other tests 
ordered or undertaken at the encounter, and to nominate the patient problem(s) associated 
with each test order placed. This allows the linkage of a test order to a single problem or 
multiple problems. Up to five orders for pathology, and two for imaging and other tests 
could be recorded at each encounter. A single test may have been ordered for the 
management of multiple problems, and multiple tests may have been used in the 
management of a single problem. 
A pathology test order may be for a single test (for example, Pap smear, HbA1c) or for a 
battery of tests (for example, lipids, full blood count). Where a battery of tests was ordered, 
the battery name was recorded rather than each individual test within the battery. GPs also 
recorded the body site for any imaging ordered (for example, x-ray chest, CT head). 
Data on investigations are reported for each year from 2003–04 to 2012–13 in the 10-year 
report A decade of Australian general practice activity 2003–04 to 2012–13.1  
12.1 Number of investigations 
Table 12.1 shows the number of encounters and problems at which a pathology or imaging 
test was ordered. There were no pathology or imaging tests recorded at three-quarters 
(75.7%) of encounters. 
At least one pathology test order was recorded at 18.1% of encounters (for 13.5% of problems 
managed), and at least one imaging test was ordered at 8.8% of encounters (for 5.9% of 
problems managed).  
Table 12.1: Number of encounters and problems for which pathology or imaging was ordered 
Pathology/imaging test 
ordered 
Number of 
encounters  
Per cent of 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Number of 
problems 
Per cent of 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Pathology and imaging ordered 2,553 2.6 2.4 2.8 1,829 1.2 1.1 1.3 
Pathology only ordered 15,268 15.5 14.9 16.0 18,825 12.3 11.9 12.8 
Imaging only ordered 6,125 6.2 6.0 6.5 7,208 4.7 4.5 4.9 
No pathology or imaging tests 
ordered 
74,618 75.7 75.0 76.5 124,655 81.7 81.2 82.3 
At least one pathology ordered 17,821 18.1 17.4 18.7 20,655 13.5 13.1 14.0 
At least one imaging ordered 8,678 8.8 8.4 9.2 9,037 5.9 5.7 6.2 
At least one other investigation 
ordered 
811 0.8 0.7 0.9 837 0.5 0.5 0.6 
At least one other investigation 
performed in the practice 
1,381 1.4 1.2 1.6 1,387 0.9 0.8 1.1 
At least one other investigation 
ordered or performed 
2,146 2.2 1.9 2.4 2,183 1.4 1.3 1.6 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
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12.2 Pathology ordering 
A report on changes in pathology ordering by GPs from 1998 to 2001 was produced in 2003.18 
A review of GP pathology orders in the National Health Priority Areas and other selected 
problems between 2000 and 2008 is reported in General practice in Australia, health priorities 
and policies 1998 to 2008.15 A report Evidence-practice gap in pathology test ordering: a comparison 
of BEACH pathology data and recommended testing was produced by the FMRC for the 
Australian Government Quality Use of Pathology Program in June 2009.17 Readers may wish 
to consider those reports in conjunction with the information presented below.  
Nature of pathology orders at encounter 
The GPs recorded 46,398 orders for pathology tests/batteries of tests, at a rate of 47.1 per 
100 encounters or 30.4 per 100 problems managed. The pathology tests recorded were 
grouped according to the categories set out in Appendix 4, Table A4.8. The main pathology 
groups reflect those used in the Medicare Benefits Schedule (MBS).83  
The distribution of pathology tests by MBS group, and the most common tests within each 
group are presented in Table 12.2. Each group and individual test is expressed as a 
proportion of all pathology tests, as a proportion of the group, as a rate per 100 encounters 
and as a rate per 100 problems managed with 95% confidence limits. 
Test orders classed as chemistry accounted for more than half the pathology test orders 
(58.9%), the most common being: lipid tests, for which there were 4.2 orders per 100 
encounters and 2.7 per 100 problems; electrolytes, urea and creatinine (3.0; 2.0); multi-
biochemical analysis (2.9; 1.9); and thyroid function tests (2.8; 1.8). Haematology tests 
accounted for 17.8% of all pathology including the most frequently ordered individual 
pathology test, full blood count (FBC). FBC tests accounted for 14.0% of all pathology, there 
being 6.6 FBC orders per 100 encounters and 4.3 per 100 problems managed. Microbiology 
accounted for 13.5% of pathology orders, with urine microscopy, culture and sensitivity 
being the most frequent in the group at 2.0 tests per 100 encounters and 1.3 per 100 problems 
managed. 
Table 12.2: Pathology orders by MBS pathology groups and most frequent individual test orders 
within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Chemistry*  27,324 58.9 100.0 27.7 26.4 29.0 17.9 17.2 18.6 
 Lipids* 4,113 8.9 15.1 4.2 3.9 4.4 2.7 2.5 2.9 
 Electrolytes, urea and creatinine* 2,987 6.4 10.9 3.0 2.8 3.3 2.0 1.8 2.1 
 Multi-biochemical analysis* 2,846 6.1 10.4 2.9 2.6 3.2 1.9 1.7 2.0 
 Thyroid function* 2,795 6.0 10.2 2.8 2.6 3.0 1.8 1.7 1.9 
 Liver function* 2,526 5.4 9.2 2.6 2.4 2.8 1.7 1.5 1.8 
 Glucose/glucose tolerance* 2,445 5.3 8.9 2.5 2.3 2.7 1.6 1.5 1.7 
 Ferritin* 1,432 3.1 5.2 1.5 1.3 1.6 0.9 0.9 1.0 
 HbA1c* 1,229 2.6 4.5 1.2 1.1 1.4 0.8 0.7 0.9 
 Chemistry; other* 1,023 2.2 3.7 1.0 0.9 1.2 0.7 0.6 0.8 
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Table 12.2 (continued): Pathology orders by MBS pathology groups and most frequent individual 
test orders within group 
Pathology test ordered Number 
Per cent  
of all 
pathology  
Per cent  
of group 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
 Prostate specific antigen* 959 2.1 3.5 1.0 0.9 1.1 0.6 0.6 0.7 
 C reactive protein  912 2.0 3.3 0.9 0.8 1.0 0.6 0.5 0.7 
 Vitamin D 822 1.8 3.0 0.8 0.7 0.9 0.5 0.5 0.6 
 Hormone assay* 741 1.6 2.7 0.8 0.7 0.8 0.5 0.4 0.5 
 Vitamin B12 638 1.4 2.3 0.6 0.6 0.7 0.4 0.4 0.5 
 Albumin/creatinine, urine* 600 1.3 2.2 0.6 0.5 0.7 0.4 0.3 0.4 
 Calcium/phosphate/magnesium* 305 0.7 1.1 0.3 0.3 0.4 0.2 0.2 0.2 
Haematology*  8,278 17.8 100.0 8.4 8.0 8.8 5.4 5.2 5.7 
 Full blood count 6,512 14.0 78.7 6.6 6.3 6.9 4.3 4.1 4.5 
 ESR 910 2.0 11.0 0.9 0.8 1.0 0.6 0.5 0.7 
 Coagulation*  627 1.4 7.6 0.6 0.6 0.7 0.4 0.4 0.5 
Microbiology*  6,244 13.5 100.0 6.3 5.9 6.7 4.1 3.8 4.3 
 Urine M,C&S* 1,932 4.2 30.9 2.0 1.8 2.1 1.3 1.2 1.4 
 Microbiology; other* 944 2.0 15.1 1.0 0.9 1.1 0.6 0.6 0.7 
 Hepatitis serology* 500 1.1 8.0 0.5 0.4 0.6 0.3 0.3 0.4 
 Faeces M,C&S* 412 0.9 6.6 0.4 0.4 0.5 0.3 0.2 0.3 
 Chlamydia* 408 0.9 6.5 0.4 0.4 0.5 0.3 0.2 0.3 
 Vaginal swab M,C&S* 313 0.7 5.0 0.3 0.3 0.4 0.2 0.2 0.2 
 Venereal disease* 284 0.6 4.5 0.3 0.2 0.3 0.2 0.2 0.2 
 HIV* 238 0.5 3.8 0.2 0.2 0.3 0.2 0.1 0.2 
 H Pylori* 189 0.4 3.0 0.2 0.2 0.2 0.1 0.1 0.1 
Cytopathology*  1,524 3.3 100.0 1.5 1.4 1.7 1.0 0.9 1.1 
 Pap smear*  1,491 3.2 97.8 1.5 1.3 1.7 1.0 0.9 1.1 
Immunology*  883 1.9 100.0 0.9 0.8 1.0 0.6 0.5 0.6 
 Immunology, other* 487 1.1 55.2 0.5 0.4 0.6 0.3 0.3 0.4 
 Anti-nuclear antibodies 162 0.3 18.3 0.2 0.1 0.2 0.1 0.1 0.1 
 Rheumatoid factor 106 0.2 12.0 0.1 0.1 0.1 0.1 0.1 0.1 
Other NEC*  869 1.9 100.0 0.9 0.7 1.0 0.6 0.5 0.7 
 Blood test  456 1.0 52.5 0.5 0.3 0.6 0.3 0.2 0.4 
 Other test NEC 235 0.5 27.0 0.2 0.2 0.3 0.2 0.1 0.2 
Tissue pathology*  789 1.7 100.0 0.8 0.7 0.9 0.5 0.4 0.6 
 Histology; skin 718 1.5 91.0 0.7 0.6 0.9 0.5 0.4 0.6 
Simple tests*  231 0.5 100.0 0.2 0.2 0.3 0.2 0.1 0.2 
Infertility/pregnancy* 256 0.6 100.0 0.3 0.2 0.3 0.2 0.1 0.2 
Total pathology tests  46,398 100.0 — 47.1 45.1 49.0 30.4 29.3 31.5 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.8, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; ESR – erythrocyte sedimentation rate; M,C&S – microscopy, culture and 
sensitivity; HIV – human immunodeficiency virus; H Pylori – test for Helicobacter pylori infection; NEC – not elsewhere classified. 
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Problems for which pathology tests were ordered 
Table 12.3 describes the problems for which pathology was commonly ordered, in 
decreasing frequency order of problem–pathology combinations. Diabetes (accounting for 
7.5% of all problem–pathology combinations), followed by hypertension, general check-ups 
and lipid disorder were the most common problems for which pathology tests were ordered.  
The two right-hand columns show the proportion of each problem that resulted in a 
pathology order, and the rate of pathology tests/batteries of tests per 100 specified problems 
when at least one test was ordered. For example, 29.4% of contacts with diabetes resulted in 
pathology orders, and when pathology was ordered for diabetes, the GPs ordered an 
average of 298 tests/batteries of tests per 100 ‘tested’ diabetes contacts. In contrast, only 
12.0% of contacts with hypertension problems resulted in a pathology test, but the resulting 
test orders accounted for almost as many tests (6.0%) as did diabetes (7.5%). This is because 
hypertension is managed far more frequently in general practice (8.6 per 100 encounters) 
than diabetes (4.2 per 100 encounters) (see Chapter 7, Section 7.4). 
Table 12.3: The 10 problems for which pathology was most frequently ordered 
Problem managed 
Number of 
problems 
Number of 
problem–
pathology 
combinations(a) 
Per cent of 
problem–
pathology 
combinations(a) 
Per cent of 
problems with 
test(b) 
Rate of pathology 
orders per 100 
problems with 
pathology(c) 
Diabetes – all* 4,186 3,663 7.5 29.4 297.8 
Hypertension* 8,482 2,926 6.0 12.0 287.7 
General check-up* 2,869 2,813 5.8 27.3 358.8 
Lipid disorder 3,292 2,114 4.3 26.9 238.8 
Weakness/tiredness 668 1,768 3.6 66.2 400.0 
Female genital check-up/ 
Pap smear*  
1,546 1,476 3.0 78.2 122.1 
Blood test NOS 389 1,169 2.4 81.3 369.3 
Abnormal test results* 1,265 1,096 2.3 49.6 174.6 
Urinary tract infection* 1,678 1,085 2.2 53.1 121.7 
Pregnancy* 1,281 965 2.0 37.0 203.8 
Subtotal 25,657 19,076 39.2 — — 
Total problems 152,517 48,642 100.0 13.5 235.5 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 46,398 
pathology test orders and 48,642 problem–pathology combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for pathology. 
(c) The rate of pathology orders placed per 100 problem contacts with at least one order for pathology. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1, <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: NOS – not otherwise specified. 
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12.3 Imaging ordering 
Readers wanting a more detailed study of imaging orders should consult the comprehensive 
report on imaging orders by GPs in Australia in 1999–00, by the FMRC using BEACH data, 
and published by the Australian Institute of Health and Welfare and the University of 
Sydney in 2001.84 A further detailed study of this subject is currently being conducted by the 
FMRC for the Australian Government Department of Health and Ageing, Diagnostic 
Imaging Quality Program. 
Nature of imaging orders at encounter 
There were 10,163 imaging test orders recorded, at a rate of 10.3 per 100 encounters and 6.7 
per 100 problems managed.  
The distribution of imaging tests by MBS group, and the most common tests within each 
group are presented in Table 12.4. Each group and individual test is expressed as a 
percentage of all imaging tests, as a percentage of the group, as a rate per 100 encounters, 
and as a rate per 100 problems with 95% confidence limits. Diagnostic radiology accounted 
for 43.3% of all imaging test orders, and ultrasound accounted for 40.8%. 
Table 12.4: Imaging orders by MBS imaging groups and the most frequent imaging tests ordered 
within group 
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
Diagnostic radiology* 4,405 43.3 100.0 4.5 4.2 4.7 2.9 2.7 3.0 
 X-ray; chest 939 9.2 21.3 1.0 0.9 1.0 0.6 0.6 0.7 
 X-ray; knee 484 4.8 11.0 0.5 0.4 0.5 0.3 0.3 0.4 
 Mammography; female 318 3.1 7.2 0.3 0.3 0.4 0.2 0.2 0.2 
 Test; densitometry  292 2.9 6.6 0.3 0.3 0.3 0.2 0.2 0.2 
 X-ray; shoulder 256 2.5 5.8 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; foot/feet 255 2.5 5.8 0.3 0.2 0.3 0.2 0.1 0.2 
 X-ray; hip  242 2.4 5.5 0.2 0.2 0.3 0.2 0.1 0.2 
 X-ray; ankle 170 1.7 3.9 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; wrist  157 1.5 3.6 0.2 0.1 0.2 0.1 0.1 0.1 
 X-ray; hand 121 1.2 2.7 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; spine; lumbosacral 108 1.1 2.5 0.1 0.1 0.1 0.1 0.1 0.1 
 X-ray; finger(s)/thumb 103 1.0 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; lumbar  102 1.0 2.3 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; abdomen  93 0.9 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 X-ray; spine; cervical 89 0.9 2.0 0.1 0.1 0.1 0.1 0.0 0.1 
Ultrasound* 4,147 40.8 100.0 4.2 4.0 4.4 2.7 2.6 2.9 
 Ultrasound; pelvis 590 5.8 14.2 0.6 0.5 0.7 0.4 0.3 0.4 
 Ultrasound; shoulder  517 5.1 12.5 0.5 0.4 0.6 0.3 0.3 0.4 
 Ultrasound; abdomen 397 3.9 9.6 0.4 0.3 0.5 0.3 0.2 0.3 
 Ultrasound; breast; female 318 3.1 7.7 0.3 0.3 0.4 0.2 0.2 0.2 
(continued) 
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Table 12.4 (continued): Imaging orders by MBS imaging groups and the most frequent imaging 
tests ordered within group  
Imaging test ordered Number 
Per cent of 
all imaging  
 Per cent 
of group 
Rate per 100 
encounters 
(n = 98,564) 
95% 
LCL 
95% 
UCL 
Rate per 100 
problems 
(n = 152,517) 
95% 
LCL 
95% 
UCL 
 Ultrasound; obstetric 311 3.1 7.5 0.3 0.3 0.4 0.2 0.2 0.2 
 Test; Doppler 139 1.4 3.4 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; kidney 124 1.2 3.0 0.1 0.1 0.2 0.1 0.1 0.1 
 Echocardiography 122 1.2 2.9 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; hip  120 1.2 2.9 0.1 0.1 0.2 0.1 0.1 0.1 
 Ultrasound; leg  111 1.1 2.7 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; thyroid 107 1.1 2.6 0.1 0.1 0.1 0.1 0.1 0.1 
 Ultrasound; neck 88 0.9 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; foot/toe(s)  88 0.9 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
 Ultrasound; kidney/ureter/  
 bladder 
88 0.9 2.1 0.1 0.1 0.1 0.1 0.0 0.1 
Computerised tomography* 1,261 12.4 100.0 1.3 1.2 1.4 0.8 0.8 0.9 
 CT scan; spine; lumbar 168 1.6 13.3 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; abdomen  165 1.6 13.1 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; brain 164 1.6 13.0 0.2 0.1 0.2 0.1 0.1 0.1 
 CT scan; head  112 1.1 8.9 0.1 0.1 0.1 0.1 0.1 0.1 
 CT scan; chest  108 1.1 8.6 0.1 0.1 0.1 0.1 0.1 0.1 
 CT scan; spine; lumbosacral  80 0.8 6.3 0.1 0.1 0.1 0.1 0.0 0.1 
Magnetic resonance imaging* 232 2.3 100.0 0.2 0.2 0.3 0.2 0.1 0.2 
 MRI; knee 78 0.8 33.6 0.1 0.1 0.1 0.1 0.0 0.1 
Nuclear medicine* 119 1.2 100.0 0.1 0.1 0.1 0.1 0.1 0.1 
Total imaging tests 10,163 100.0 — 10.3 9.9 10.8 6.7 6.4 6.9 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.9 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: LCL – lower confidence limit; UCL – upper confidence limit; CT – computerised tomography. 
Problems for which imaging tests were ordered 
Table 12.5 lists the problems for which imaging was commonly ordered, in decreasing 
frequency order of problem–imaging combinations. Back complaint accounted for 5.1% of all 
orders, followed by osteoarthritis (4.9%), and sprain/strain (3.9%).  
The two right-hand columns show the proportion of each problem that resulted in an 
imaging test, and the rate of imaging tests per 100 specified problems when at least one test 
was ordered. For example, 16.0% of contacts with osteoarthritis resulted in an imaging test, 
and 112.1 tests were ordered per 100 osteoarthritis contacts when at least one test was 
ordered. 
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Table 12.5: The 10 problems for which an imaging test was most frequently ordered 
Problem managed 
Number of 
problems 
Number of  
problem–imaging 
 combinations(a) 
Per cent of 
problem–imaging 
combinations 
Per cent  
of problems 
with test(b) 
Rate of imaging 
orders per 100 
problems with 
imaging(c) 
Back complaint* 2,906 520 5.1 15.5 115.1 
Osteoarthritis* 2,789 500 4.9 16.0 112.1 
Sprain/strain* 1,357 402 3.9 23.5 126.0 
Pregnancy* 1,281 383 3.7 29.3 102.2 
Fracture*  896 376 3.7 37.5 112.0 
Bursitis/tendonitis/synovitis NOS  1,110 362 3.5 27.6 118.2 
Shoulder syndrome 616 308 3.0 40.1 124.4 
Abdominal pain* 720 303 2.9 36.3 115.8 
Injury musculoskeletal NOS  880 302 2.9 29.3 117.1 
Breast lump/mass (female) 178 182 1.8 72.0 142.5 
Subtotal 12,732 3,637 35.4 — — 
Total problems 152,517 10,263 100.0 5.9 113.6 
(a) A test was counted more than once if it was ordered for the management of more than one problem at an encounter. There were 10,163 
imaging test orders and 10,263 problem–imaging combinations. 
(b) The percentage of total contacts with the problem that generated at least one order for imaging. 
(c) The rate of imaging orders placed per 100 tested problem contacts with at least one order for imaging. 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes (see Appendix 4, Table A4.1 <purl.library.usyd.edu.au/sup/9781743323779>). 
Note: NOS – not otherwise specified. 
12.4 Other investigations 
Other investigations include diagnostic procedures ordered by the GP or undertaken by the 
GP or practice staff at the encounter. GPs ordered 856 other investigations during the 
study year, and GPs or practice staff undertook 1,421 other investigations. There were, in 
total, 2,278 other investigations either ordered or undertaken (Table 12.6). 
The first section of Table 12.6 lists the other investigations ordered by GPs. The second lists 
the other investigations undertaken in the practice by GPs or practice staff. The third section 
lists the total other investigations (either ordered or undertaken in the practice). Each 
investigation is expressed as a percentage of total other investigations ordered or 
undertaken, as a rate per 100 encounters, and as a rate per 100 problems, each with 
95% confidence limits. Electrical tracings were the most common group of other 
investigations ordered or undertaken, making up 43.8% of other investigations, followed by 
physical function test (28.8%). 
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12.5 Changes in investigations over the decade 
2003–04 to 2012–13 
Data on investigations are reported for each year from 2003–04 to 2012–13 in Chapter 12 of 
the companion report A decade of Australian general practice activity 2003–04 to 2012–13.1 In 
that report, changes over time are measured as change in the management of problems (that 
is, as a rate per 100 problems). This reflects change in how GPs are managing problems, and 
accounts for the significant increase in the number of problems managed per encounter over 
the decade (see Section 7.8). The major changes are highlighted below. 
• At least one pathology test was ordered for 11.9% of problems managed in 2003–04 
rising to 13.5% of problems in 2012–13. The number of pathology tests ordered increased 
from 24.1 tests (or battery of tests) per 100 problems managed in 2003–04 to 30.4 per 100 
problems in 2012–13. The largest increase was in orders for chemical pathology, which 
increased from 13.0 per 100 problems in 2003–04 to 17.9 per 100 problems in 2012–13. 
Haematology increased at a slower rate, from 4.6 per 100 problems in 2003–04 to 5.4 in 
2012–13.  
• Between 2003–04 and 2012–13 the number of problems managed per 100 encounters rose 
from 146.3 to 154.7 (Table 5.1). Both the rise in the proportion of problems generating at 
least one pathology test and the rise in the number of problems managed at encounter 
contributed to an overall increase in the proportion of encounters involving a pathology 
test. This rose from 15.5% of encounters in 2003–04 to 18.1% in 2012–13, which suggests 
that in 2012–13 one or more pathology tests were ordered at about 8 million more 
encounters nationally than in 2003–04. 
• The rate of pathology tests ordered per 100 encounters increased from 35.2 per 100 
encounters in 2003–04 to 47.1 in 2012–13, which extrapolates to approximately 
25.8 million more tests (or batteries of tests) ordered in 2012–13 than a decade earlier.  
• At least one imaging test was ordered for 5.1% of all problems managed in 2003–04, 
rising to 5.9% of all problems in 2012–13. The proportion of encounters generating 
imaging orders increased from 7.2% in 2003–04 to 8.8% in 2012–13. This resulted in an 
estimated 4.2 million more encounters nationally at which imaging was ordered in  
2012–13 than in 2003–04. 
• The number of imaging tests ordered increased from 5.6 tests per 100 problems managed 
in 2003–04 to 6.7 per 100 problems in 2012–13. Total imaging orders per 100 encounters 
increased significantly from 8.2 per 100 encounters in 2003–04 to 10.3 in 2012–13, 
suggesting that nationally there were 5.2 million more imaging orders in  
2012–13 than in 2003–04. 
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13 Patient risk factors 
General practice is a useful intervention point for health promotion because the majority of 
the population visit a GP at least once per year. In 2012–13, 85% of Australians visited a GP 
at least once (personal communication, DoHA, June 2013). GPs have substantial knowledge 
of population health, screening programs and other interventions. They are therefore in an 
ideal position to advise patients about the benefits of health screening, and to counsel 
individuals about their lifestyle choices.  
Since the beginning of the BEACH program (1998), a section at the bottom of each encounter 
form has been used to investigate aspects of patient health or healthcare delivery not covered 
by general practice consultation-based information. These additional substudies are referred 
to as SAND (Supplementary Analysis of Nominated Data). The SAND methods are 
described in Section 2.6.  
The patient risk factors collected in BEACH include body mass index (BMI) (calculated using 
self-reported height and weight), self-reported alcohol consumption and self-reported 
smoking status. These patient risk factors are investigated for a subsample of 40 of the 100 
patient encounters recorded by each GP. An example of the encounter form with the patient 
risk factor SAND questions is included as Appendix 1. The methods used in the risk factor 
substudies reported in this chapter are described in each section below. 
Data on patient risk factors measured in SAND are reported for each of the 10 most 
recent years in the companion report A decade of Australian general practice activity 2003–04 to 
2012–13.1 
Abstracts of results and the research tools used in other SAND substudies from April 1998 to 
March 2013 have been published. Those conducted: 
• from April 1998 to March 1999 were published in Measures of health and health care delivery 
in general practice in Australia.26 
• from April 1999 to July 2006 were published in Patient-based substudies from BEACH: 
abstracts and research tools 1999–2006.27 
• since August 2006 have been published in each general practice annual reports28-33 
• in the 2012–13 BEACH year are provided in Chapter 15 of this publication. 
13.1 Body mass index 
From the most recent publicly available data, high body mass (BMI) was the third highest 
contributor to the total burden of disease in Australia in 2003, accounting for 7.5% of the total 
burden,85 an increase from 4.3% of the total burden and sixth rank in 1996.86  
In 2013, the Organisation for Economic Co-operation and Development (OECD) reported 
that Australia’s adult obesity rates in 1987, 1999, 2006 and 2011 were among the highest in 
the world (10.8%, 21.7%, 24.6% and 28.3% of adults respectively), with Australia’s adult 
obesity rate equal third globally, behind only the United States and Mexico and on par with 
New Zealand.87 In 2007 Australia was fourth, with obesity rates 2% below that of New 
Zealand, but in the ensuing 5 years, Australia caught up to New Zealand (Australia 
increased 4% to 28.3%, New Zealand increased 2% to 28.4%).87 In the same 5-year period, 
obesity rates in the United Kingdom and United States increased by about 1% to 36.5%, and 
Mexico increased by 2% to 32.4%.87 
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Australia’s obesity rate of 28.3% in 2011 is much higher than the average for the 15 OECD 
countries with recent measured data (22.8%). The growing prevalence of obesity in Australia 
foreshadows increases in related health problems (such as diabetes and cardiovascular 
diseases) and escalating health care costs in future.88 
The Australian Health Survey results (2011–12), based on trained interviewer measured data, 
estimated that 35% of Australians aged 18 years and over were overweight (BMI 25–<30) and 
28% were obese (BMI 30 or more). Men were more likely to be overweight (42%) than 
women (28%), but obesity rates were the same (28% among both men and women).89  
The Australian Health Survey also reported that 25% of children aged 2–17 years were 
classified as overweight or obese (18% overweight, 7% obese).89  
The Australian government has recognised the epidemic of overweight and obesity, and the 
impact on future health costs and negative health outcomes. New guidelines about the 
clinical management of overweight and obesity were released by the National Health and 
Medical Research Council in May 2013.90 
Method 
Patient BMI was investigated for a subsample of 40 of each GP’s 100 patient encounters. Each 
GP was instructed to ask the patient (or their carer in the case of children): 
• What is your height in centimetres (without shoes)? 
• What is your weight in kilograms (unclothed)? 
Metric conversion tables (from feet and inches; from stones and pounds) were provided to 
the GP. 
The BMI for an individual was calculated by dividing weight (kilograms) by height (metres) 
squared. The WHO recommendations91 for BMI groups were used. They specify that an 
adult (18 years and over) with a BMI: 
• less than 18.5 is underweight 
• greater than or equal to 18.5 and less than 25 is normal weight 
• greater than or equal to 25 and less than 30 is overweight 
• of 30 or more is obese. 
The reported height for adult patients was checked against sex-appropriate upper and lower 
height limits from the ABS.92 Adults whose self-reported height was outside the sex-
appropriate limits were excluded from the analysis. 
The standard BMI cut-offs described above are not appropriate in the case of children. 
Cole et al. (2000 & 2007) developed a method to calculate the age–sex-specific BMI cut-off 
levels for underweight, overweight and obesity specific to children aged 2–17 years.93,94 
There are four categories defined for childhood BMI: underweight, normal weight, 
overweight and obese. This method, based on international data from developed Western 
cultures, is applicable in the Australian setting.  
The reported height of children was checked against age–sex-appropriate upper and lower 
height limits from the ABS and Centres for Disease Control.92,95 Children whose self-reported 
height was outside the age–sex-appropriate limits were excluded from the analysis. 
The BEACH data on BMI are presented separately for adults (aged 18 years and over) and 
children (aged 2–17 years).  
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Results 
Body mass index of adults 
The sample size was 31,452 patients aged 18 years and over at encounters with 975 GPs. 
• Over half (61.2%) of these adults were overweight (34.6%) or obese (26.6%) (Table 13.1). 
• Just over one-third (36.2%) of adult patients had a BMI in the normal range, and 2.6% of 
adults were underweight (Table 13.1). Underweight was more prevalent among females 
than males. 
• Males were more likely to be overweight or obese (69.2%, 95% CI: 68.1–70.2) than 
females (56.1%, 95% CI: 55.0–57.2) (results not tabulated). 
• Overweight/obesity was most prevalent among male patients aged 65–74 years (76.9%) 
and 45–64 years (75.7%) (Figure 13.1).  
• This pattern was also noted in female patients, with overweight/obesity most prevalent 
in those aged 65–74 years (68.7%) and 45–64 years (63.5%) (Figure 13.1). 
• Underweight was most prevalent among patients aged 18–24 years (7.3%, 95% CI:  
6.2–8.4) (results not tabulated).  
• Of young adults (aged 18–24 years), 9.1% of females and 3.4% of males were 
underweight, and among those aged 75 years and over, 4.6% of females and 1.3% of 
males were underweight (Figure 13.2). 
Our overall and sex-specific prevalence estimates of overweight/obesity among patients at 
general practice encounters (61% of adults, 69% of males and 56% of females) are remarkably 
consistent with the ABS 2011–12 figures from the Australian Health Survey (based on 
measured BMI data), which reported that 63% of adults aged 18 and over (70% of men and 
56% of females) were overweight or obese.19  
Readers interested in the prevalence of the three WHO-defined levels of obesity will find 
more information and discussion in Chapter 7 of General practice in Australia, health priorities 
and policies 1998 to 2008.96  
Estimation of body mass index for the adult general practice patient population 
The BEACH study provides data about patient BMI from a sample of the patients attending 
general practice. As older people attend a GP more often than young adults, and females 
attend more often than males, they have a greater chance of being selected in the subsample. 
This leads to a greater proportion of older and female patients in the BEACH sample than in 
the total population who attend a GP at least once in a year. The 2012–13 BEACH sample 
was weighted to estimate the BMI of the GP–patient attending population (that is, the 
15.1 million adult patients who attended a GP at least once in 2012–13 (personal 
communication, DoHA, June 2013), using the method described by Knox et al. (2008).23 This 
statistical adjustment had little effect on the resulting proportions. 
The estimates for the adult GP–patient attending population (after adjusting for age–sex 
attendance patterns) suggest that 26.0% of the adult patient population were obese, 34.4% 
were overweight, 37.0% were normal weight and 2.5% were underweight (Table 13.1).  
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Table 13.1: Patient body mass index (aged 18 years and over) 
 Male(a)  Female(a)  Total respondents 
BMI class 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,171) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,064) 
Per cent  
in patient 
population 
(95% CI)(b)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,452) 
Per cent  
in patient 
population 
(95% CI)(b) 
Obese 26.7 
(25.7–27.7)) 
26.1 
(25.0–27.2)  
26.6 
(25.7–27.5) 
26.0 
(25.1–27.0)  
26.6 
(25.8–27.4) 
26.0 
(25.2–26.9) 
Overweight 42.5 
(41.5–43.4) 
41.4 
(40.3–42.5)  
29.5 
(28.8–30.2) 
28.4 
(27.6–29.1)  
34.6 
(34.0–35.2) 
34.4 
(33.7–35.1) 
Normal 29.8 
(28.7–30.8) 
31.4 
(30.2–32.5)  
40.4 
(39.4–41.4) 
41.9 
(40.9–43.0)  
36.2 
(35.4–37.0) 
37.0 
(36.1–37.9) 
Underweight 1.1 
(0.9–1.3) 
1.2 
(1.0–1.4)  
3.5 
(3.2–3.8) 
3.6 
(3.3–4.0)  
2.6 
(2.4–2.8) 
2.5 
(2.3–2.7) 
(a) Patient sex was not recorded for 217 respondents. 
(b) Estimation of BMI among the total adult general practice patient population (that is, patients aged 18 years and over who attended a GP at 
least once in 2012–13). Source: Unpublished Medicare data, personal communication, DoHA, June 2013 (n = 15.1 million). 
Note: BMI – body mass index; CI – confidence interval. 
 
 
 
Figure 13.1: Age–sex-specific rates of overweight/obesity among sampled adults, 2012–13  
(95% CI) 
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18–24 25–44 45–64 65–74 75+
 Male 3.4 1.1 0.7 0.8 1.3
 Female 9.1 3.7 1.9 2.2 4.6
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Figure 13.2: Age–sex-specific rates of underweight among sampled adults, 2012–13 (95% CI) 
 
Body mass index of children 
BMI was calculated for 3,069 patients aged 2–17 years at encounters with 806 GPs. 
• Just over one-quarter of children (26.4%, 95% CI: 24.6–28.1) were classed as overweight 
or obese, including 9.0% (95% CI: 7.9–10.2) obese and 17.3% (95% CI: 15.9–18.7) 
overweight (results not tabulated). 
• There was no difference in the prevalence of overweight/obesity among male (27.5%,  
95% CI: 25.1–29.9) and female children (25.3%, 95% CI: 23.0–27.7) (results not tabulated). 
• The age-specific rates of obesity followed similar patterns for both sexes 
(Figures 13.3 and 13.4). 
Readers interested in further detail and discussion about overweight and obesity in children 
attending general practice will find more information in Cretikos et al. (2008) General practice 
management of overweight and obesity in children and adolescents in Australia.97 
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Figure 13.3: Age-specific rates of obesity, overweight, normal weight and underweight among 
sampled male children, 2012–13 
 
 
 
 
 
 
Figure 13.4: Age-specific rates of obesity, overweight, normal weight and underweight among 
sampled female children, 2012–13  
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13.2 Smoking (patients aged 18 years and over) 
Tobacco smoking is the leading cause of ill health, drug-related death and hospital 
separations in Australia.98 It is a major risk factor for coronary heart disease, stroke, 
peripheral vascular disease, several cancers, respiratory disorders and other diseases.99 The 
most recent publicly available data has identified smoking as the risk factor associated with 
the greatest disease burden, accounting for 7.8% of the total burden of disease in Australia in 
2003,85 a decrease from 9.7% of total burden in 1996.86  
In 2013, the OECD reported that Australia has been remarkably successful in reducing 
tobacco consumption by more than half, from 30.6% of adults in 1986 to 15.1% in 2010, now 
one of the lowest smoking rates in OECD countries. They surmised that most of the decline 
could be attributed to public awareness campaigns, advertising bans and increased taxation. 
In December 2012, Australia became the first (and currently only) country to require tobacco 
products to be sold in plain packaging.87,88  
According to the 2010 National Drug Strategy Household Survey (NDSHS), 15.1% of 
Australians aged 14 years and over smoked daily: 16.4% of males and 13.9% of females.100 
The 2011–12 Australian Health Survey reported that 16.1% of Australians aged 18 years and 
over were daily smokers: 18.1% of males and 14.1% of females.89 
Method 
GPs were instructed to ask adult patients (18 years and over): 
• What best describes your smoking status?  Smoke daily 
 Smoke occasionally 
 Previous smoker 
 Never smoked 
Results 
The smoking status of 32,499 adult patients was established at encounters with 976 GPs. 
Table 13.2 shows that: 
• 14.4% of sampled adult patients were daily smokers 
• significantly more male (17.6%) than female patients (12.4%) were daily smokers (results 
not tabulated) 
• only 2.6% of sampled adult patients were occasional smokers 
• more than one-quarter of sampled adults (27.7%) were previous smokers. 
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Table 13.2: Patient smoking status (aged 18 years and over) 
 Male  Female  Total respondents 
Smoking 
status 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,518) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,758) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 32,499) 
Per cent in 
patient 
population 
(95% CI)(a) 
Daily 17.6 
(16.6–18.6) 
21.3 
(20.1–22.4)  
12.4 
(11.7–13.0) 
13.8 
(13.1–14.6)  
14.4 
(13.7–15.1) 
17.3 
(16.4–18.1) 
Occasional 3.2 
(2.8–3.6) 
4.2 
(3.6–4.7)  
2.1 
(1.9–2.4) 
2.5 
(2.2–2.8)  
2.6 
(2.3–2.8) 
3.3 
(2.9–3.6) 
Previous 36.6 
(35.4–37.8) 
30.5 
(29.4–31.6)  
22.1 
(21.3–22.9) 
21.2 
(20.4–21.9)  
27.7 
(27.0–28.5) 
25.5 
(24.7–26.2) 
Never 42.6 
(41.4–43.8) 
44.1 
(42.8–45.4)  
63.4 
(62.4–64.5) 
62.5 
(61.4–63.6)  
55.3 
(54.4–56.3) 
54.0 
(53.0–55.0) 
(a) Estimation of smoking status among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2012–13). Source: Unpublished Medicare data, personal communication, DoHA, June 2013 
(n = 15.1 million). 
Note: Missing data removed (patient sex missing for 223 respondents). CI – confidence interval. 
 
Daily smoking was least prevalent among older adults aged 65–74 and 75 years or more 
(8.2% and 3.8% respectively) and most prevalent among adult patients aged 25–44 years 
(20.9%) (results not tabulated). Over half (55.3%) of the male and 23.5% of the female patients 
aged 75 years and over were previous smokers, but only 4.2% of males and 3.7% of females 
in this age group were daily smokers (Figures 13.5 and 13.6). 
 
 
 
 
Figure 13.5: Smoking status – male age-specific rates among sampled patients, 2012–13  
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Figure 13.6: Smoking status – female age-specific rates among sampled patients, 2012–13 
Estimation of smoking in the adult general practice patient population 
The BEACH study provides data about patient smoking habits from a sample of the patients 
attending general practice. As older people attend a GP more often than young adults, and 
females attend more often than males, they have a greater chance of being selected in the 
subsample. This leads to a greater proportion of older and female patients in the BEACH 
sample than in the total population who attend a GP at least once in a year. The 2012–13 
BEACH sample was weighted to estimate the smoking status of the GP–patient attending 
population (that is, the 15.1 million adult patients who attended a GP at least once in  
2012–13 [personal communication, DoHA, June 2013]), using the method described by Knox 
et al. (2008).23  
After adjusting for age–sex attendance patterns, we estimated that 17.3% of the patient 
population aged 18 or more were daily smokers, 3.3% were occasional smokers, 25.5% were 
previous smokers and 54.0% had never smoked. Male patients in the total general practice 
population were significantly more likely to be daily (21.3%), occasional (4.2%) and previous 
smokers (30.5%), than females patients (13.8%, 2.5% and 21.2%, respectively) (Table 13.2).  
13.3 Alcohol consumption (patients aged 18 years 
and over) 
Among people aged 65 years and over, low to moderate consumption of alcohol has been 
found to have a preventive effect against selected causes of morbidity.101 Following a review 
of the evidence, the National Health and Medical Research Council (NHMRC) stated that at 
low levels of consumption, alcohol has some cardiovascular health benefits in certain age 
groups (middle-aged and older males and women after menopause). Low levels of alcohol 
consumption raise high-density lipoprotein cholesterol and reduce plaque accumulations in 
arteries. Alcohol can also have a mild anti-coagulating effect. However, the authors of the 
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review noted that the extent of cardiovascular risk reduction is uncertain, and the potential 
cardiovascular benefits can be gained from other means, such as exercise or modifying the 
diet.102 From the most recent publicly available data, in 2003, alcohol consumption accounted 
for 3.3% of the total burden of disease in Australia; however, after taking into account the 
benefit derived from low to moderate alcohol consumption, this fell to 2.3%.85 
The Australian Health Survey classified alcohol use for those aged 18 years or more based on 
the estimated average daily consumption of alcohol during the previous week. The results 
indicated that 11.7% drank at levels considered to be risky (13.4% of males and 10.1% of 
females), based on the 2001 NHMRC guidelines.19 Based on the NHMRC 2009 guidelines, 
19.5% of adults drank at levels exceeding the guidelines (29.1% of males and 10.1% of 
females).19 
The 2010 NDSHS found that 20.1% of people aged 14 years and over (29.0% of males and 
11.3% of females) drank at levels considered to put them at risk of harm from alcohol-related 
disease or injury over their lifetime. The NDSHS also found that 28.4% of people aged 14 
years or older (38.2% of males and 18.9% of females) drank (at least once in the previous 
month) in a pattern that placed them at risk of an alcohol-related injury from a single 
drinking occasion.100 These alcohol consumption risk levels were based on the NHMRC 2009 
guidelines.102 
For consistency over time, this report uses the definitions of alcohol-related risk developed 
by WHO (see ‘Method’ below).103 This differs from the definition in the NHMRC guidelines. 
Method 
To measure alcohol consumption, BEACH uses AUDIT-C,104 which is the first three items 
from the WHO Alcohol Use Disorders Identification Test (AUDIT),103 with scoring for an 
Australian setting.105 The AUDIT-C has demonstrated validity and internal consistency and 
performs as well as the full AUDIT tool.106 The three AUDIT-C tool is practical and valid in a 
primary care setting to assess ‘at-risk’ alcohol consumption (heavy drinking and/or active 
alcohol dependence).104 The scores for each question range from zero to four. A total (sum of 
all three questions) score of five or more for males, or four or more for females, suggests that 
the person’s drinking level is placing him or her at risk.105 
GPs were instructed to ask adult patients (18 years and over): 
• How often do you have a drink containing alcohol? Never 
 Monthly or less 
 Once a week/fortnight 
 2–3 times a week 
 4 times a week or more 
• How many standard drinks do you have on a typical day when you are drinking?  
 _______________ 
• How often do you have six or more standard drinks on one occasion?  
 Never 
 Less than monthly 
 Monthly 
 Weekly 
 Daily or almost daily 
A standard drinks chart was provided to each GP to help the patient identify the number of 
standard drinks consumed. 
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Results 
Patient self-reported alcohol consumption was recorded for 31,640 adult patients (18 years 
and over) at encounters with 975 GPs. 
• About one-quarter of sampled adults reported drinking alcohol at at-risk levels (24.1%) 
(Table 13.3). 
• At-risk drinking was more prevalent among male (29.3%) than female patients (20.8%) 
(Table 13.3). 
• At-risk drinking was most prevalent in those aged 18–24 years, particularly among men. 
In this age group almost half the males and one-third of females reported at-risk alcohol 
consumption (Figure 13.7). 
• The proportion of patients who were at-risk drinkers decreased with age among both 
males and females (Figure 13.7). 
These estimates are not directly comparable with the results from the 2011–12 Australian 
Health Survey19 or the 2010 NDSHS100. They all use different definitions for risky levels of 
alcohol consumption, and different adult populations (patients aged 18 years or more for 
BEACH, persons aged 15 or 18 years or more for the Australian Health Survey, and persons 
aged 14 years or more for the NDSHS).  
Readers interested in the relationship between morbidity managed and alcohol consumption 
will find more information in Proude et al. (2006) The relationship between self-reported alcohol 
intake and the morbidities managed by GPs in Australia.107 
Table 13.3: Patient alcohol consumption (aged 18 years and over) 
 Male  Female  Total respondents 
Alcohol 
consumption 
Per cent in 
BEACH sample 
(95% CI) 
(n = 12,274) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 19,366) 
Per cent in 
patient 
population 
(95% CI)(a)  
Per cent in 
BEACH sample 
(95% CI) 
(n = 31,640) 
Per cent in 
patient 
population 
(95% CI)(a) 
At-risk drinker 29.3 
(28.2–30.5) 
33.1 
(31.8–34.4)  
20.8 
(19.9–21.7) 
22.3 
(21.3–23.2)  
24.1 
(23.3–24.9) 
27.3 
(26.3–28.2) 
Responsible 
drinker 
47.6 
(46.4–48.8) 
45.3 
(44.0–46.5)  
42.1 
(41.0–43.1) 
43.0 
(41.9–44.1)  
44.2 
(43.3–45.1) 
44.1 
(43.1–45.0) 
Non-drinker 23.1 
(22.0–24.2) 
21.7 
(20.5–22.8)  
37.2 
(35.9–38.5) 
34.7 
(33.4–36.0)  
31.7 
(30.6–32.8) 
28.7 
(27.6–29.7) 
(a) Estimation of alcohol consumption among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2012–13). Source: Unpublished Medicare data, personal communication, DoHA, June 2013 
(n = 15.1 million). 
Note: CI – confidence interval. 
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Figure 13.7: Age–sex-specific rates of at-risk alcohol consumption in sampled patients, 2012–13  
Estimation of alcohol consumption levels in the adult general practice patient 
population 
The BEACH study provides data about patient alcohol consumption from a sample of the 
patients attending general practice. As older people attend a GP more often than young 
adults, and females attend more often than males, they have a greater chance of being 
selected in the subsample. This leads to a greater proportion of older and female patients in 
the BEACH sample than in the total population who attend a GP at least once in a year. The 
2012–13 BEACH sample was weighted to estimate the prevalence of at-risk alcohol 
consumption among the GP–patient attending population (that is, the 15.1 million adult 
patients who attended a GP at least once in 2012–13 (personal communication, DoHA, June 
2013), using the method described by Knox et al. (2008).23  
After adjusting for age–sex attendance patterns we estimated that 27.3% of the patient 
population were at-risk drinkers, 44.1% were responsible drinkers and 28.7% were non-
drinkers. Males in the general practice attending population were significantly more likely to 
be at-risk drinkers (33.1%) than females (22.3%) (Table 13.3).  
13.4 Risk factor profile of adult patients 
All patient risk factor questions (BMI, smoking and alcohol consumption) were asked of the 
same subsample of patients. This allows us to build a risk profile of this sample. For the 
purposes of this analysis, being overweight or obese, a daily smoker or an at-risk drinker 
were considered risk factors. A risk factor profile was prepared for the 30,345 adult patients 
from 974 GPs, for whom data were available in all three elements. (Table 13.4). 
• About half (52.0%) the sampled adult respondents had one risk factor. The most 
common was overweight (23.2% of adults) followed by obesity (18.5%). 
• Almost 1 in 5 patients (18.8%) had two risk factors, the most common combinations 
being: 
18–24 25–44 45–64 65–74 75+
Male at-risk 42.3 37.8 33.4 25.4 11.5
Female at-risk 33.4 22.7 22.1 17.2 12.8
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– overweight and at-risk alcohol consumption – 6.7% of patients 
– obesity and at-risk alcohol consumption – 4.5% of patients 
– daily smoking and at-risk alcohol consumption – 2.7% of patients. 
• A small group of patients (3.4%) had all three risk factors. 
Table 13.5 shows the number of risk factors by patient sex. 
• Females were significantly more likely to have no risk factors (30.2%) than males (18.9%). 
• Females were significantly less likely to have two or three risk factors (15.1% and 2.2% 
respectively) than males (24.5% and 5.3%). 
Estimation of the risk profile of the adult general practice patient population 
The 2012–13 BEACH sample was weighted to estimate the risk profile of the GP–patient 
attending population; that is, the 15.1 million adult patients who attended a GP at least once 
in 2012–13.  
After adjusting for age–sex attendance patterns we estimated that:  
• one-quarter of patients had no risk factors (24.8%) 
• half of the adult patients had one risk factor (49.9%), the most common being overweight 
(21.5% of adults) followed by obesity (17.0%) 
• 1 in 5 patients had two risk factors (20.9%), the most common combinations being 
overweight and at-risk alcohol consumption (7.3%), followed by obesity and at-risk 
alcohol consumption (4.7%)  
• 4.4% of patients who attend general practice had three risk factors (Table 13.4) 
• significantly more female than male patients had no risk factors (30.6% and 18.0% 
respectively). Male patients were also more likely to have two and three risk factors 
(26.7% and 6.5%) than females (15.9% and 2.5%) (Table 13.5). 
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Table 13.4: Risk factor profile of patients (aged 18 years and over) 
Number of risk factors  Number 
Per cent in 
BEACH sample  
(n = 30,345) 
95% 
LCL 
95% 
UCL 
Per cent in 
patient 
population(a) 
95% 
LCL 
95% 
UCL 
No risk factors 7,836 25.8 25.0 26.6 24.8 23.9 25.7 
One risk factor 15,779 52.0 51.3 52.7 49.9 49.2 50.7 
 Overweight only 7,027 23.2 22.5 23.8 21.5 20.9 22.1 
 Obese only 5,611 18.5 17.8 19.1 17.0 16.4 17.6 
 At-risk alcohol level only 2,148 7.1 6.7 7.5 7.7 7.2 8.2 
 Current daily smoker only 993 3.3 3.0 3.5 3.8 3.5 4.1 
Two risk factors 5,695 18.8 18.1 19.4 20.9 20.2 21.6 
 Overweight and at-risk alcohol level 2,046 6.7 6.4 7.1 7.3 6.9 7.7 
 Obese and at-risk alcohol level 1,351 4.5 4.2 4.7 4.7 4.4 5.0 
 Daily smoker and at-risk alcohol level 813 2.7 2.5 2.9 3.4 3.1 3.6 
 Overweight and current daily smoker 787 2.6 2.4 2.8 3.0 2.7 3.2 
 Obese and current daily smoker 698 2.3 2.1 2.5 2.6 2.3 2.8 
Three risk factors 1,035 3.4 3.1 3.7 4.4 4.0 4.7 
 Overweight and current daily smoker 
and at-risk alcohol level 
601 2.0 1.8 2.2 2.6 2.3 2.8 
 Obese and current daily smoker and 
at-risk alcohol level 
434 1.4 1.3 1.6 1.8 1.6 2.0 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2012–13). Source: Unpublished Medicare data, personal communication, DoHA, June 2013 
(n = 15.1 million). 
Note: LCL – lower confidence limit; UCL – upper confidence limit. 
Table 13.5: Number of risk factors, by patient sex 
 Male  Female 
Number of risk factors 
Per cent in BEACH 
sample (95% CI) 
(n = 11,827) 
Per cent in patient 
population 
(95% CI)(a)  
Per cent in BEACH 
sample (95% CI) 
(n = 18,518) 
Per cent in patient 
population 
(95% CI)(a) 
No risk factors 18.9 
(18.0–19.8) 
18.0 
(17.0–19.0)  
30.2 
(29.3–31.2) 
30.6 
(29.6–31.7) 
One risk factor 51.3 
(50.2–52.3) 
48.8 
(47.7–50.0)  
52.5 
(51.6–53.3) 
50.9 
(50.0–51.8) 
Two risk factors 24.5 
(23.5–25.4) 
26.7 
(25.6–27.7)  
15.1 
(14.5–15.8) 
15.9 
(15.2–16.6) 
Three risk factors 5.3 
(4.9–5.8) 
6.5 
(5.9–7.1)  
2.2 
(1.9–2.4) 
2.5 
(2.3–2.8) 
(a) Estimation of risk factor profile among the total adult general practice patient population (that is, patients aged 18 years and over who 
attended a GP at least once in 2012–13). Source: Unpublished Medicare data, personal communication, DoHA, June 2013 
(n = 15.1 million).  
Note: CI – confidence interval. 
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13.5 Changes in patient risk factors over the decade 
2003–04 to 2012–13 
To investigate changes over time in prevalence of these patient risk factors, results are 
reported from the BEACH sample data for each year from 2003–04 to 2012–13 in the 
companion report A decade of Australian general practice activity 2003–04 to 2012–13.1 
The major changes between 2003–04 and 2012–13 are summarised below. 
• The prevalence of obesity in adults attending general practice increased significantly, 
from 22.1% to 26.6%, an increase apparent in both male and female patients. In parallel, 
the prevalence of normal weight in adults attending general practice decreased 
significantly, from 40.7% to 36.2%. 
• The prevalence of obesity in sampled children aged 2–17 years decreased from 11.8% to 
9.0%; a decrease noted only for male children. A corresponding increase in the 
prevalence of normal weight was noted from 57.9% to 62.5%; and was apparent for both 
male children and female children (56.0% to 61.8% and 59.4% to 63.2% respectively). 
• Prevalence of daily and occasional smoking decreased significantly among sampled 
adults aged 18 years and over, from 17.6% and 4.3%, respectively, to 14.5% and 2.6%. 
• The prevalence of at-risk alcohol consumption among sampled adults aged 18 years and 
over attending general practice decreased significantly from 26.7% to 24.1% 
• The proportion of sampled adults aged 18 years and over with one risk factor 
(overweight/obesity, at-risk drinking, daily smoker) increased significantly from 49.0% 
to 52.0%; the increase was noted for both male and female patients. 
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14 FEATURE—Type 2 diabetes 
14.1 Background 
Patients with Type 2 diabetes constitute almost 10% of the patients presenting to GPs in 
Australia (Table 14.1). Most of these patients have additional co-morbidities, some related 
and others unrelated to their diabetes. Many policies and initiatives have been developed to 
address the increasing prevalence of Type 2 diabetes; however the prevalence continues to 
rise, along with the associated complications and disability. General practice has the major 
role in caring for patients with Type 2 diabetes and associated multimorbidity, and this 
section of the report highlights the care given by GPs to these patients. Some problem and 
concept labels in this chapter include grouped ICPC-2 and ICPC-2 PLUS codes (see 
Chapter 2). A full list of code groups is provided in Appendix 4. 
Specific policies and initiatives regarding Type 2 diabetes and 
associated risk factors 
Many specific policy changes and funding initiatives are detailed in a ‘History of key MBS 
primary care initiatives 1999–2010’ on the Australian Government Department of Health and 
Ageing website.108 
• 1999: The Australian Government introduced the Enhanced Primary Care package (EPC) 
which included remuneration to GPs for their participation in the multidisciplinary care 
of patients with chronic or complex conditions such as diabetes.109 
• 2000: In June, the World Health Organization lowered the diagnostic value for fasting 
plasma/blood glucose concentrations, which had the effect of raising the potential 
number of patients diagnosed with diabetes.110 
• 2000: An initiative by the Queensland Government, ‘Diabetes mellitus 2000–04’, was 
followed by similar initiatives in all other states and territories. 
• 2001: The Australian Government introduced a $76 million program that included 
incentives to GPs and GP Divisions for programs aiming to improve diabetes care in 
general practice.111 The National Integrated Diabetes Program included a Medicare item 
number for Diabetes Annual Cycle of Care, which also attracted Practice Incentive 
Program (PIP) funding points. New National Health and Medical Research Council 
(NHMRC) Guidelines for the detection and management of Type 2 diabetes were 
released.112 
• 2004: The EPC multidisciplinary care plan for chronic disease management was 
superseded by the Allied Health and Dental Care Initiative, allowing patients with a care 
plan to access Medicare rebates for five allied health or dental services a year. This led to 
a doubling in the number of claims for care plan items from the MBS. At the same time 
the Australian Government launched its Action Plan on diabetes. 113 
• 2004: The Australian Primary Care Collaboratives (previously the National Primary Care 
Collaboratives), (initially a $14.6 million, 3-year program to help GPs improve patient 
clinical outcomes) was launched in 2004 and a second phase was funded in 2007. One 
major subject of the Collaboratives quality improvement program was diabetes.114 
• 2005: GP Management Plans (GPMP) and team care arrangements replaced the EPC.  
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• 2007: The criteria for PBS coverage of prescriptions for lipid lowering agents was 
widened allowing many more patients with Type 2 diabetes to be prescribed these 
drugs.115 
• 2008: Type 2 Diabetes Risk Evaluation (item 713) was introduced to the MBS. 
• 2011: The Diabetes Care Project (DCP) is a 3-year pilot that is part of the Australian 
Government’s response to the growing incidence and prevalence of chronic disease in 
Australia. The pilot will test new ways of providing more flexible, better coordinated 
care, to improve the management of care for people with diabetes.  
• 2011: The Australian National Preventive Health Agency (ANPHA) was established to 
focus on alcohol and tobacco use and on obesity. 
14.2 Prevalence of Type 2 diabetes in general 
practice patients  
The prevalence of Type 2 diabetes in BEACH samples of patients attending general practice 
has been studied in a number of BEACH SAND studies (see Chapter 2 for SAND methods). 
SAND studies that use an initial ‘filter’ question regarding the presence of a diagnosis have 
been shown to result in higher prevalence estimates than studies that investigate the 
prevalence of multiple conditions using multiple tick boxes.27 The results of SAND studies of 
Type 2 diabetes that used filter questions are set out in Table 14.1. 
 Table 14.1: Prevalence of Type 2 diabetes in SAND studies27-33 
SAND study abstract number Study year Patients in study Prevalence (per cent) 95% LCL 95% UCL 
Abstract 86 2005–06 3,099 7.7 6.4 9.0 
Abstract 94 2006 2,713 8.3 6.7 9.8 
Abstract 107 2006–07 2,331 8.8 7.1 10.4 
Abstract 108 2007 2,832 7.5 6.1 8.9 
Abstract 115 2007 2,784 7.7 6.6 8.9 
Abstract 119 2007–08 5,989 8.5 7.4 9.5 
Abstract 135 2008 2,921 11.2 9.4 13.1 
Abstract 148 2009 3,021 9.0 7.5 10.5 
Abstract 153 2009 3,087 7.4 6.1 8.6 
Abstract 164 2010 2,579 11.3 9.6 13.1 
Abstract 166 2010 2,789 8.0 6.5 9.4 
Abstract 172 2010 2,839 6.6 5.4 7.7 
Abstract 173 2010–11 4,626 7.6 6.5 8.6 
Abstract 185 2011–12 5,730 8.1 7.1 9.1 
Abstract 193 2012 2,825 9.8 8.2 11.4 
Note: LCL—lower confidence limit; UCL—upper confidence limit 
Using BEACH SAND data from 2005, Knox et al. estimated the prevalence of Type 2 diabetes 
in a BEACH sample of over 9000 patients to be 7.2% (95% CI: 6.5–7.9); 5.7% (95% CI: 5.1–6.3) 
in the GP attending population and 5.0% (95% CI: 4.5–5.5) in the general population.23 This is 
higher than the National Health Survey 2004–05 estimate of 3.5% in the general 
population,116 but less than the estimated 7.1% of the population 25 years and older reported 
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from the AusDiab study of 1999–2000, as this figure included previously undiagnosed 
patients with Type 2 diabetes identified during the survey and was limited to persons aged 
at least 25 years.117 
Using BEACH SAND data from 2008–09, Harrison et al. estimated the prevalence of Type 2 
diabetes in a BEACH sample of over 8,700 patients to be 8.3% (95% CI: 7.5–9.1); 6.2% (95% 
CI: 5.6–6.9) in the GP attending population and 5.5% (95% CI: 4.9–6.0) in the general 
population.25 This is higher than the National Health Survey 2007–08 estimate of 3.5% in the 
general population118, but similar to the 4.2% of patients with diagnosed diabetes (Type 1 
and 2) in adults aged 18 years and over found in the 2011–12 National Health Measures 
Survey.119 A further 0.9% of patients in this survey had biometric measures diagnostic of 
diabetes.119 These results suggest that estimates based on person self-report alone are an 
underestimate of the true prevalence of Type 2 diabetes. 
14.3 Multimorbidity occurring with Type 2 diabetes 
Using the methods developed by Harrison et al., we investigated the population prevalence 
of co-morbidity in patients with Type 2 diabetes using data from a BEACH SAND substudy 
in 2008–09.25 As stated above, the prevalence of Type 2 diabetes in the sample of patients was 
estimated as 8.3%. 
Nearly all (95.6%) the sampled Type 2 diabetes patients had at least one other diagnosed 
chronic condition, 87.1% had two or more, 72.4% had three or more, about half (53.9%) had 
four or more and 38.6% had five or more diagnosed chronic co-morbidities. 
For patients with Type 2 diabetes at GP encounters, the most common co-morbidities were: 
hypertension (71.5%), hyperlipidaemia (48.9%), osteoarthritis (43.2%), IHD (28.4%), GORD 
(22.2%) and depression (17.7%). 
After adjustment for population attendance rates by age-sex we estimated that the 
population level prevalence of people with both Type 2 diabetes and: hypertension was 
3.7%; hyperlipidaemia was 2.7%; osteoarthritis was 2.1%; IHD was 1.4%; GORD was 1.1%; 
depression was 1.0%. Extrapolation of these proportions to the June 2008 ABS population 
estimate (21.5 million) suggested that people with both Type 2 diabetes and: hypertension 
numbered 800,000 people; hyperlipidaemia 575,000, osteoarthritis 450,000; IHD 300,000; 
GORD 250,000; and depression 200,000. 
14.4 Pathology test ordering for Type 2 diabetes at 
encounter 
Between 2003–04 and 2012–13, there was no significant increase in the likelihood of GPs 
ordering at least one pathology test for Type 2 diabetes at encounters where this was 
managed. At least one pathology test was ordered at 29% of Type 2 diabetes contacts in 
2013–13.  
The number of pathology tests ordered per 100 Type 2 diabetes problems managed increased 
from 72.1 (95% CI: 65.0–79.1) in 2003–04 to 87.6 (95% CI: 80.0–95.6) per 100 Type 2 diabetes 
contacts in 2006–07, however there has been no significant increase since that time. The rate 
at which HbA1c tests were ordered for Type 2 diabetes did not change significantly over the 
past decade (Figure 14.1). 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 1+ path test 28.8 30.2 30.6 31.4 30.0 33.3 32.4 31.4 33.4 29.6
 Path test rate 72.1 78.4 80.9 87.6 85.1 93.1 92.7 91.6 100.8 88.5
 HbA1c rate 22.7 23.3 24.4 25.6 23.4 27.0 26.3 26.7 27.9 25.2
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Note: 1+ path – at least one pathology test (per cent of Type 2 diabetes contacts); path – pathology. 
Figure 14.1: Pathology test—likelihood of order; test order rate, and HbA1c test order rate per 100 
Type 2 diabetes contacts, 2003–04 to 2012–13 (95% CI) 
14.5 Referrals given for Type 2 diabetes at 
encounter 
There was a significant increase in the rate at which patients were referred for Type 2 
diabetes, from 10.1 (95% CI: 8.6–11.6) per 100 contacts in 2003–04 to 15.4 (95% CI: 13.3–17.5) 
per 100 contacts in 2012–13.  
The rate of referrals to specialists did not change significantly between 2003–04 and 2012–13 
(Figure 14.2). 
The rate of referrals to allied health professionals more than doubled from 4.2 (95% CI:  
3.2–5.3) per 100 Type 2 diabetes problems in 2003–04 to 10.2 (95% CI: 8.5–11.8) per 100 in 
2012–13 with a major change between 2007–08 and 2012–13, perhaps in response to the 
national program changes (Figure 14.2). 
This increase may have been due to the introduction of the National Integrated Diabetes 
Program (2001),111 which encouraged partnerships with other health care professionals and 
gave support for the Divisions of General Practice to work with GPs and other health 
professionals to improve access to better care for people with diabetes.  
 
 
Rate per 100 Type 2 diabetes contacts 
BEACH year 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 Specialist 5.5 6.2 6.2 4.9 5.9 5.5 4.3 5.1 5.8 4.7
 Allied health 4.2 4.4 5.1 5.1 5.4 6.9 7.5 8.1 8.6 10.2
 Total 10.1 10.8 11.4 10.3 11.8 12.7 12.3 13.9 14.9 15.4
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Figure 14.2: Referral rates per 100 Type 2 diabetes contacts, 2003–04 to 2012–13 (95% CI) 
14.6 Management rate 
As shown in Figure 14.3 there was a 33% increase in the management rate of Type 2 diabetes 
in general practice, from 3.0 per 100 encounters in 2003–04 (95% CI: 2.8–3.2) to 4.0 per 100 
encounters in 2012–13 (95% CI: 3.7–4.3). There was no significant increase in the rate of new 
diagnoses of Type 2 diabetes which has stayed constant at a rate of around 0.2 new cases per 
100 encounters.  
The patients 
The rate at which Type 2 diabetes was managed increased over the study period for all age 
groups of patients aged 45 years and older. There was no change for patients younger than 
45 years of age. The significant increase in the rate of management of Type 2 diabetes applied 
to both male and female patients (Figure 14.4). 
 
Rate per 100 Type 2 diabetes contacts 
BEACH year 
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0–24 25–44 45–64 65–74 75+ Male Female
2003–04 0.1 1.0 4.4 6.6 5.0 3.7 2.4
2008–09 0.1 0.9 5.2 8.5 5.9 4.8 3.1
2012–13 0.1 1.1 5.3 8.5 6.5 5.0 3.3
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
T2D (all) 3.0 2.9 3.3 3.4 3.6 3.8 3.5 3.7 3.9 4.0
New T2D 0.18 0.18 0.20 0.18 0.23 0.22 0.19 0.20 0.18 0.21
0.0
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1.0
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Note: T2D (all) includes all patients with Type 2 diabetes; New T2D includes Type 2 diabetes patients newly diagnosed at the encounter 
Figure 14.3: Type 2 diabetes management rate and new cases per 100 encounters, 2003–04 to 2012–13 
(95% CI)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.4: Age-specific and sex-specific management rates of Type 2 diabetes (95% CI)  
Rate per 100 encounters 
BEACH year 
Age-specific and sex-specific rate per 100 encounters 
Patient age (years) and sex 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 Blood glucose lowering 57.3 52.3 58.7 56.6 54.6 59.4 55.2 54.1 53.9 50.1
 Insulin 5.4 5.8 5.9 6.8 6.7 7.2 8.9 7.8 8.6 8.3
 Other 9.3 11.5 11.9 13.4 13.6 14.1 15.0 15.8 14.1 13.1
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Medications prescribed, supplied, advised 
There was no change in total medication rates per 100 Type 2 diabetes problem contacts from 
2003–04 (72.0, 95% CI: 67.3–76.8) to 2012–13 (71.5, 95% CI: 66.3–76.6). The majority of 
medications recorded for management of patients’ Type 2 diabetes were oral blood glucose 
lowering agents whose ordering rate did not change significantly during the study period. 
Insulin medication rates per 100 Type 2 diabetes problems managed increased from 5.4 (95% 
CI: 4.3–6.5) per 100 Type 2 diabetes problems in 2003–04 to 8.3 (95% CI: 6.9–9.7) in 2012–13 
and ‘other medications’ significantly increased from 9.3 (95% CI: 7.7–10.9) per 100 Type 2 
diabetes problems managed in 2003–04 to 13.1 (95% CI: 11.1–15.0) in 2012–13 (Figure 14.5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14.5: Medication rates per 100 Type 2 diabetes contacts, 2003–04 to 2012–13 (95% CI) 
 
A breakdown of changes over time in the ‘other medication’ group is shown in Figure 14.6. 
• While rates of anti-thrombotic agents, mainly aspirin antiplatelet therapy, showed some 
variability from year to year, there was no significant difference in the rate in 2012–13 
from that of 2003–04.  
• The rate of anti-hypertensive prescription/supply for Type 2 diabetes also fluctuated 
during the study period, however the rate in 2012–13 did not differ from that of 2003–04.  
• Lipid lowering agent prescription/supply for Type 2 diabetes showed a steady increase 
over the 10 years. In 2003–04, lipid medication was prescribed/supplied at a rate of 2.1 
(95% CI: 1.5–2.8) per 100 Type 2 diabetes problems managed, while in 2012–13 the rate 
had more than doubled to 5.5 (95% CI 4.6–6.5). 
• The miscellaneous group includes a wide range of therapeutic agents. Prescription/ 
supply rates did not change significantly over the study period. 
Rate per 100 Type 2 diabetes contacts 
BEACH year 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 Anti-thrombotic 1.0 1.8 1.2 2.4 1.7 1.8 2.4 1.5 1.8 1.0
 Anti-hypertensive 2.2 2.8 3.0 3.6 3.9 3.4 4.0 5.2 4.0 3.6
 Lipid lowering 2.1 2.9 2.9 4.3 4.2 5.7 5.5 6.0 5.6 5.5
 Miscellaneous 4.0 3.9 4.8 3.2 3.8 3.2 3.1 3.1 2.7 3.0
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Figure 14.6: Other medication rates per 100 Type 2 diabetes contacts, 2003–04 to 2012–13 (95% CI)  
Other treatments 
The rate at which other treatments (including procedures, and clinical treatments such as 
advice, education and counselling) were recorded for the management of Type 2 diabetes 
remained fairly constant from 2003–04 to 2004–05. Between 2004–05 and 2005–06 the rate 
decreased significantly from 43.9 (95% CI: 40.1–47.7) per 100 Type 2 diabetes problems to 
32.4 (95% CI: 29.0–35.9) and then remained at the lower level for 2 years. It then increased 
and by 2012–13 was back to 2003–04 levels (Figure 14.7). 
• Clinical treatments followed a similar pattern to total other treatments, dropping 
significantly from 38.5 (95% CI: 34.9–42.0) per 100 Type 2 diabetes problems managed in 
2004–05 to 26.8 (95% CI: 23.7–29.9) in 2006–07, then increasing steadily to be marginally 
higher at 33.3 (95% CI: 29.9–36.8) per 100 Type 2 diabetes problems by 2012–13. 
• The rate of at which procedures were used in the management of Type 2 diabetes stayed 
relatively stable (Figure 14.7). 
While the sudden decrease in other treatments between 2004–05 and 2005–06 coincided with 
several new major diabetes initiatives, GPs overall were recording fewer other treatments. 
The research team believes that the decrease may reflect the increasing use of practice nurses 
to provide advice and education, and to undertake procedures (such as treating leg ulcers) 
independent of the GP–patient encounter. The subsequent increase in other treatments by 
GPs could have been influenced by the changes in practice nurse rebates from the MBS. 
Rate per 100 Type 2 diabetes contacts 
BEACH year 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 Procedural 6.9 5.5 4.7 4.7 6.5 5.3 5.2 6.6 6.2 5.5
 Clinical 33.6 38.5 27.7 26.8 28.9 31.5 32.6 33.1 34.8 33.3
 Total 40.5 43.9 32.4 31.5 35.4 36.8 37.8 39.7 41.0 38.8
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Figure 14.7: Other treatment rates per 100 Type 2 diabetes contacts, 2003–04 to 2012–13 (95% CI)  
14.7 Time utilisation of patients with Type 2 
diabetes 
Length of consultation 
Measured length of consultation (recorded finish time minus recorded start time in minutes) 
was introduced to BEACH in 2000–01 for a subsample of 40% of the GP–patient encounters. 
These analyses include all timed encounters for which Medicare/DVA item numbers were 
recorded. Over the 10 years 2003–04 to 2012–13, encounters at which Type 2 diabetes was 
managed were significantly longer (by about 2.5 minutes) than encounters where Type 2 
diabetes was not managed. This difference was apparent in each individual year with 
encounters where Type 2 diabetes was managed between 1.7 and 3.0 minutes longer than 
encounters where Type 2 diabetes was not managed. The average length of consultations 
involving Type 2 diabetes management also significantly increased by 2 minutes, from 16.8 
(95% CI: 16.1–17.5) minutes in 2003–04 to 18.4 (95% CI: 17.7–19.1) minutes in 2012–12. In 
contrast the average length of other consultations did not change significantly (Figure 14.8). 
Encounter frequency per year 
In 2008–09 we estimated that: 5.5% of the Australian population had diagnosed Type 2 
diabetes, equating to 1.2 million people; 8.3% of patients sampled at encounters had 
diagnosed Type 2 diabetes, equating to about 9.4 million encounters with patients with  
Rate per 100 Type 2 diabetes contacts 
BEACH year 
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Type 2 diabetes; and Type 2 diabetes was managed at a rate of 3.8 per 100 encounters, 
equating to it being managed 4.3 million times in general practice in 2008–09.25 This would 
mean that the average person with Type 2 diabetes attended general practice about 7.8 times 
in 2008–09 and had their Type 2 diabetes managed 3.6 times a year.  
We examined this result by doing another SAND substudy on resource use by Type 2 
diabetes patients in 2010–11. The mean number of annual GP encounters reported by 
sampled Type 2 diabetes patients at encounters was 13.5 (95% CI: 12.2–14.8). The mean 
number of GP visits at which Type 2 diabetes was managed was 5.0 (5% CI: 4.5–5.6).  
However, samples drawn from encounter data will always somewhat over-represent 
patients who are more frequent attenders. We therefore adjusted the 2010–11 result by 
applying statistical weights which accounted for the chance of someone being in our sample 
based on the number of times they attended general practice. With this weighted data we 
estimated that patients with diagnosed Type 2 diabetes attended a GP 8.4 times per year on 
average (95% CI: 7.4–9.5) in 2010–11. We also estimated that patients with Type 2 diabetes 
who attended general practice have their diabetes managed by a GP 3.9 times per year on 
average (95% CI: 3.5–4.3). 
From these two independent methods of estimating the number of times people with Type 2 
diabetes attend general practice and have their Type 2 diabetes managed, we get two sets of 
similar results (7.8 and 8.4 visits a year including 3.6 and 3.9 Type 2 diabetes managements 
per year). In contrast the average consultation rate for all patients attending general practice 
at least once was about 6.3 per year in each sample.32 
GP time utilisation per year 
General practitioner time utilisation per year can be estimated as the product of the 
consultation length and the frequency of encounters and is expressed in hours per year. 
While these results give some indication of the disease burden of Type 2 diabetes, 
unpublished research by the Centre has shown that co-morbidity in patients with Type 2 
diabetes is the major contributor to this increased resource utilisation. 
Annual GP time utilisation in 2008–09 was about 2.2 hours per patient with Type 2 diabetes 
attending general practices, compared with about 1.6 hours for all patients attending general 
practices. Just 2 years later, in 2010–11, GP annual time utilisation by patients with Type 2 
diabetes, was about 2.6 hours and about 1.6 hours for all patients attending general practices. 
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2003–04 2004–05 2005–06 2006–07 2007–08 2008–09 2009–10 2010–11 2011–12 2012–13 
 With diabetes 16.8 17.3 16.9 17.4 17.1 17.1 17.7 17.1 17.9 18.4
 Without diabetes 15.1 15.1 14.9 15.0 15.0 14.5 15.2 15.0 15.1 15.4
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Figure 14.8: Mean length (minutes) of consultations: encounters claimable from Medicare/DVA 
with and without management of Type 2 diabetes, 2003–04 to 2012–13 (95% CI) (unweighted 
sample data)  
14.8 Management of Type 2 diabetes in 2012–13 
Figure 14.9 provides an overview of the management of Type 2 diabetes at GP encounters 
during 2012–13. 
Type 2 diabetes was managed in BEACH 3,948 times in the year from April 2012 to March 
2013, at a rate of 4.0 per 100 general practice encounters (Figure 14.9). This extrapolates to 
more than 5 million encounters at which Type 2 diabetes was managed in general practice 
across Australia in that year. 
Sex and age of patients 
Females accounted for 46% of encounters at which Type 2 diabetes was managed (Type 2 
diabetes encounters), a significantly smaller proportion than average for all encounters in 
BEACH. The sex-specific rates showed Type 2 diabetes management rates of 5.0 per 100 total 
encounters with males and 3.3 per 100 encounters with females. 
The age distribution for Type 2 diabetes encounters showed significant differences from the 
total BEACH data. There were higher than average proportions with patients aged: 45–64 
years (36.8%), aged 65–74 years (29.9%) and aged 75 years and over (26.5%). Age-specific 
rates of Type 2 diabetes management were highest among those age groups.  
Average length (minutes) 
BEACH year 
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Reasons for encounter 
Diabetes was the most common reason for encounter stated by patients (30.7 per 100 Type 2 
diabetes encounters). Request for prescription was a reason given by patients at 23.7 per 100 
Type 2 diabetes encounters. 
Other problems managed 
Hypertension was the most commonly managed other problem with Type 2 diabetes, 
managed at a rate of 24.5 per 100 Type 2 diabetes encounters. This was followed by lipid 
disorders at 9.2 per 100 Type 2 diabetes encounters and immunisation/vaccination at 5.2 per 
100 of these encounters. Osteoarthritis and ischaemic heart disease (at 4.3 and 3.6 per 100 
Type 2 diabetes encounters respectively) were managed at significantly higher than average 
rates for BEACH. The pattern of other problems managed with Type 2 diabetes is consistent 
with the older age of Type 2 diabetes patients, the known consequences of the disease and 
the measured prevalence of co-morbidities (reported above). 
Medications 
The rate of medications prescribed/advised/supplied, 72 per 100 Type 2 diabetes problems 
managed, was above the BEACH average of 66 per 100 problems managed at. Metformin 
was the medication most frequently prescribed, at a rate of 28.5 per 100 Type 2 diabetes 
problems managed and at 2.9 per 100 of these encounters when combined with sitagliptin. 
Gliclazide was prescribed at the rate of 10.1 per 100 problems. Insulins in the top 10 
medications were together prescribed at a rate of 6.6 per 100 Type 2 diabetes problems. 
Other treatments 
The rate of other treatments provided, 39 per 100 of these problems, was above the average 
35 per 100 problems for BEACH. Most commonly the other treatment was 
counselling/advice – nutrition/weight (provided at a rate of 7.9 per 100 Type 2 diabetes 
problems managed) followed by counselling about the diabetes, and counselling/education 
about its treatment.  
Referrals  
The average referral rate for BEACH is 9.5 per 100 problems managed. Patients were referred 
for their Type 2 diabetes at a rate of 15.4 per 100 Type 2 diabetes problems managed. 
Referrals were made most frequently to podiatrists (4.2 per 100 Type 2 diabetes problems), 
ophthalmologists (2.5 per 100 Type 2 diabetes problems) and dietician/nutritionists (2.2 per 
100 Type 2 diabetes problems).  
Pathology and imaging orders 
The pathology ordering rate of 89 per 100 Type 2 diabetes problems managed was three 
times the average for BEACH. HbA1c test was the test most commonly ordered, at a rate of 
25.3 per 100 of these problems. A lipid profile was ordered for 13.1 per 100 Type 2 diabetes 
problems.  
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The patients  
Sex  Per cent  Rate(a) 
Males  54.1 5.0 
Females  45.9 3.3 
 
Age group  
25–44 years  6.2 1.1 
45–64 years  36.8 5.3 
65–74 years  29.9 8.5 
75+ years  26.5 6.5 
Reasons for encounter 
n = 7,141 (181 per 100 diabetes† encounters) 
Rate per 100 diabetes† encounters(b) 
Diabetes – all * 30.7 
Prescription – all* 23.7 
Test results* 16.6 
General check-up* 8.0 
Administrative procedure NOS 7.7 
Endocrine check-up* 6.8 
Cardiovascular check-up* 5.2 
Hypertension* 4.1 
Immunisation/vaccination – all*  4.1 
Follow-up encounter endocrine 4.0 
Other problems managed 
n = 5,385 (136 per 100 diabetes† encounters) 
Rate per 100 diabetes† encounters(b) 
Hypertension* 24.5 
Lipid disorder 9.2  
Immunisation/vaccination – all* 5.2 
Osteoarthritis* 4.3 
Ischaemic heart disease* 3.6 
Gastro-oesophageal reflux disease * 3.2 
Depression* 3.1 
Back complaint* 2.6 
General check-up* 2.1 
Vitamin/nutritional deficiency 2.0 
Medications (prescribed and supplied)  
n = 2,823 (72 per 100 diabetes† problems) 
Rate per 100 diabetes† problems(c) 
Metformin 28.5 
Gliclazide 10.1 
Insulin glargine 3.9 
Metformin/sitagliptin 2.9 
Insulin aspart 2.7 
Rosuvastatin 2.0 
Atorvastatin  2.0 
Sitagliptin 1.5 
Glimepiride 1.2 
Pioglitazone 1.1 
Other treatments 
n = 1,532 (39 per 100 diabetes† problems) 
Rate per 100 diabetes† problems(c) 
Counselling/advice – nutrition/weight* 7.9 
Counselling – problem* 5.3 
Advice/education – treatment* 5.2 
Other administrative procedure/document 
(excluding sickness certificate)* 4.9 
Advice/education – medication* 3.4 
Referrals 
n = 609 (15 per 100 diabetes† problems) 
Rate per 100 diabetes† problems(c) 
Podiatrist/chiropodist 4.2  
Ophthalmologist 2.5 
Dietitian/nutritionist 2.2 
Diabetes educator 2.1 
Endocrinologist 1.1 
Pathology 
n = 3,495 (89 per 100 diabetes† problems) 
Rate per 100 diabetes† problems(c) 
HbA1c* 25.3 
Lipids* 13.1 
Albumin/creatinine, urine* 8.9 
Full blood count 8.3 
Multi-biochemical analysis* 7.4 
Electrolytes, urea and creatinine* 6.5 
Figure 14.9: Management of Type 2 diabetes, 2012–13 
(a) Specific rate per 100 encounters in each gender or age group  
(b) Expressed as a rate per 100 encounters at which Type 2 diabetes was managed 
(c) Expressed as a rate per 100 Type 2 diabetes problems managed 
* Includes multiple ICPC-2 and ICPC-2 PLUS codes 
† Type 2 diabetes is defined as ICPC-2 code T90, and includes non-insulin dependent diabetes, diabetes mellitus, adult onset 
diabetes and insulin-treated Type 2 diabetes. 
Type 2 diabetes† 2012–13 
n = 3,948 (4.0 per 100 encounters) 
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14.9 Discussion 
Type 2 diabetes is one of the most significant chronic diseases besetting the Australian 
population. It has a high prevalence and a significant pool of undiagnosed patients, which 
may increase its prevalence in coming years as programs to improve detection rates are 
implemented. 
Type 2 diabetes causes morbidity in its own right, and produces significant consequent 
morbidity in the form of ischaemic heart disease, renal disease, obesity and secondary 
osteoarthritis. Patients with Type 2 diabetes also have significant levels of other 
multimorbidity such as gastro-oesophageal reflux disease and depression. Patients with 
Type 2 diabetes therefore present a complex management challenge for patients, clinicians 
and clinical teams. 
Managing patients with Type 2 diabetes and co-morbidity requires careful monitoring of 
their clinical state and this is reflected in the high levels of pathology ordering for these 
patients. Many patients also self-monitor their blood glucose levels in addition to referred 
pathology testing.120 
Complexity of management is also reflected in a high level of referrals of Type 2 diabetes 
patients, particularly to allied health professionals. This ‘team care’ is encouraged by 
guidelines and MBS incentives for care planning and team care arrangements. 
As a consequence of more intensive management, the management rate of diabetes increased 
33% over the 10 years from 2003–04 to 2012–13, despite no change in the incidence of new 
cases. The management rate of 4 per 100 patient encounters (Figure 14.3) reflects only the 
management of patients with Type 2 diabetes for that problem. The management of patients 
with Type 2 diabetes for all their problems is more than double that rate. 
The age-specific management rate increased in all age groups 45 years and older during the 
decade to 2012–13, and in both male and female patients. The ageing population is also 
contributing to the increasing management rate. 
As a consequence of the complexity of managing Type 2 diabetes, the availability of new 
treatment modalities, management of risk factors for consequent morbidity and other co-
morbidity, medication management presents difficulties for both clinician and patient. This 
is reflected not only in the use of blood lowering drugs and insulin, but also in the use of 
anti-thrombotic drugs, anti-hypertensives and particularly lipid lowering drugs. These 
patients are also on a wide variety of other medications for a multitude of other morbidities. 
While the resulting poly-pharmacy reduces the risk of disease progression it results in a 
significant risk of adverse drug reactions.77 Concerns about the medical management of 
diabetes and self monitoring of blood glucose have led to a review of products used in the 
management of diabetes by the Pharmaceutical Benefits Advisory Committee.121 
General practices provide clinical treatments (such as counselling, advice and education 
about diabetes and its treatment) at a rate of 33.3 per 100 Type 2 diabetes contacts. This may 
be provided by the GPs, by practice nurses or by co-located allied health professionals. 
GPs provide care to patients with Type 2 diabetes at significantly higher levels than to other 
patients. Both the length of consultation with patients with Type 2 diabetes and the 
frequency with which they are seen, is significantly higher than for all patients seen in 
general practice. The average time currently allocated by GPs to patients with Type 2 
diabetes is 2.6 hours per year. In contrast the average time spent with all patients attending 
general practice is 1.6 hours per year. Additional unquantified time is allocated by practice 
nurses and, as indicated by the referral rate, by allied health professionals. We can conclude 
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that the management of Type 2 diabetes in primary care is very resource intensive and that 
the resource utilisation is bound to increase in the future. 
14.10 Conclusion 
In the past decade, the management of Type 2 diabetes has changed in line with changes to 
guidelines for treatment and in response to many government initiatives to improve clinical 
practice in regard to patients with Type 2 diabetes. General practice has responded with 
increased management time devoted to these patients both for the management of Type 2 
diabetes and the management of patient co-morbidity. 
Patients with Type 2 diabetes will require increased primary care resources in the future and 
the main resource provision in Australia will continue to be by general practices and 
associated allied health professionals. 
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15 SAND abstracts and research tools 
Since BEACH began in April 1998, a section on the bottom of each encounter form has been 
used to investigate aspects of patient health or healthcare delivery not covered by general 
practice consultation-based information. These additional substudies are referred to as 
SAND (Supplementary Analysis of Nominated Data). The SAND methods are described in 
Section 2.6. All substudies were approved by the Human Ethics Committee of the University 
of Sydney. 
The Family Medicine Research Centre (FMRC) and most of the organisations supporting the 
BEACH program select topics for investigation in the SAND studies. In each BEACH year, 
up to 20 substudies can be conducted in addition to the study of patient risk behaviours (see 
Chapter 13). Topics can be repeated to increase the size of the sample and its statistical 
power. 
This chapter includes the abstracts and research tools for SAND substudies conducted from 
April 2012 to March 2013. The subjects covered in the abstracts in this chapter are listed in 
Table 15.1, with the sample size for each topic. 
Table 15.1: SAND abstracts for 2012–13 and sample size for each  
Abstract 
number Subject 
Number of 
respondents  
Number  
of GPs 
195 Nocturnal leg cramps among general practice patients 2681 91 
196 Travel advice and vaccination 2,955 102 
197 Chronic kidney disease and dyslipidaemia in general practice patients – 2012 3,121 101 
198 Influenza and pneumococcal vaccination in general practice patients aged 15 years or over(a) 2,545 101 
199 Anticoagulant and antiplatelet use by general practice patients 2,860 100 
200 Overactive bladder and influenza/pneumococcal vaccination in older patients(b) 1,436  87 
201 Asthma control in general practice patients – 2012(c) 2,536 102 
202 Diagnosis of chronic obstructive pulmonary disease in general practice patients – 2012 2,911 100 
203 Neuropathic pain in general practice patients 2,654 90 
204 Care provided to general practice patients by medical and/or surgical specialists 5,732  193 
205 Private prescriptions and generic substitution of medications in general practice 
patients 2,978 102 
206 Asthma, chronic obstructive pulmonary disease and respiratory symptoms in general 
practice patients 2,589 91 
207 Management of allergic asthma in general practice patients 2,522 85 
208 Lifestyle risk factors 2,838 98 
209 Patient use of the internet for health information 2,944 100 
210 Management of hypertension in general practice patients 2,820 95 
(a) Substudy limited to patients aged 15 years and over. 
(b) Substudy limited to patients aged 45 years and over. 
(c) Substudy limited to patients aged 15 years and over. 
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SAND abstract number 195: Nocturnal leg cramps among general 
practice patients  
Organisation collaborating for this study: Family Medicine Research Centre 
Issues: The proportion of patients attending general practice who (currently or in the past), 
had nocturnal leg cramps (NLC); oral treatment of NLC; the relationship of NLC with the 
use of diuretics, long-acting beta agonists (LABA) and/or statins, including timing of 
initiation relative to onset of NLC, and cessation of medication due to NLC.  
Sample: 2,681 patients from 91 GPs; data collection period: 05/06/2012 – 09/07/2012  
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: Initiation time was placed into one of four categories: (i) <1 year 
before the onset of NLC; (ii) 1+ years before the onset; (iii) after the onset; or (iv) at a time not 
known. Medication which had been ceased because of NLC was presumed to belong to 
category (i).  
Summary of results  
There were no significant differences between the age or sex distributions of patients in this 
study and those of patients at all BEACH encounters in 2011–12. Of 2,681 respondents, 267 
(10.0%, 95% CI: 7.8–12.1) were currently experiencing NLC and 166 (6.2%, 95% CI: 4.7–7.7) 
had previously experienced NLC, a total of 433 patients (16.2%, 95% CI: 13.3–19.0). The 
prevalence of NLC increased with age (>24 years old), but did not differ by sex.  
Of 418 respondents with current/previous NLC, 32.5% (95% CI: 26.4–38.6) reported at least 
one oral treatment for NLC. The top three treatments were: magnesium (Mg) (not elsewhere 
classified) (40.5% of all treatments); quinine sulphate/bisulphate (11.5%); and 
rutin/bioflavinoids/Mg/vitamin B6 (10.8%). Of those with current/previous NLC: 4.1% 
were currently taking quinine, and 0.7% tonic water; 20.2% were currently taking a diuretic 
and 11.3% ceased a diuretic due to NLC; 14.2% were taking a LABA and 11.5% ceased a 
LABA due to NLC; and 34.8% were taking a statin and 8.6% ceased a statin due to NLC.  
Of the 84 diuretics (currently taken by 79 patients), the most common were frusemide 
(39.3%), irbesartan/hydrochlorothiazide (15.5%) and indapamide (13.1%). Of 52 LABAs (52 
patients), the most common were fluticasone/salmeterol (53.8%), budesonide/eformoterol 
(30.8%) and salmeterol (9.6%). Of 122 statins (122 patients), the most common were 
atorvastatin (48.4%), rosuvastatin (32.8%) and simvastatin (13.9%).  
In each medication class, the proportion of reports that were in category (i) provided an 
approximate indication of the strength of evidence for a causal association between that 
medication and NLC. For diuretics, 44.4% of 124 reports were in category (i), which was 
significantly greater than both the 19.4% in category (ii) and the 13.7% in category (iii). This 
implies a causal association between diuretics and the onset of NLC. Similarly for the 102 
reports of LABAs, 54.9% were in (i), which was significantly greater than both the 13.7% in 
(ii) and the 18.6% in (iii), implying a causal association between LABAs and the onset of 
NLC. However, for the 178 reports of statins, there were no significant differences between 
the proportions in each category, 29.2%, 23.0% and 26.4% respectively, although these figures 
were not adjusted for the longer durations of categories (ii) and (iii), compared with (i).  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 196: Travel advice and vaccination 
Organisation collaborating for this study: CSL Biotherapies Pty Ltd  
Issues: Proportion of patients who travelled overseas in previous 2 years; for most recent trip 
– main reason, countries visited (multiple), whether stayed overnight in rural area; whether 
travel advice sought and from whom; for which diseases was patient fully vaccinated and 
was the risk of infection discussed; proportion who had recommended 
vaccination/prophylaxis prior to most recent trip, and reasons if not. 
Sample: 2,955 patients from 102 GPs; data collection period: 02/05/2012 – 04/06/2012.  
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: Countries for which vaccination should be considered were 
sourced from the Center of Disease Control’s yellow book and the World Health 
Organization’s geoserver. 
Summary of results  
The age and sex distributions of the patients in the sample was similar to those at all 2011–12 
BEACH encounters, except there were fewer 0–14 year olds. Of 2,955 respondents, 690 
(23.0%, 95% CI: 19.8–26.3) had travelled overseas in the previous 2 years. Main reason for 
most recent trip was given by 671 patients, of these: 65.7% cited ‘holiday’; 29.5% ‘visit 
friends/relatives’, and 6.4% ‘business’. Countries most frequently visited were the United 
Kingdom (10.0% of destinations), United States of America (8.9%), New Zealand (8.8%), 
Thailand (6.4%) and Bali (5.0%). Most frequent countries where patients stayed overnight in 
a rural area were the United Kingdom (11.3% of destinations), New Zealand (10.9%), Italy 
(5.7%) and Thailand (5.2%). 
Of 670 respondents, 36.1% sought travel advice before their trip: 29.9% (n = 200) from their 
GP, 3.7% (n = 25) from a travel clinic and 1.5% (n = 10) from the internet. The number of 
respondents to each vaccine question varied. The proportion vaccinated ranged from 40.5% 
for hepatitis A and 36.0% for hepatitis B to the lowest rates of 0.7% for Japanese encephalitis 
and 1.8% for rabies. Malaria prophylaxis had been arranged for 11.8% of travellers.  
Two-thirds (66.1%, n = 448) of patients travelled to destinations where vaccination should 
have been considered. The most common risk diseases were typhoid (60.1% of trips), 
hepatitis A (55.9%) and hepatitis B (64.2%), and rabies (50.1%). Of 423 patients travelling to a 
country with infection risk who answered the travel advice question, only 42.7% sought 
advice before their trip. Of those travelling to a country with a risk of infection risk, the 
proportion fully vaccinated against the risk varied from 50.9% for hepatitis A and 44.6% for 
typhoid, to 3.2% for rabies and 1.5% for Japanese encephalitis. Patients who sought advice 
from a GP before travelling were significantly more likely to have been fully vaccinated 
against common diseases in their destination before they travelled than those who sought no 
advice. 
Of the 345 patients who were not fully vaccinated for infection risks associated with their 
destinations, only 110 patients gave reasons. The most common were: patient objection 
(31.8%); the GP did not think it was needed/required (22.7%); patient did not raise travel 
plans with their GP (13.6%); they raised the issue but left it too late (7.3%); the patient did not 
realise they were at risk of infection in their country of destination (2.7%).  
We conclude that patients travelling overseas can reduce unnecessary risk by seeing their GP 
well in advance. 
The following page contains the recording form and instructions with which the data in this substudy were collected.  
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SAND abstract number 197: Chronic kidney disease and 
dyslipidaemia in general practice patients – 2012 
Organisation collaborating for this study: Merck, Sharp & Dohme (Australia) Pty Ltd 
Issues: The proportion of patients attending general practice who: had kidney function 
assessed in the past 12 months; had one or more of eight listed conditions; had been 
diagnosed with chronic kidney disease (CKD) by GP or specialist. For those with CKD: stage 
of disease; proportion on dialysis; lipid, and urine albumin, albumin/creatinine ratio levels; 
and lipid medications.  
Sample: 3,121 patients from 101 GPs; data collection period: 27/03/2012 – 01/05/2012  
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results 
The age and sex distributions of patients did not significantly differ from those of all patients 
at 2011–12 BEACH encounters. Of 3,119 respondents: 36.5% had not had a kidney function 
test in the previous 12 months; 3.4% had had all three kidney function tests (i.e. serum 
creatinine, urine albumin, and albumin/creatinine ratio]; 45.6% serum creatinine only; 3.7% 
serum creatinine and urine albumin; 2.0% serum creatinine and albumin/creatinine ratio; 
and for 7.8% test status was not known.  
Among 3,089 respondents: 27.4% had hypertension; 20.1% dyslipidaemia; 10.1% diabetes; 
5.1% coronary heart disease; 4.7% other cardiovascular disease; 2.2% albuminuria; 1.9% 
previous myocardial infarction; and 1.5% had peripheral vascular disease. Among all 3,089 
patients, 38.6% (95% CI: 35.2–41.9) had at least one of the morbidities/risk factors listed 
above, while 93.0% (95% CI: 90.1–95.9) of 228 CKD patients had one or more.  
Of 3,080 respondents, 232 (7.5%, 95% CI: 5.7–9.4) had diagnosed CKD, which (after 
adjustment) suggests a CKD prevalence of 4.4% (95% CI: 3.3–5.5) in the Australian 
population. Age-specific CKD prevalence in the sample was: 5.5% for 45–64 year-olds; 14.0% 
for 65–74; and 25.2% for 75 or over. Prevalence did not significantly differ between males and 
females. Of the 232 CKD respondents, 80.2% had been diagnosed by a GP, 15.1% by a 
specialist and 4.7% by both.  
The stage of CKD was known for 228 patients: 14.0% were at stage 1; 28.1% were at stage 2; 
50.9% were at stage 3; 2.2% were at stage 4; and 1.8% were at stage 5. Only three patients 
were on dialysis. 
The mean lipid levels were: total cholesterol, 4.7 mmol/L (n = 213 respondents); low density 
lipoprotein cholesterol, 2.5 mmol/L (n = 191 respondents); high density lipoprotein 
cholesterol, 1.4 mmol/L (n = 195 respondents); and triglyceride, 1.7 mmol/L (n = 204). Of 87 
CKD patients, mean albumin/creatinine ratio was 14.0 mg/mmol.  
Of 215 CKD patients, 32.6% were currently not taking any lipid medication, 62.3% were 
taking one lipid medication and 4.7% were taking two. A total of 145 CKD patients were 
taking 157 lipid-lowering medications. Atorvastatin accounted for 40.1% of these, 
rosuvastatin for 25.5% and simvastatin for 15.9%.  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 198: Influenza and pneumococcal 
vaccination in general practice patients aged 15 years or over 
Organisation collaborating for this study: CSL Biotherapies Pty Ltd  
Issues: Among patients aged 15 years or over attending general practice: the proportion with 
indications for influenza or pneumococcal vaccination; proportion who had received 
influenza and/or pneumococcal vaccine; payment mode of supply; reason(s) vaccine not 
given; proportion aware of the influenza and pneumococcal disease campaign; and whether 
the campaign prompted patients to see their GP about vaccination.  
Sample: 2,545 patients (aged 15 years or over) from 101 GPs; data collection period: 
27/03/2012 – 01/05/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: Risk factors for influenza and pneumococcal infection were 
adapted from the Australian Immunisation Handbook (9th Edition, 2008, NHMRC) and 
listed on the SAND form with tick-boxes. 
Summary of results 
Compared with patients aged 15 years or over at all 2011–12 BEACH encounters, this SAND 
sample had a smaller proportion of patients aged 15–24 years and 75 or over, and more aged 
45–64 years, but the sex distributions did not differ.  
The prevalence of at least one risk factor for influenza was 53.6% (95% CI: 49.3–57.9) and for 
pneumococcal disease was 57.7% (95% CI: 53.7–61.6). The most common risk factors were: 
age 65 years or over (32.3%), unspecified chronic disease (26.1%), chronic heart disease 
(11.9%), chronic lung disease (11.1%), diabetes (10.0%) and tobacco smoking (9.8%). Of the 
2,545 respondents, 24.9% had one risk factor for influenza, 18.7% had two and 7.6% had 
three. For pneumococcal disease, the figures were 27.1%, 20.0% and 7.9% respectively.  
Proportion vaccinated: Of 2,522 respondents, the proportion vaccinated against influenza 
was 47.3% (95% CI: 43.7–51.0), comprising 70.6% of those with at least one risk factor, and 
20.2% of those with no risk factors. For pneumococcal disease, of 2,443 respondents, 25.7% 
(95% CI: 22.5–28.9) were vaccinated, (42.9% of those at risk and 1.6% of not at risk patients).  
Mode of Supply: For 78.9% of 1,162 respondents the influenza vaccine had been free; for 
4.5% it was subsidised by government; and for 16.6% it was privately funded. Parallel 
proportions among 593 patients who had received pneumococcal vaccine were 93.6%, 4.4% 
and 2.0%.  
Reasons vaccine had not been given: For influenza, among 362 unvaccinated patients at 
risk, 36.7% had not been vaccinated because of patient objection, 30.4% for an ‘other’ reason 
and 19.1% were not considered at risk by the GP. For pneumococcal disease, among 680 
unvaccinated patients at risk, the results for these reasons were 20.7%, 36.6% and 31.3%.  
Campaign awareness and response: Of 2,420 patients, 36.0% had seen a consumer 
awareness campaign about vaccination. Among patients with at least one risk factor, there 
was no significant difference in campaign awareness between age groups, or between 
vaccinated and unvaccinated groups. Of those 839 who had seen the campaign, 34.7% had 
been prompted to speak with their GP.  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 199: Anticoagulant and antiplatelet use by 
general practice patients  
Organisation collaborating for this study: Pfizer Australia Pty Ltd 
Issues: The prevalence among patients attending general practice, of diagnosed: atrial 
fibrillation (AF), deep vein thrombosis, pulmonary embolism, heart valve disease and/or 
acute coronary syndrome; anticoagulant and antiplatelet medications taken for these 
conditions and duration of current use; for patients on warfarin, availability of INR results 
from previous six months, proportion of these reflecting uncontrolled INR; for patients with 
AF, CHADS score for risk of stroke compared with GP’s perception of risk, glomerular 
function testing, and level of renal function. 
Sample: 2,860 patients from 100 GPs; data collection period: 02/05/2012 – 04/06/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: CHADS score for estimating risk of stroke;(a) Kidney Health 
Australia categories.(b) 
Summary of results  
The age and sex distributions of the patient sample did not differ from those of all patients at 
2011–12 BEACH encounters. At least one listed condition was reported for 324 patients 
(11.3%, 95% CI: 9.5–13.1). Prevalence of: AF was 5.5%; acute coronary syndrome 3.7%; heart 
valve disease 1.7%; deep vein thrombosis 1.4%; and pulmonary embolism 0.7%. After 
adjustment for attendance rates, in the attending population prevalence of: at least one listed 
condition was 6.6%; AF 2.9%; acute coronary syndrome 2.2%; heart valve disease 0.9%; deep 
vein thrombosis 1.0%; and pulmonary embolism 0.5%. Among 320 respondents to 
medication use: 40.0% (n = 128) were on warfarin—mean duration 54 months (n = 103); 
28.1% (n = 90) were taking prescribed aspirin—mean duration 60 months (n = 55); 15.9%  
(n = 51) were on clopidogrel—mean duration 43 months (n = 36); 12.2% (n = 39) were on 
over-the-counter aspirin—mean duration 56 months (n = 25); 1.3% (n = 4) were on 
dabigatran—mean duration 10 months (n = 4). 
Of 122 respondents on warfarin, 32.0% had 6–8 INR results, and a further 32.0% had 12–23 
INR results available from the previous 6 months. Of 110 respondents on warfarin, 82.7% 
had at least half of their INR results in the normal range (i.e. between 2.0 and 3.0). 
CHADS score is a clinical prediction rule for estimating the risk of stroke in patients with AF. 
For 148 AF respondents, CHADS score suggested 7.4% were at low risk, 48.0% were at 
moderate risk, and 44.6% were at high risk of stroke. For 144 AF respondents, according to 
GP opinion 18.1% were at low risk, 46.5% were at moderate risk and 35.4% were at high risk. 
Of patients grouped as high risk using the CHADS score, 55.4% were also grouped as high 
risk by the GP, while 35.4% were considered moderate, and 9.2% were considered low risk. 
Of 150 respondents with AF, 138 (92.0%) had glomerular filtration rates (GFR) from the 
previous 12 months, the majority (78.7% of the 150 AF patients) having estimated GFR 
(eGFR). Using Kidney Health Australia categories, of the 138, 5.8% had normal results, 51.4% 
had mild kidney damage, 40.6% had moderate damage, and 2.2% had severe damage. 
(a) Gage BF, van Walraven C, Pearce L, Hart RG, Koudstaal PJ, Boode BS et al. Selecting patients with atrial fibrillation for anticoagulation: 
stroke risk stratification in patients taking aspirin. Circulation 2004;110(16):2287–92 
(b) Kidney Health Australia. Chronic Kidney Disease (CKD) Management in General Practice. Kidney Health Australia, Melbourne, 2007 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 200: Overactive bladder and 
influenza/pneumococcal vaccination in older patients 
Organisation collaborating for this study: CSL Biotherapies Pty Ltd 
Issues: In this SAND, we report two separate issues affecting patients aged 45 and over 
attending general practice: (part 1) proportion with a diagnosed overactive bladder and/or 
bladder symptoms, and if so, the severity of problems, and management; (part 2) proportion 
that had discussed influenza and/or pneumococcal vaccination with any health professional 
in the previous 12 months, and if so, what had prompted this. 
Sample: 1,436 patients (aged 45 years and older) from 87 GPs; data collection period: 
05/06/2012 – 09/07/2012.  
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results 
(Part 1) There were no significant differences between the age and sex distributions of these 
patients and patients aged 45 years and older at all BEACH encounters in 2011–12. 
Of 1,337 respondents, 165 (12.3%, 95% CI: 8.7–16.0) had been diagnosed with overactive 
bladder. Compared with all 1,337 respondents, these overactive bladder patients were 
significantly more likely to be aged 75 or over. Sex-specific rates showed significantly higher 
prevalence among females (16.0%, 95% CI: 11.1–20.9) than males (7.5%, 95% CI: 4.7–10.2). 
Of the 165 overactive bladder patients, 49.7% indicated they had urgency, 47.3% frequency, 
44.9% nocturia and 39.4% urge incontinence, and 36 (21.8%) did not report any current 
symptoms suggesting that their overactive bladder is being satisfactorily managed.  
Of the 1,172 respondents without overactive bladder, 288 (24.6%) had at least one symptom, 
including: 9.6% (of 1,172) with urgency; 8.6% frequency; 13.9% nocturia; and 7.8% urge 
incontinence.  
Of 1,337 respondents, 453 (33.9%) had overactive bladder and/or at least one bladder 
symptom. Of these, 433 reported the severity of problems caused by their bladder condition, 
which was further categorised as mild 37.4%, moderate 54.7% or severe 7.9%.  
Of the 453 above: 13.9% reported the current or most recent treatment was medication only; 
15.2% reported ‘other treatment’ only; 67.6% neither medication nor ‘other treatment’; and 
3.3% both. Of 64 respondents taking medication, 45 (70.3%) took it as prescribed, 7 (10.9%) 
only when symptomatic and 12 (18.8%) had discontinued. Of 80 reported medications, 
oxybutynin accounted for 28.8%, systemic antibacterials 12.5% and solifenacin 10.0%. Of the 
8 reported discontinuations, 3 were of oxybutynin. Of the 86 ‘other treatments’ reported, 
incontinence pads comprised 37.2% and therapeutic exercises 17.4%. 
(Part 2) Of 1,405 respondents aged 45 years and older, 963 (68.5%) had discussed influenza or 
pneumococcal vaccination with a health professional in the previous 12 months. Of these, the 
prompt for discussion was: the patient’s medical condition for 54.4%; patient age for 53.0%; 
patient vaccination status for 22.7%; recall notice from practice for 20.6%; and ‘other’ reasons 
for 4.6% (of which the most common was ‘work’).  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
151
   
 
152
  
 
SAND abstract number 201: Asthma control in general practice 
patients – 2012  
Organisation collaborating for this study: AstraZeneca Pty Ltd (Australia) 
Issues: The prevalence of diagnosed asthma among patients aged 18 years and over 
attending general practice; GP perception of level of asthma control; patient perception of 
impact of asthma on their lives; asthma medications taken in previous month and use of 
these in the previous week; patient report of being woken by asthma at night, morning 
asthma, activity limitation, shortness of breath and wheezing; asthma control rated by the 
Asthma Control Questionnaire(a) (ACQ5) score compared with GP opinion. 
Sample: 2,536 patients aged 18 years and over from 102 GPs; data collection period: 
10/07/2012 – 13/08/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: The Asthma Control Questionnaire (5-item version - ACQ5)(a) 
was used to determine level of asthma control. 
Summary of results 
The prevalence of diagnosed asthma among 2,536 respondents aged 18 years and over was 
12.8% (95% CI: 11.0–14.6) (n = 324). The age and sex-specific rates of asthma did not 
significantly differ across patient demographic groups. 
Among 317 patients for whom asthma control was rated by the GP, 74.4% were categorised 
as well-controlled, 19.6% partially controlled, and 6.0% poorly controlled. Among 318 who 
reported the impact of asthma on their lives, 41.8% rated impact as ‘a little’, and 35.5% 
indicated ‘no impact at all’. For 14.8%, asthma had a moderate impact, for 5.3% it impacted 
quite a lot, and for 2.5% asthma impacted a great deal on their lives. 
A total of 414 medications for asthma had been taken in the previous month by the 324 
patients with asthma. Salbutamol accounted for 41.3%, fluticasone/salmeterol 25.1%, and 
budesonide/eformoterol 14.0%. Frequency of use in the previous week was reported for 391 
medications. For 13.8% of these medications none had been taken in the previous week, 
while for 39.6% they had been taken 11 or more times in the previous week. Of the 414 
medications, 387 could be linked to the patient’s level of asthma control. Respondents whose 
asthma was poorly controlled were twice as likely to record medications used 11+ times in 
the previous week (67.9%) than well-controlled respondents, for whom only 33.5% of 
medications had been used 11+ times in the previous week. 
Among 317 respondents to the ACQ5, in the previous week 52.2% were never woken at 
night by asthma; 54.4% had no asthma symptoms on waking in the morning; 54.7% were not 
limited in their activities due to asthma; 42.3% had no shortness of breath; 39.4% had no 
wheezing. The ACQ5 score showed that 26.8% of respondents had a score of 0 and therefore 
were classed as having good control. Only 2 patients (0.6%) had an average score of more 
than 5 and were classed as having poor control. A comparison was made between level of 
asthma control in the opinion of the GP and ACQ5 categories. Statistical tests showed a 
positive correlation between ACQ5 score and GP opinion of level of asthma control 
(Spearman correlation 0.60, 95% CI: 0.53–0.67). 
(a) Juniper E.F, O’Byrne P.M, et al. Measuring asthma control: Clinic questionnaire or daily diary? Am J Respir Crit Care Med 2000;162:1330–4. 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 202: Diagnosis of chronic obstructive 
pulmonary disease in general practice patients – 2012 
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd. 
Issues: The proportion of general practice patients diagnosed with chronic obstructive 
pulmonary disease (COPD) (with/without asthma); duration of COPD and asthma; most 
recent asthma exacerbation; proportion who had spirometry for COPD diagnosis, who 
performed this and time since the most recent test; other diagnostic tests used; current 
smoking status; and duration of smoking and quitting.  
Sample: 2,911 patients from 100 GPs; data collection period: 10/07/2012 – 13/08/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results 
The sex distribution of the 2,911 respondents did not significantly differ from that of patients 
at all 2011–12 BEACH encounters, but there was a significantly smaller proportion aged  
25–44 years (19.3%) than average (22.8%).  
Estimated prevalence of COPD (+/- asthma) was 4.3% (95% CI: 3.4–5.2), including 1.8% with 
COPD-with-asthma and 2.5% COPD-without-asthma. Prevalence of asthma-without-COPD 
was 10.4%. After weighting, the estimated prevalence of COPD (+/- asthma) and of asthma 
(+/- COPD), among the patient population who attend Australian general practices at least 
once in a year, were 2.6% (95% CI: 2.0–3.2) and 11.8% (95% CI: 10.0–13.7), respectively. 
For COPD (+/- asthma), there were no differences in sex-specific prevalence. The age-
specific prevalence was significantly higher in the two oldest age-groups, 75 years or over 
(11.0%) and 65–74 years (7.8%) than in the younger age groups.  
Of 116 respondents with COPD, median duration since diagnosis was 10 years (mean 11.4 
years). Of 40 COPD-with-asthma respondents, median duration since diagnosis was 19.5 
years (mean 27.9 years) and median time since last asthma exacerbation was 6 months.  
Among 121 COPD respondents, spirometry had been used for diagnosis for 77 (63.6%, 95% 
CI: 53.7–73.6). These were performed by one or more practitioners: a specialist in 46.8% of 
cases, a GP in 44.2% and a practice nurse in 18.2%. The most recent spirometry was within 
the last year in 46.1% of cases.  
Among COPD respondents, non-spirometry diagnostic factors used were: clinical history 
(85.9%); smoking history (79.0%); chest X-ray (72.4%); electronic forced expiratory volume 
meter (50.7%); and bronchodilator non-response (37.9%). There were a median of 3 
diagnostic factors per patient.  
Of 121 COPD respondents, 28.9% (95% CI: 19.8–38.1) were current smokers, 60.3% (95% CI: 
50.4–70.3) past smokers and 10.7% (95% CI: 4.8–16.7) had never smoked.  
Of 33 COPD current smokers, mean smoking duration was 43.0 years, median 40 years. Of 
65 COPD past smokers, mean was 34.6 and median 35 years. Of 63 past smokers, the mean 
time since quitting was 14.3 years and the median was 10 years.  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 203: Neuropathic pain in general practice 
patients  
Organisation collaborating for this study: Pfizer Australia Pty Ltd 
Issues: The proportion of general practice patients who have been diagnosed with, or had 
symptoms of, neuropathic pain; the description of symptoms; duration between symptom 
onset and first consulting a GP; reasons for delay in seeking treatment if greater than 6 
months; reasons for seeking GP’s help; the time interval between first seeking treatment and 
diagnosis of neuropathic pain; and who made the diagnosis.  
Sample: 2,654 patients from 90 GPs; data collection period: 14/08/2012 – 17/09/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results  
The sex distribution of respondents in this study did not differ from that of patients at all 
2011–12 BEACH encounters. However, a significantly greater proportion were aged 0–14 
years (16.9%) than at total BEACH encounters (11.8%) and a significantly smaller proportion 
were aged 65–74 years (10.1% cf. 13.2%).  
Of the 2,654 respondents, 226 (8.5%, 95% CI: 6.7–10.3) reported neuropathic pain. Of these, 
77.9% had diagnosed neuropathic pain and 22.1% had symptoms of undiagnosed 
neuropathic pain. Of patients with neuropathic pain, 61.5%were female. There was no 
difference in the sex-specific rates (8.4% each). The 45–64 year age-group had the highest 
age-specific prevalence (15.8%), and this group accounted for almost half (48.7%) of all 
neuropathic pain patients.  
There were 439 responses from 225 patients who described the nature of the neuropathic 
pain: most commonly ‘shooting pain’ (52.9% of patients), ‘burning’ (47.6%) and ‘pins and 
needles’ (44.0%). Of 205 respondents, waiting time between symptom onset and first GP 
consultation was <3 months for 70.2%, 3–6 months for 14.6% and >6 months for 15.1%. 
neuropathic pain had not been previously discussed with a GP by 22 respondents.  
For those who waited >6 months, 30 respondents gave 37 reasons: ‘hoped pain would self-
resolve’ (40.0% of patients); ‘other reason’ (40.0%); and ‘pain was tolerable’ (20.0%) were the 
top three. Among 204 patients, 505 responses were recorded regarding the issue(s) that 
prompted them to seek a GP consultation: ‘unable to tolerate pain’ (59.3% of patients), ‘pain 
interfering with normal daily routine’ (55.9%), ‘pain interfering with sleep’ (51.0%) and ‘pain 
interfering with physical activity’ (51.0%) were the top four.  
Of 170 patients with diagnosed neuropathic pain, time from initial GP consultation to 
diagnosis was <3 months for 75.9%, 3–6 months for 10.6% and >6 months for 13.5%. 
Neuropathic pain had been diagnosed by a GP for 64.9% of patients, by a non-specified 
specialist for 14.6% and by a neurologist for 9.9%.  
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 204: Care provided to general practice 
patients by medical and/or surgical specialists 
Organisation collaborating for this study: Family Medicine Research Centre 
Issues: The proportion of patients attending general practice who had consulted a medical 
and/or surgical specialist in the previous 12 months; the types of specialists consulted; the 
problem(s) involving specialist management; whether specialist care was ongoing; duration 
of specialist care; reason(s) specialist management was requested. 
Sample: 5,732 patients from 193 GPs; data collection period: 18/09/2012 – 26/11/2012.  
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>  
Summary of results 
The age and sex distributions of the sampled patients did not differ significantly from those 
of patients at all BEACH encounters in 2011–12. 
Almost half (46.1%, 95% CI: 43.6–48.6) of the sampled patients had consulted a medical 
and/or surgical specialist in the previous 12 months. The likelihood of having consulted a 
specialist increased significantly with patient age: from 28.7% (95% CI: 19.0–38.4) of children 
aged < 1 year, to 68.4% (95% CI: 64.0–72.7) of patients aged 75 years or more. Of the 2,643 
patients who had consulted at least one specialist, 2,631 provided details about the types of 
specialists seen. Most (67.1%) of these patients had consulted only one type, 21.9% had 
consulted two types, and 11.0% had consulted three or more specialist types in the previous 
12 months.  
There were 3,859 specialist types consulted, the most common being: cardiologist (11.9%), 
ophthalmologist (8.9%), orthopaedic surgeon (8.3%) and unspecified/general surgeon 
(7.9%). There were 4,045 problems managed by these specialists for the sampled patients. 
The most common problems were: ischaemic heart disease (3.6%), diabetes (3.2%), malignant 
skin neoplasm (2.6%), atrial fibrillation (2.2%) and cataract (2.2%). 
Of the 3,859 specialist types consulted, the question about current specialist care was 
answered for 3,689. Of these, 72.1% were still currently under the care of the specialist. 
Duration of specialist management, reported for 3,567 patients, averaged 41.3 months 
(3.4 years). Specialist care had been provided for less than 12 months by 48.8% of specialists, 
1–4 years for 25.1% and ≥ 5 years for 26.0%. 
Reason(s) for specialist management were provided for 3,782 specialist types consulted. Of 
these, 64.7% of specialists were consulted for continuing management of the problem, 46.8% 
for management advice, 30.6% for diagnostic assistance (multiple responses allowed), and 
8.9% of specialist types were consulted for tests or procedures only. For occasions of 
specialist management of an ongoing nature (n = 3,445; i.e. not for a test or procedure only), 
duration of management was reported for 3,249. The average duration of specialist 
management (to date) was 43.4 months (3.6 years), 46.1% being for less than 12 months, and 
27.5% being for 5 years or longer. 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 205: Private prescriptions and generic 
substitution of medications in general practice 
Organisation collaborating for this study: Family Medicine Research Centre 
Issues: The proportion and types of medications that were written as private prescriptions; 
the proportion of all prescriptions written for which generic substitution was not allowed; 
the types of medications for which generic substitution was not allowed. 
Sample: 2,978 patients from 102 GPs; data collection period: 18/09/2012 – 22/10/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: ‘Private prescriptions’ were defined as medications intended to 
be dispensed outside the Pharmaceutical Benefits Scheme (PBS) or Repatriation 
Pharmaceutical Benefits Scheme (RPBS), excluding those that fall below the PBS/RPBS 
subsidy threshold. 
Summary of results 
The age and sex distributions of the 2,966 patients who responded to the questions about 
private prescriptions and the 2,938 patients who responded about generic substitution did 
not differ from all patients at 2011–12 BEACH encounters. 
Private prescriptions: In total there were 243 medications identified as private prescriptions 
(9.8% of all medications prescribed), written at a rate of 8.2 per 100 encounters (95% CI:  
6.0–10.3). Of these, corticosteroids accounted for 10.3%, medications for erectile dysfunction 
for 4.9%, and fixed combination progestogens and oestrogens for 4.5%. 
No prescriptions were written at 47.6% (n = 1,413) of the 2,966 encounters. At 45.0% of 
encounters (n = 1,336) no private prescriptions were provided. At least one private 
prescription was provided at 7.3% (n = 217) of encounters: all prescriptions being private at 
4.3% (n = 128) of encounters; and some being private at 3.0% (n = 89). 
Generic substitution: There were 2,461 medications prescribed at the 1,525 encounters 
where at least one medication was prescribed, and where generic substitution status 
(allowed versus not allowed) was indicated. Of these, 6.7% (n = 166 medications) were 
identified as ‘generic substitution not allowed’. Generic substitution was allowed for 
prescribed medications at a rate of 77.1 (95% CI: 69.9–84.2) per 100 encounters, and not 
allowed at a rate of 5.6 per 100 encounters (95% CI: 2.1–9.0).  
Vitamin K antagonists, plain angiotensin II antagonists and macrolides each accounted for 
5.4%, and angiotensin-converting enzyme (ACE) inhibitors 4.8% of medications for which 
generic substitution was not allowed. 
No prescriptions were written at 48.1% (n = 1,413) of the 2,938 encounters; generic 
substitution was allowed for all prescribed medications at 48.2% (n = 1,416) of encounters; 
generic substitution was not allowed for any of the prescribed medications at 3.5% (n = 103) 
of encounters; and was allowed for some prescriptions at 0.2% (n = 6) of encounters. 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 206: Asthma, chronic obstructive 
pulmonary disease and respiratory symptoms in general practice 
patients 
Organisation collaborating for this study: National Prescribing Service Ltd 
Issues: The prevalence of respiratory conditions, including asthma, chronic obstructive 
pulmonary disease (COPD), post viral cough, other respiratory symptoms; whether 
respiratory conditions were managed at the encounter; current medications for respiratory 
conditions; rates of lung function testing in previous 2 years; asthma control; severity of 
COPD; action plan status. 
Sample: 2,589 patients from 91 GPs; data collection period: 23/10/2012 – 26/11/2012. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: A card classifying asthma control based on the Global Initiative 
for Asthma (GINA) Global strategy for asthma management and prevention, and defining 
COPD severity based on the COPD-X 2011 guidelines, was supplied to participating GPs. 
Summary of results 
The age and sex distributions of the 2,589 respondents did not differ from those of all 
patients at 2011–12 BEACH encounters. 
Of 2,589 patients, 498 (19.2%, 95% CI: 17.1–21.4) reported at least one of the listed respiratory 
conditions at the time of the visit. Asthma was reported for 11.1% (95% CI: 9.5–12.8) of 
patients (n = 288), 5.2% (95% CI: 4.0–6.4) had COPD (n = 135), 0.8% had post viral cough  
(n = 22), 3.8% had other respiratory symptoms (n = 99). There were no significant differences 
in sex-specific rates of these conditions. The highest age-specific rates were: 15.8% (5–14 
years) for asthma; 14.1% (75 years or more) for COPD; 2.7% (5–14 years) for post viral cough; 
7.9% (<5 years) for other respiratory symptoms. 
Of 498 patients with at least one respiratory condition, 44.4% had the condition managed at 
the encounter, most frequently for ‘diagnosis’ and to ‘manage exacerbation’. One-quarter 
(25.7%) of those with asthma and 23.7% of those with COPD had been managed for that 
condition at the encounter. 
For 472 of the 498 patients with at least one respiratory condition, medication data were 
recorded. At least one respiratory medication was recorded for 370 (78.4%) patients, with a 
total of 612 medications listed. Classified at the generic level, 37.3% of the 612 medications 
were salbutamol, 20.3% were fluticasone/salmeterol and 13.1% were tiotropium. Grouped 
by respiratory medication groups, 40.2% were short-acting beta agonists (SABA), 32.2% were 
fixed dose combination long-acting beta agonists/inhaled corticosteroid (LABA/ICS) and 
14.7% were anticholinergics.  
Of 410 respondents with at least one respiratory condition, lung function was tested (in the 
previous 2 years) for one-third (37.3%). Spirometry was used in 28.5%, peak flow in 11.0% 
(2.2% had both). Of 246 patients with asthma, 17.1% had spirometry, and of 127 patients with 
COPD, 55.1% had spirometry in the previous 2 years. 
Using the GINA tool, asthma was classified as well controlled for 76.4% of 275 patients with 
asthma, and uncontrolled for 5.8%. An action plan had been developed for 26.3% of 262 
patients with asthma. COPD was mild in 42.9% of 126 patients, and severe in 14.3%. More 
than one-third (36.3%) of 124 patients with COPD had an action plan. 
The following pages contain the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 207: Management of allergic asthma in 
general practice patients  
Organisation collaborating for this study: Novartis Pharmaceuticals Australia Pty Ltd. 
Issues: The prevalence of diagnosed asthma; the prevalence of asthma triggered by 
allergens; tests confirming diagnosis; duration and severity of asthma; medication and 
duration of medication use; GP perception of asthma control; other managements for allergic 
asthma during the previous 12 months (listed, tick-box, multiple responses allowed).  
Sample: 2,522 patients from 85 GPs; data collection period: 27/11/2012 – 14/01/2013. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website:  
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>  
Summary of results 
A significantly larger proportion of the 2,522 respondents in this SAND sample were female 
(61.5%, 95% CI 58.3–64.7) than the proportion at all BEACH encounters in 2011–12 (56.5%, 
95% CI: 55.7–57.3), but the age distribution did not differ. 
Asthma had been diagnosed in 353 patients (14.0%, 95% CI: 12.0–16.0). There was no 
difference in prevalence among males (12.7%) and females (14.9%), and the age-specific 
prevalence ranged from 9.9% of patients aged 65–74 years to 17.8% of 15–24 years olds. Of all 
patients, 6.1% (n = 153) had allergic asthma, with no significant difference in sex-specific or 
age-specific rates. 
The majority (83.7%) of patients with allergic asthma had been diagnosed more than 5 years 
earlier. At least one test had been used to confirm diagnosis for 61.6% of the 153 patients, 
most commonly spirometry (45.0%); peak flow (23.8%); skin prick (14.6%); total 
immunoglobulin E (IgE) (5.3%) and allergen specific IgE test (5.3%). Severity was reported 
for 150 patients: 58.7% had mild allergic asthma, 35.3% moderate, and 6.0% severe. Asthma 
medication was taken by 73.9% of patients with mild allergic asthma, by all those with 
moderate allergic asthma, and by 88.9% of patients with severe allergic asthma. 
No asthma medication was taken by 15.7% of patients with allergic asthma (n = 24). The 
remaining 129 patients reported taking a total of 201 medications for allergic asthma 
management. Almost half (48.3%) of the reported medications were short-acting beta 
agonists (SABA) and 36.8% were long-acting beta agonists/inhaled corticosteroid 
(LABA/ICS) combination medications. Salbutamol accounted for 47.3%, and fluticasone/ 
salmeterol combination accounted for 22.9% of medications taken for allergic asthma. 
Duration of use was reported for 150 of the 201 medications. Duration of use at the current 
dose was most commonly 7–12 months (for 24.7% of medications), and 0–6 months (for 
24.0%), including 4% that were initiated at the recorded encounter. 
Of the 153 patients with allergic asthma, the GP opinion of asthma control was reported for 
148. In 85.1% of patients, the GP considered the asthma to be well-controlled (n = 126); 
partially controlled for 14.2% (n = 21), and uncontrolled for one patient (0.7%). Of 124 
patients taking medication, 82.3% (n = 102) were well controlled; 16.9% were partially 
controlled, and one patient was uncontrolled. All patients with allergic asthma who were not 
on medication (n = 24) were regarded as well controlled. 
Other managements for allergic asthma used during the past year were also reported: 54.7% 
(of 150 patients) visited a GP; 25.0% (of 148) had oral corticosteroid initiated; 8.8% (of 148) 
attended an accident and emergency department; 5.4% (of 147) saw a specialist; 5.4% (of 148) 
had dose of oral corticosteroid increased; and 4.7% (of 148) were admitted to hospital. 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 208: Lifestyle risk factors 
Organisations collaborating for this study: FMRC and the National Heart Foundation 
Issues: The proportion of patients attending general practice who have: one or more of the 
listed chronic disease(s) and/or listed lifestyle risk factor(s). Whether patients with risk 
factors had these managed at this visit and/or in the previous 12 months. Other services to 
which patients had been advised/referred for the management of their risk factors. 
Sample: 2,838 patients from 98 GPs; data collection period: 15/01/2013 – 18/02/2013. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>  
Methods for this substudy: Risk factors were drawn from SNAP guidelines.(a) 
Summary of results  
Among this sample, there was a smaller proportion of males (38.1%, 95% CI: 34.6–41.7 
compared with 43.5%, 95% CI: 42.7–44.3) and a larger proportion of patients aged 65–74 
years than in the total BEACH 2011–12 sample (16.9%, 95% CI: 14.6–19.1 compared with 
13.4%, 95% CI: 12.8–13.9).  
Of 2,727 respondents to the chronic disease questions, 46.0% had at least one of the listed 
conditions: 19.9% had one, 14.4% two, and 11.7% had three. Most prevalent was 
hypertension (33.6%), then: dyslipidaemia (26.9%); diabetes (11.6%); other cardiovascular 
disease (10.6%); and chronic kidney disease (4.6%).  
Of 2,653 respondents to the lifestyle risk factor questions, 39.2% (n = 1,040) had at least one 
risk factor: 21.1% had one, 13.5% two, and 4.6% had three or more. Most prevalent was 
overweight or obesity (23.8%), then: too little physical activity (18.9%); smoking (8.9%); poor 
nutrition (7.0%); and excess alcohol consumption (4.4%). The most prevalent combinations 
were overweight/obesity and low physical activity (21.3%); poor nutrition and low physical 
activity (5.0%).  
Of 2,542 respondents to the risk factor and chronic conditions questions, 25.6% (n = 652) had 
at least one chronic condition and at least one lifestyle risk factor. Of respondents with at 
least one lifestyle risk factor (n = 986), 49.9% had hypertension; 40.6% dyslipidaemia, 20.8% 
diabetes; 16.4% other cardiovascular disease; and 7.1% had chronic kidney disease.  
Of respondents with at least one chronic condition (n = 1,115), 40.1% were 
overweight/obese; 33.9% had too little physical activity; 10.7% had poor nutrition; 7.7% were 
smokers; and 5.8% had excess alcohol consumption.  
Of the 1,026 patients with risk factors, 37.9% had these risk factors managed at this encounter 
(i.e. ‘today’), a further 44.2% had them managed in the previous 12 months, GPs believed 
managing risk factors was not appropriate for 6.7% of patients, leaving 11.2% of patients 
who did not have their risk factors managed over the previous 12 months. 
Of the 354 patients who had been advised to use/referred to a service (today or in the 
previous 12 months), the type of service was reported for 319, of whom 69.3% were 
advised/referred to a health professional; 24.8% to a commercial health activity; 18.5% to a 
telephone/online advice service; and 15.7% were advised/referred to an other service or 
organisation. 
(a) Royal Australian College of General Practitioners. Smoking, Nutrition, Alcohol and Physical activity (SNAP): a population health guide to 
behavioural risk factors in general practice. Melbourne: RACGP, 2004. Viewed 30 July 2013, 
<www.racgp.org.au/download/documents/Guidelines/snapguide2004.pdf>. 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 209: Patient use of the internet for health 
information 
Organisation collaborating for this study: Family Medicine Research Centre 
Issues: The proportion of attending general practice patients who had used the internet in 
the previous month; frequency of internet use; device(s) used to access the internet (multiple 
response allowed); whether health information was obtained; types of health information 
obtained (multiple response allowed); and whether the information sought related to 
problems discussed or managed by the GP at the visit. 
Sample: 2,944 patients from 100 GPs; data collection period: 15/01/2013 – 18/02/2013. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>.  
Methods for this substudy: Socio-economic Indexes for Areas (SEIFA 2006) Index of 
Relative Socio-economic Advantage and Disadvantage 
<www.abs.gov.au/ausstats/abs@.nsf/mf/2039.0/> was used to measure relative socio-
economic advantage and disadvantage based on the patient's postcode of residence.  
Summary of results 
The age and sex distributions of this sample differed from all patients at BEACH encounters 
in 2011–12 in that there was a smaller proportion of males, and of patients aged less than  
15 years in this sample. 
Of the 2,944 respondents, 1,866 (63.4%, 95% CI: 59.8–67.0) had accessed the internet in the 
previous month, and this proportion did not differ among males and females. Of 1,855 
respondents who accessed the internet, 69.9% used it daily. Most patients (87.1%) used a 
laptop/desktop computer, 42.9% used a smart phone and 22.7% used a tablet.  
Overall, 28.1% (n = 827) of patients had used the internet to obtain health information in the 
previous month: 57.2% sought information related to a specific illness or disease, 31.7% used 
it for diet/fitness, 28.7% for undiagnosed symptoms, and 25.3% for medication information. 
Around 1-in-6 (17.1%) patients had obtained health information related to a problem 
discussed or managed by the GP at the current visit.  
Patient age was significantly associated with rates of overall and health related internet use. 
Those most likely to have used the internet were aged 15–24 years (91.7%) and 25–44 years 
(89.0%). Those aged 25–44 years were most likely to have used it to obtain health information 
(48.7%), and also most likely to have used it for information related to problem(s) discussed 
or managed by the GP at the current visit (30.2%).  
Patients aged 75 years and older were least likely to use the internet overall (23.5%) and for 
health information (5.4%, n = 30). Of the 30 respondents who sought health information on 
the internet, the information related to a problem managed by the GP for 21 patients. 
Patients from the most socio-economically advantaged area (highest SEIFA score) (32.2%, 
95% CI: 26.9–37.5) were more likely than those from the most disadvantaged area (lowest 
SEIFA score) (16.3%, 95% CI: 9.7–22.9) to use the internet for health information and to obtain 
information that was related to problem(s) discussed or managed by the GP (19.6%, 95% CI: 
15.2–24.0 compared with 8.4%, 95% CI: 2.7–14.1).  
There were no statistically significant relationships between patient sex, location or English-
speaking status and internet use. 
The following page contains the recording form and instructions with which the data in this substudy were collected. 
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SAND abstract number 210: Management of hypertension in 
general practice patients 
Organisation collaborating for this study: National Prescribing Service Ltd 
Issues: The prevalence of diagnosed hypertension among patients attending general 
practice. For patients with hypertension: their demographics; medication use for 
hypertension (including number and types taken); use of ambulatory and/or home blood 
pressure monitoring in previous 12 months; current blood pressure; assessment of blood 
pressure control; management plan for patients with uncontrolled blood pressure; 
investigation of secondary causes; assessment of absolute cardiovascular risk. 
Sample: 2,820 patients from 95 GPs; data collection period: 19/02/2013 – 25/03/2013. 
Method: Detailed in the paper entitled SAND Method 2012–13 on this website: 
<sydney.edu.au/medicine/fmrc/publications/sand-abstracts>. 
Summary of results  
The age and sex distributions of the patients responding to this substudy did not differ from 
all patients at 2011–12 BEACH encounters. Prevalence of diagnosed hypertension was 27.7% 
(95% CI: 24.7–30.7) (n = 780) among patients in the waiting room, 17.8% (95% CI: 15.5–20.0) 
of all patients attending general practice, and 14.8% (95% CI: 12.8–16.7) of the population. 
Prevalence did not differ among male and female patients. Sample prevalence increased 
significantly with age, to a peak of 58.0% (95% CI: 51.2–64.9) of those aged 75 years and over. 
Information about medications taken for hypertension was provided for 757 patients, 95.5% 
(n = 723) of whom were currently taking medication. There were 1,093 medications recorded, 
some of which were combination products. Plain angiotensin-converting enzyme (ACE) 
inhibitors accounted for 19.0% of medications, followed by plain angiotensin II antagonists 
(17.8%). There were 433 patients (59.9%) taking one medication, 220 (30.4%) taking two 
medications, 60 (8.3%) taking three medications and 10 (1.4%) taking four medications for 
hypertension. 
Home blood pressure monitoring and/or ambulatory blood pressure monitoring had been 
used by 26.2% of patients (n = 196) in the previous 12 months. Patients’ current blood 
pressure measured at the encounter (in mmHg) showed that the mean systolic blood 
pressure was 135 and the median was 133 in 760 patients, and the mean diastolic blood 
pressure was 76 and the median 78 in 759 patients.  
In the clinical opinion of the GP, blood pressure was not well controlled in 18.8% of 745 
patients. A comparison was undertaken between the current blood pressure (measured at 
the encounter), the GPs’ clinical opinion of blood pressure control and the National Heart 
Foundation diagnostic categories. Of 139 patients whose blood pressure was not well 
controlled, 72 (51.8%) had isolated systolic hypertension, 23 (16.6%) had mild hypertension 
and 20 (14.4%) had moderate hypertension. Of 598 patients whose blood pressure was 
regarded as well controlled, 137 (22.9%) had isolated systolic hypertension. 
Of 137 patients with uncontrolled blood pressure, a change in management plan was 
proposed for 81.8% of patients. Proposed changes included dose titration of existing 
medication (17.5% of 137 respondents) and adding a medication (16.1%).  
Of 754 patients with hypertension, 15.6% had been investigated in the previous 12 months to 
identify any secondary cause of hypertension, and 52.8% had been assessed for absolute 
cardiovascular disease risk in the past. 
The following page contains the recording form and instructions with which the data in this substudy were collected.  
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Abbreviations 
ABS Australian Bureau of Statistics 
ACE angiotensin-converting enzyme  
ACRRM Australian College of Rural and Remote Medicine 
AF Atrial fibrillation 
AHS allied health service 
AHW Aboriginal health worker 
ASGC Australian Standard Geographical Classification 
ATC Anatomical Therapeutic Chemical (classification) 
BEACH Bettering the Evaluation and Care of Health 
BMI body mass index 
CAPS Coding Atlas for Pharmaceutical Substances 
CI confidence interval (in this report 95% CI is used) 
CKD chronic kidney disease 
COPD chronic obstructive pulmonary disease 
CT computerised tomography 
DoHA Australian Government Department of Health and Ageing 
DVA Australian Government Department of Veterans’ Affairs 
ENT Ear, nose and throat 
FMRC Family Medicine Research Centre 
FTE full-time equivalent 
GFR glomerular filtration rate 
GP general practitioner 
HbA1c haemoglobin, type A1c 
ICPC International Classification of Primary Care 
ICPC-2 International Classification of Primary Care – Version 2 
ICPC-2 PLUS a terminology classified according to ICPC-2 
INR international normalised ratio 
LABA long-acting beta agonist 
LCL lower confidence limit 
MBS Medicare Benefits Schedule 
M,C&S microscopy, culture and sensitivity 
NDSHS National Drug Strategy Household Survey 
NESB non-English-speaking background 
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NHMRC National Health and Medical Research Council 
NLC Nocturnal leg cramp 
OTC over-the-counter (medications advised for over-the-counter purchase) 
PBS Pharmaceutical Benefits Scheme 
PN Practice nurse 
RACGP Royal Australian College of General Practitioners 
RFE reason for encounter 
RRMA Rural, Remote and Metropolitan Area classification 
SABA short-acting beta agonist 
SAND Supplementary Analysis of Nominated Data 
SAS Statistical Analysis System 
UCL upper confidence limit 
URTI upper respiratory tract infection  
WHO World Health Organization 
Wonca World Organization of Family Doctors 
Symbols 
— not applicable 
< less than 
> more than 
NEC not elsewhere classified 
n number 
NOS not otherwise specified 
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Glossary 
A1 Medicare items: see MBS/DVA items: A1 Medicare items. 
Aboriginal: The patient identifies himself or herself as an Aboriginal person. 
Activity level: The number of general practice A1 Medicare items claimed during the previous 
3 months by a participating GP. 
Allied health services: Clinical and other specialised health services provided in the 
management of patients by allied and other health professionals including physiotherapists, 
occupational therapists, dietitians, dentists and pharmacists. 
Chapters (ICPC-2): The main divisions within ICPC-2. There are 17 chapters primarily 
representing the body systems. 
Chronic problem: See Diagnosis/problem: Chronic problem. 
Commonwealth concession card: An entitlement card provided by the Australian Government, 
which entitles the holder to reduced-cost medicines under the Pharmaceutical Benefits 
Scheme and some other concessions from state and local government authorities. 
Complaint: A symptom or disorder expressed by the patient when seeking care. 
Component (ICPC-2): In ICPC-2 there are seven components that act as a second axis across all 
chapters. 
Consultation: See Encounter. 
Diagnosis/problem: A statement of the provider’s understanding of a health problem 
presented by a patient, family or community. GPs are instructed to record at the most 
specific level possible from the information available at the time. It may be limited to the 
level of symptoms. 
• New problem: The first presentation of a problem, including the first presentation of a 
recurrence of a previously resolved problem, but excluding the presentation of a 
problem first assessed by another provider. 
• Old problem: A previously assessed problem that requires ongoing care, including 
follow-up for a problem or an initial presentation of a problem previously assessed by 
another provider. 
• Chronic problem: A medical condition characterised by a combination of the following 
characteristics: duration that has lasted or is expected to last 6 months or more, a pattern 
of recurrence or deterioration, a poor prognosis, and consequences or sequelae that 
impact on an individual’s quality of life. (Source: O’Halloran J, Miller GC, Britt H 2004. 
Defining chronic conditions for primary care with ICPC-2. Fam Pract 21(4):381–6).  
• Work-related problem: Irrespective of the source of payment for the encounter, it is likely 
in the GP’s view that the problem has resulted from work-related activity or workplace 
exposure, or that a pre-existing condition has been significantly exacerbated by work 
activity or workplace exposure. 
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Encounter (enc): Any professional interchange between a patient and a GP. 
• Indirect: Encounter where there is no face-to-face meeting between the patient and the GP 
but a service is provided (for example, prescription, referral). 
• Direct: Encounter where there is a face-to-face meeting of the patient and the GP. 
Direct encounters can be further divided into: 
– MBS/DVA-claimable: Encounters for which GPs have recorded at least one MBS item 
number as claimable, where the conditions of use of the item require that the patient 
be present at the encounter.  
– Workers compensation: Encounters paid by workers compensation insurance. 
– Other paid: Encounters paid from another source (for example, state). 
General practitioner (GP): A medical practitioner who provides primary comprehensive and 
continuing care to patients and their families within the community (Royal Australian 
College of General Practitioners). 
Generic medication: See Medication: Generic. 
GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, A19, 
A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
GP consultation service items: See MBS/DVA items: GP consultation service items.  
MBS/DVA items: MBS item numbers recorded as claimable for activities undertaken by GPs 
and staff under the supervision of GPs. In BEACH, an MBS item number may be funded by 
Medicare or by the Department of Veterans’ Affairs (DVA). 
• A1 Medicare items: Medicare item numbers 1, 2, 3, 4, 13, 19, 20, 23, 24, 25, 33, 35, 36, 37, 38, 
40, 43, 44, 47, 48, 50, 51, 601, 602. 
• GP consultation service items: Includes GP services provided under the MBS professional 
services category including MBS items classed as A1, A2, A5, A6, A7, A14, A17, A18, 
A19, A20, A22 and selected items provided by GPs classified in A11, A15 and A27. 
• MBS/DVA item categories: (Note: item numbers recorded in BEACH in earlier years 
which are no longer valid are mapped to the current MBS groups) 
– Surgery consultations: Identified by any of the following item numbers: short 3, 52, 
5000, 5200; standard 23, 53, 5020, 5203; long 36, 54, 2143, 5040; prolonged 44, 57, 2195, 
5060, 5208. 
– Residential aged care facility: Identified by any of the following item numbers: 20, 35, 
43, 51, 92, 93, 95, 96, 5010, 5028, 5049, 5067, 5260, 5263, 5265, 5267. 
– Home or institution visits (excluding residential aged care facilities): Identified by any of 
the following item numbers: 4, 19, 24, 33, 37, 40, 47, 50, 58, 59, 60, 65, 87, 89, 90, 91, 
503, 507, 5003, 5023, 5043, 5063, 5220, 5223, 5227, 5228. 
– GP mental health care: Identified by any of the following item numbers: 2700, 2701, 
2702, 2704, 2705, 2710, 2712, 2713, 2715, 2717, 2721, 2723, 2725. 
– Chronic disease management items: Identified by any of the following item numbers: 
720, 721, 722, 723, 724, 725, 726, 727, 729, 730, 731, 732. 
– Health assessments: Identified by any of the following item numbers: 700, 702, 703, 
704, 705, 706, 707, 708, 709, 710, 712, 713, 714, 715, 717, 718, 719. 
– Case conferences: Identified by any of the following item numbers: 139, 734, 735, 736, 
738, 739, 740, 742, 743, 744, 747, 750, 762, 765, 771, 773, 775, 778. 
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– Attendances associated with Practice Incentives Program payments: Identified by any of 
the following item numbers: 2497, 2501, 2503, 2504, 2506, 2507, 2509, 2517, 2518, 2521, 
2522, 2525, 2526, 2546, 2547, 2552, 2553, 2558, 2559, 2574, 2575, 2577, 2598, 2600, 2603, 
2606, 2610, 2613, 2616, 2620, 2622, 2624, 2631, 2633, 2635, 2664, 2666, 2668, 2673, 2675, 
2677, 2704, 2705. 
– Practice nurse/Aboriginal health worker/allied health worker services: Identified by any of 
the following item numbers: 711, 10950, 10951, 10960, 10966, 10970, 10986, 10987, 
10988, 10989, 10993, 10994, 10995, 10996, 10997, 10998, 10999, 16400, 82210. 
– Acupuncture: Identified by any of the following item numbers: 173, 193, 195, 197, 199. 
– Diagnostic procedures and investigations: Identified by item numbers: 11000–12533. 
– Therapeutic procedures: Identified by item numbers: 13206–23042 (excluding 16400). 
– Surgical operations: Identified by item numbers: 30001–52036. 
– Diagnostic imaging services: Identified by item numbers: 55037–63000. 
– Pathology services: Identified by item numbers: 65120–74991. 
Medication: Includes medication that is prescribed, provided by the GP at the encounter or 
advised for over-the-counter purchase. 
• Generic: The generic name of a medication is its non-proprietary name, which describes 
the pharmaceutical substance(s) or active pharmaceutical ingredient(s). 
• GP-supplied: The medication is provided directly to the patient by the GP at the 
encounter. 
• Over-the-counter (OTC): Medication that the GP advises the patient to purchase OTC (a 
prescription is not required for the patient to an OTC medication). 
• Prescribed: Medications that are prescribed by the GP (that is, does not include 
medications that were GP-supplied or advised for over-the-counter purchase). 
Medication status: 
• New: The medication prescribed/provided at the encounter/advised is being used for 
the management of the problem for the first time. 
• Continued: The medication prescribed/provided at the encounter/advised is a 
continuation or repeat of previous therapy for this problem. 
• Old: See Continued. 
Morbidity: Any departure, subjective or objective, from a state of physiological wellbeing. 
In this sense, sickness, illness and morbid conditions are synonymous. 
Patient status: The status of the patient to the practice. 
• New patient: The patient has not been seen before in the practice. 
• Patient seen previously: The patient has attended the practice before. 
Problem managed: See Diagnosis/problem. 
Provider: A person to whom a patient has access when contacting the healthcare system. 
Reasons for encounter (RFEs): The subjective reasons given by the patient for seeing or 
contacting the general practitioner. These can be expressed in terms of symptoms, diagnoses 
or the need for a service. 
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Recognised GP: A medical practitioner who is: 
• vocationally recognised under Section 3F of the Health Insurance Act, or 
• a holder of the Fellowship of the Royal Australian College of General Practitioners who 
participates in, and meets the requirements for, quality assurance and continuing 
medical education as defined in the Royal Australian College of General Practitioners 
(RACGP) Quality Assurance and Continuing Medical Education Program, or 
• undertaking an approved placement in general practice as part of a training program for 
general practice leading to the award of the Fellowship of the Royal Australian College 
of General Practitioners, or undertaking an approved placement in general practice as 
part of some other training program recognised by the RACGP as being of equivalent 
standard. (Source: Commonwealth Department of Health and Aged Care 2001. Medicare 
benefits schedule book. Canberra: DHAC).  
Referral: The process by which the responsibility for part, or all, of the care of a patient is 
temporarily transferred to another health care provider. Only new referrals to specialists and 
allied health services, and for hospital and residential aged care facility admissions arising at 
a recorded encounter, are included. Continuation referrals are not included. Multiple 
referrals can be recorded at any one encounter. 
Repatriation Health Card: An entitlement card provided by the Department of Veterans’ 
Affairs that entitles the holder to access a range of repatriation health care benefits, including 
access to prescription and other medications under the Pharmaceutical Benefits Scheme. 
Rubric: The title of an individual code in ICPC-2. 
Significant: This term is used to refer to a statistically significant result. Statistical significance 
is measured at the 95% confidence level in this report.  
Torres Strait Islander: The patient identifies himself or herself as a Torres Strait Islander 
person. 
Work-related problem: See Diagnosis/problem. 
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Appendices 
Appendix 1: Example of a 2012–13 recording form 
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Appendix 2: GP characteristics questionnaire, 
2012–13 
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Appendix 3: Patient information card, 2012–13 
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Appendix 4: Code groups from ICPC-2 and 
ICPC-2 PLUS 
Available at: <purl.library.usyd.edu.au/sup/9781743323779>, see ‘Electronic editions and 
downloads’. 
Table A4.1:  Code groups from ICPC-2 and ICPC-2 PLUS – reasons for encounter  
and problems managed 
Table A4.2: Code groups from ICPC-2 and ICPC-2 PLUS – chronic problems 
Table A4.3: Code groups from ICPC-2 and ICPC-2 PLUS – problems managed by  
practice nurses 
Table A4.4: Code groups from ICPC-2 and ICPC-2 PLUS – clinical treatments 
Table A4.5: Code groups from ICPC-2 and ICPC-2 PLUS – procedures 
Table A4.6: Code groups from ICPC-2 and ICPC-2 PLUS – clinical measurements 
Table A4.7: Code groups from ICPC-2 and ICPC-2 PLUS – referrals 
Table A4.8:  Code groups from ICPC-2 and ICPC-2 PLUS – pathology test orders  
(MBS groups) 
Table A4.9:  Code groups from ICPC-2 and ICPC-2 PLUS – imaging test orders  
(MBS groups) 
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The book provides a summary of results from the 15th 
year of the BEACH program, a continuing national study 
of general practice activity in Australia.
From April 2012 to March 2013, 978 general 
practitioners recorded details of 97,800 GP–patient 
encounters, at which patients presented 152,278 
reasons for encounter and 152,517 problems were 
managed. For an ‘average’ 100 problems managed, 
GPs recorded: 66 medications (including 54 prescribed, 
6 supplied to the patient and 6 advised for over-the-
counter purchase); 11 procedures; 24 clinical treatments 
( advice and counselling); 6 referrals to specialists and 3 
to allied health services; orders for 30 pathology tests 
and 7 imaging tests.
A subsample study of more than 31,000 patients 
suggests prevalence of measured risk factors in the adult 
(18 years and over) population who attended general 
practice at least once in 2012–13 were: obesity—26%; 
overweight—34%; daily smoking—17%; at-risk 
alcohol consumption—27%. One in four people in 
the attending population had at least two of these 
risk factors.
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